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Abstract 
Five aminophosphine complexes of Ru(II) have been prepared as potential 
chemotherapeutic agents and characterised by NMR and X-ray crystallography. The 
chelate ring-opening process of the bidentate aminophosphine ligand in the complex 
cis, trans-[Ru(H,NCH,CH1PPh,-N,P)2C1,] has been investigated by 2D NMR 
methods. The complex undergoes a ring-opening reaction in coordinating solvents 
via the cleaving of the Ru-N bond. This exposes a potential binding site on the 
metal, and leads to the possibility of in vivo reactivity. 
A range of water-soluble Ru(II)arene complexes of the type [(7 6-arene)Ru"X(L-L)] 
[(ri6-arene)Ru11X(L)2] and [( 6-arene)Ru"X7L], arene = benzene, p-cymene, 
alkylbenzoate, biphenyl, L-L = ethylenediamine, L = acetonitrile, isonicotinamide, 
X= Cl, Br, I, have been synthesised with an aim to produce anticancer active agents. 
They have been characterised by NMR and X-ray crystallography. The hydrolysis 
of {( 6-p-cymene)Ru"Cl(en)] and [(r 6-biphenyl)Ru11Cl(en)] has been followed by 
HPLC and ESI-MS and an HPLC assay developed for use in studies relating to 
biological testing. 
The reactions of the of Ru(II)arene complex [( 6-p-cymene)Ru"Cl(en)] with the 
nucleotides 5'GMP, 5'CMP, 5'AMP and 5'TMP have been investigated by NMR. 
The complex [( 6-p-cymene)RuCl(en)] binds to 5 'GMP at the N7 of the guanine 
moiety. On reaction with a 14mer duplex oligonucleotide of known sequence it was 
found to lower the melting temperature of the duplex significantly to a level 
comparable to cisplatin. The complex forms mono and bis adducts with the 
oligonucleotide in a guanine specific manner, as elucidated by HPLC separation, 
ESI mass spectrometry and enzymatic digestion. 
Cytotoxic studies on Ru(II) compounds revealed a significant effect against the 
ovarian cancer cell line A2780. Cross resistance studies indicate that the complex 
111 
[( 6-p-cymene)Ru"Cl(en)] is influenced by the protein p53, but 
biphenyl)Ru"C1(en)] possibly functions as an inhibitor of topoisomerases. 
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Chapter 1 	 Introduction 
1. Introduction 
This thesis is mainly concerned with the synthesis of ruthenium(II) complexes and 
their potential applications as therapeutic agents for the treatment of cancer. 
Although there are no ruthenium drugs in current clinical use, it is widely considered 
that this situation will change in the not too distant future. Metals in general have 
had an increasing role to play in medicinal and biological applications in the last 
three decades and many reviews and publications have appeared on this subject.' 
This introduction chapter, however, will deal specifically with ruthenium complexes 
that have been investigated for activity. It begins with a brief introduction to the 
chemistry of ruthenium and a short introduction to cancer, followed by a summary 
of data for various ruthenium agents that have appeared in the literature. 
1.1 Ruthenium 
Ruthenium (atomic number 44, mass no. 101.07) is found in Group VIII of the 
Periodic table, and along with osmium, rhodium, iridium, palladium and platinum 
forms the group of metals known as the platinum metals. Ruthenium was 
discovered in 1844 by Karl Kotchovitch Klaus in the residues left behind after crude 
platinum from the Urals had been dissolved in aqua regia. This was actually an 
extension of work by G. W. Osann back in 1826, and Klaus named the new metal 
ruthenium after the Latin name for Russia, Ruthenia. 
Ruthenium is generally found in the metallic state along with other platinum metals 
and the coinage metals. Major sources are the nickel-copper sulfide ores found in 
South Africa and Sudbury, Canada, and in the river sands of the Ural mountains. It 
has an estimated natural abundance of 1 x 10 ppm in the earth's crust.2 Extraction 
is typically from platinum concentrates obtained as anodic slimes from the 
electrolytic refinement of nickel. Treatment with aqua regia removes Pt, Pd, and Au, 
and silver is removed as its soluble nitrate by heating with PbCO2 and treating with 
nitric acid. The remaining insoluble residue yields Ru, Os, Jr and Rh. 
2 
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Currently the main use for Ru is as an additive for hardening of platinum and 
palladium, although the scarcity, and hence high cost, limits its use. 
Ruthenium has seven isotopes, ranging from 96 to 104, with 112  Ru being the most 
abundant at 31.6 %. This has the effect of limiting the accuracy of the molecular 
weight. Its electronic configuration is [Kr] 4d7 5s', it has an electronegativity of 2.2 
and is typically metallic, with a hexagonal close packed structure and a high melting 
point of 2334. 
Ruthenium is virtually unaffected by non-oxidising agents, and is at its most reactive 
with oxidising agents, however it is stable to atmospheric attack. It is capable of 
reaching the group oxidation state (+8). This is in contrast to iron which is very 
easily reduced at +6. The lowest oxidation state in which it forms oxides at is +4 
RuO2. Ru02 is formed from the action of 02  on Ru metal at 1250° C and it is from 
this compound that the most commonly used laboratory source of ruthenium, 
RuC11.3H-,0, is formed by reduction with concentrated hydrochloric acid. Though 
containing Ru(III) species such as RuC13.3H,0, it also appears to contain some 
polynuclear Ru(IV) complexes.3 It is soluble in water, alcohols, acetone and many 
simple organic solvents and therefore is good for reactions with ligands. This 
Ru(III) compound can also be reoxidised to Ru07 by 02  at the lower temperature of 
500 -700° C. 
The most relevant oxidation states for bioinorganic chemistry are Ru II, III and IV. 
Ru(II) forms diamagnetic d6 complexes which exhibit octahedral geometry with the 
notable exception of the square-pyramidal complex RuC12(PPh3)3. The reactions of 
Ru(II) often proceed with retention of configuration, suggesting an associative 
mechanism.' Ru(III) is the best known oxidation state and complexes are always 
low-spin octahedral with one unpaired electron. They are particularly amenable to 
nitrogen containing ligands. There are relatively few Ru(IV) complexes in 
comparison with Ru(II) and Ru(III). They all have octahedral or distorted octahedral 
configuration. They are potentially useful as DNA oxidising agents as they are 
conveniently reduced in solution. 
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1.2 Cancer 
Cancer is the second leading cause of death in western countries.' It will affect one 
in three individuals at some stage during their life and causes one in five deaths in 
the developed world.' Cancer is not a new phenomenon, cancer lesions have even 
been found in dinosaur bones. It is partially due to medical advances in controlling 
other former major fatal diseases such as tuberculosis, and the increase in pollutants 
and synthetic materials in the environment today that have become known as 
carcinogens that it has developed into a more notable risk. 
Cancer is not one disease, but many that differ depending on the site and origin of 
the tumour. Different types of cancers have different characteristics and require 
different treatment. The nomenclature for these diseases varies. Some are named 
after the individual who first described the condition e.g. Hodgkin's lymphoma, and 
some are simply named after the tissue of origin. 
Cancer is the abnormal growth, reproduction and spread of body cells. A cancer cell 
does not know when to stop growing or respond to the normal cell signals telling it 
when it is time to die. The medical term for a tumour is a neoplasm, a relatively 
autonomous growth of tissue, and a cancerous tumour is a malignant neoplasm that 
is potentially dangerous to the host. Malignant tumours have the capability to 
metastasise, i.e. proliferate secondary tumours to other parts of the body, and these 
are frequently the lethal aspect of a cancer. There is no clinically used agent at 
present for the treatment of metastases and it is in this area in particular that 
ruthenium is hoped to find success! Metastasis may occur when the tumour reaches 
a critical size and sheds cells into the circulatory system. It may also occur via the 
lymphatic system, or when improper surgery has resulted in the spreading of cells. 
Cancer cells act differently to normal cells. In cultures they can pile up or grow 
freely while normal cells require to "plate down" and only grow to the thickness of a 
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monolayer. They are also much more aggressive than normal cells and tend to 
multiply at a much accelerated rate. 
There are three main proposed mechanisms for the formation of a cancerous 
growth.' 
Mutation, involving the loss, rearrangement or substitution of DNA in a cell, 
although this has been shown to not be always necessary for cancer formation, 
e.g. mouse tetracarcinoma develops without having any altered genes. 
Addition and integration of new viral genetic material into a cell's genes as a 
result of tumour producing viruses - known to happen in chickens,' hamsters, 
mice and monkeys. 
Epigenesis, which is when there is no change in the genetic material, but in its 
expression by the cell. 
1.2.1 Treatment of cancers 
After diagnosis of a cancer there are a few options left open to the oncologist to 
decide how to proceed with treatment, depending largely on the cancer type, stage of 
progression and location. 	The main ones are surgery, radiation therapy, 
immunotherapy and chemotherapy. 
The first line of attack against tumours is usually surgery. This is particularly 
beneficial if the tumour has not yet metastasised. However disseminated forms of 
cancer such as leukaemia cannot be treated surgically. Surgery is always used in 
conjunction with some other kind of treatment to help prevent remission. 
Radiation treatment e.g. with y-rays from radio-isotopes such as "Co and X-rays. 
The radiation is aimed at the site of the tumour to prevent surrounding area damage 
as the rays are extremely toxic.' Radiation sensitisers are used to increase damage to 
localised areas without having to increase the radiation dose. 
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Immunotherapy is really a follow-up treatment rather than a first line of attack. This 
involves the administration of agents that will stimulate the body to destroy the last 
of the cancer cells left after surgery or radiation therapy. Non-specific agents have 
been used to generate the immune response in patients as specific immunotherapy 
(immunisation with the patients own tumour) has been found to be unsuccessful, 
although specific immunotherapy may develop! 
Chemotherapy, the treatment of cancer with drugs, is an area of intense research 
with great hopes for the future. Unfortunately it is limited in its efficacy by a 
number of factors. The size of the tumour is very important. Even if the drug 
therapy managed to kill 99.9 % of a 100 g tumour, this would still leave 108  cells, 
which would probably be too many for a body to cope with. Side effects of drugs 
can be quite severe due to the similarity between cancerous and normal cells. Drugs 
particularly affect rapidly dividing cells (like cancers) as they tend to attack the cell 
at the various points during the cell division process. This leaves healthy rapidly 
dividing cells such as hair follicles, the gastrointestinal lining and bone marrow cells 
of the immune system open to attack. This results in some of the typical side-effects 
experienced with chemotherapy: hair loss, nausea and poor immuno-response. 
The main types of drugs in use are:' 
Antimetabolites: these inhibit a metabolic pathway essential for reproduction or 
survival of cancer cells. 
Alkylating agents: reactive compounds that act upon DNA, RNA and certain 
enzymes. This group includes the inorganic compounds carboplatin and cisplatin, 
drugs that was found to be extremely effective in the treatment of testicular cancer. 
Antibiotics: a number of antibiotics have shown activity against tumours 
Antimitiotic agents: these arrest cells in metaphase of cell division and interfere with 
the synthesis of transfer RNA. 
At present, drug treatments tend to be palliative rather than curative. They work best 
during the DNA synthesis stage of cell division, which means that fast replicating 
tumour cells are more susceptible. Young tumours divide more rapidly, growing 
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exponentially, so early diagnosis gives a much better chance of survival as they are 
less resistant. But as a tumour ages growth slows and resistance can set in. Often 
combination treatments are necessary to overcome developing resistance and 
provide different forms of attack. 
Although great progress in the treatment of cancer has been made in the past few 
decades, it is clear that there is still a great deal of work yet to be done, and it is 
certain that inorganic chemistry and the development of new treatments based on 
metals and inorganic compounds has a very important role to play in this research. 
1.3 Ruthenium and medicine 
The stimulus for investigation into ruthenium complexes as anti-cancer agents was 
the success of cisplatin in treatments against testicular and ovarian carcinomas and 
tumours of the bladder and head and neck, although the forefathers of ruthenium 
pharmacology could be considered as Dwyer and co-workers.9 In 1965, 4 years 
before the activity of cisplatin was recognised, they reported the anti-tumour effects 
of Ru(II) trischelates containing 1,1 0-phenanthroline. 
1.3.1 Ruthenium and selectivity 
An advantage of ruthenium is its selectivity for tumour cells. It has been found that 
ruthenium remains for up to 96 h in tumour tissues with concentrations of four times 
the rest of the body.1° The selectivity of ruthenium for tumour cells indicates 
potential selective cytotoxicity, and is probably linked to transferrin, the iron 
transport protein found in the blood. Yet the question remains as to how it actually 
gets to the tumour. One strong possibility is that the ruthenium is picked up in the 
bloodstream by the iron transport protein transferrin and transported around the 
body. Transferrin mediated uptake of metal ions in tumour cells is a form of specific 
intake and is a result of the elevated requirements of tumour cells for nutrients 
(hence they possess more transferrin receptors than normal cells) due to their 
accelerated and uncontrolled growth.''  
7 
Chapter 1 	 Introduction 
There has been previous investigations into the possibility of Ru uptake by 
transferrin. The diaqua intermediates of the potential anticancer agent trans-
[Cl4(Im)7Ru] and its indazole analogue bind to apotransferrin with a 2:1 
stoichiometry with the heterocycles remaining attached. The release of the intact 
complex is promoted by citrate.'7  
Transferrin uptake of trans-[RuC14(Ind)2] is apparently important to the transport of 
the complex, despite most of the complex being bound in the bloodstream by the 
protein albumin. 12  This, and its imidazole analogue trans- [RuC14(Im),], do not bind 
to A!',-Tf, suggesting that binding is at the iron binding sites of the protein. 
Crystallographic evidence shows the imidazole complex binding to a histidine 
residue at the iron sites." There are also seventeen surface histidine residues in 
transferrin though, and they also appear to bind the complex, as they do 
{Ru(H2O)(NH3)5]2. 14,15 
This transferrin uptake of ruthenium in the blood may reduce the toxicity of the drug 
by preventing it from binding with other molecules in the body until it has been 
delivered to the tumour cell. It is even possible that the anticancer activity exhibited 
by many ruthenium agents may, to some extent, be due to a depletion of Fe from 
cells and proteins. 
Transferrins (TO are a family of glycoproteins (a protein linked to a polysaccharide) 
that transport iron around the mammalian vascular system. Iron is an essential 
element used in dioxygen transport (haemoglobin) and metabolism and participates 
in a variety of electron transport pathways. Transferrins are bilobal proteins of 
approx. 80 kDa, each lobe containing a binding site for Fe(III). The lobes are 
termed the N-lobe and the C-lobe after the chain terminus it contains. Each lobe 
contains two sub-domains that form a cleft which closes around the iron during 
binding. The Fe(III) binds with carbonate (C032 ) as a synergistic binding ion. The 
protein first binds carbonate with side-chains from a nearby arginine and threonine 
residues and two peptide N-Hs in a binding pocket so that the protein is now 
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organised to bind Fe(III) in an oxygen ligand rich octahedral environment, using two 
oxygens from the carbonate, two phenolate oxygens from tyrosines, a nitrogen from 
histidine and a carboxylate from aspartic acid.'6 
The Fe(III) is now solubilised in an otherwise unfavourable environment and is 
transported through the body to cells where only the iron bound form, and not the 
unbound (apoTf), is taken up by transferrin receptors on the cell membrane. This 
indicates the importance of the change in conformation of the protein on metal 
binding. The receptor is then taken up into an endosomal compartment in the cell, 
and via H pumps, lowers the compartment pH to 5-6, thereby protonating the 
tyrosinate oxygens and releasing the iron.'6 
Ruthenium's position below iron in the periodic table means that it may mimic some 
of its properties. Indeed, both persist mainly as +2 and +3 ions in aqueous solution 
and both are concentrated in villi of the small intestine and distributed around the 
body from there. Various Ru-complex - transferrin studies have been performed" 
and binding has been observed. Release of ruthenium is promoted by acidification 
and presence of a citrate chelating agent, a situation not unlike that of iron being 
released from transferrin in endosomal compartments of low pH. The crystal 
structure of a Ru(III) complex bound to lactoferrin has been solved.' 7 The complex 
trans-[RuCI 4Ind,] - was found to bind to His in the iron binding sites with 
displacement of chloride but the indazole ligands intact. 
Transferrin may promote the concentration of ruthenium in tumour cells due to the 
higher than normal number of transferrin receptors on tumour cells. This is due to 
the increased iron requirement, as the cells are growing and dividing at an 
accelerated rate. 
This selective build up in tumour cells means that ruthenium could perhaps be 
utilised as a diagnostic device, by administration of the radioactive isotope 97Ru. 
This has a half-life of 2,9 days, which is long enough to allow synthesis and quality 
control of the radio-pharmaceutical, but sufficiently short that even strongly retained 
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1.3.3 Ruthenium and metastases 
Metastases, secondary tumours proliferated from the primary tumour, are often the 
cause of death in a case of cancer. These tumours do not respond to the same 
treatment as the primary neoplasm as they exhibit different clonogenicity and 
antigenicity. Ruthenium complexes exhibit a significant and specific action against 
tumour metastases, which is a novel approach as none of the currently available anti-
cancer agents exhibit such a property. This was first demonstrated with cis- and 
trans-[RuCI,(DMSO)4] •25  Presently, [HIm] [trans-RuC14(DMSO)Im], (NAMI-A) (Im 
= imidazole) a complex which has recently entered clinical trials, shows the best 
antimetastatic activity and has shown activity at low doses and free of a detectable 
cytotoxicity for primary tumours and the host itself.26 This will be further discussed 
in Section 1.4.3. 
A difficulty associated with detecting activity for ruthenium compounds in vitro is 
their low cytotoxicity, yet significant effects in vivo. An excellent example of this is 
the lack of effect of NAMI-A on tumour cells in vitro as opposed to its excellent 
effect in viva.27 This cannot be explained by interactions with the matrix in which 
the tumour cells are kept in in vitro, as shown by the complete inactivity of several 
compounds up to millimolar concentrations when tested against TLX5 tumour cells 
kept in sterile Dulbecco's saline, which is calcium and magnesium free .21  It is 
possible that a complicated pattern of host interactions may be involved. This would 
also help explain the metastatic activity. Contrary to first impressions, this lack of 
cytotoxicity is actually a potentially advantageous factor for the ruthenium drugs as 
it implies a low, or absent, bone marrow or epithelial toxicity at active dosages.29 
The initial cytotoxicity studies on complexes were carried out on Ehrlich ascites 
carcinoma and P388 leukaemia cell-lines. These have low predictivity for human 
systems but were used as accept or reject screening mechanisms, which led to poor 
results. Examples of the difficulty in correlating in viva and in vitro tests are the high 
DNA synthesis inhibition of [RuC1(NIH3)5]Cl, "and its negligible anti-tumour 
activity, and [RuCH3CH,COO(N}13)5]Cl, which exhibits no inhibition of DNA 
synthesis and good anti-tumour activity.30 
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1.3.4 Ruthenium and nitric oxide 
A molecule that has been gaining more 
recognition recently for its biological relevance o 	
\\ 	 - 
is nitric oxide. 	Formerly almost entirely  
considered the domain of environmental 	0 . 
chemists and catalytic studies, it is now known 	
Oi,,, N 
to play a key part in the regulation of blood 	CI' "  
pressure, act as a neurotransmitter and also has a 	O\ ) 
role in the macrophagic immune response. It is 
created in the body by the enzyme nitric oxide 
synthase which catalyses the transformation of 	
Figure 1.1 Structure of 
arginine to citrulline. Organonitrates have been 	
K[Ru ... (Hedta)Cl] 32 
used medically for some time as vasodilators 
and act by releasing nitric oxide. Acetylcholine, a transmitter found at neuro- 
synapses also releases nitric oxide during its function. 	Dysfunction in the 
metabolism of nitric oxide can lead to hypertension, diabetes, epilepsy and septic 
shock. Septic shock is a condition brought on due to excess nitric oxide and has a 
greater than 50% mortality rate, therefore there is a need for new drugs to reduce 
nitric oxide levels. Nitric oxide has a similar coordination chemistry to carbon 
monoxide and complexes with ruthenium are well known.3 ' The Ru-NO bond can 
exist in both anionic and cationic complexes, in which it is remarkably stable, being 
able to persist through a variety of oxidation-reduction and substitution reactions. 
Almost any ligand can be present with NO. NO reacts with Ru(III)-d5, reducing the 
Ru(III)—>Ru(II) with the ligand formally being NO. Ruthenium could therefore 
conceivably be used as a nitric oxide scavenger. 	Ruthenium - 
polyaminocarboxylates32 are presently being investigated for their activity, 
particularly K[Ru(Hedta)Cl], see Figure 1.1.. Hedta leaves one coordination site 
available for NO and, being soluble in water, the complex should remain in the 
blood. Models of disease activity have indicated the potential therapeutic benefit of 
rutheni um-polyaminocarboxylates.32 
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Nitric oxide is also toxic towards tumours, due to the formation of metal-nitrosyl 
bonds.32 Three key proteins involved in energy metabolism have been identified as 
the targets of macrophagic attack in tumour cells. All contain non-haem iron as 
iron-sulphur clusters and it is these irons that are nitrosylated. Ribonucleotide 
reductase, an enzyme involved in DNA synthesis, is also inhibited. 12 
Ruthenium polyaminocarboxylates are potential antitumour agents as well as NO 
scavengers. For example, a labile Ru(III) complex with chloride and pdta ligands, 
pdta = 1 ,2-propylenediaminetetracetate,33 shows good antitumour activity, thought to 
be via crosslinking of guanines on DNA. The chlorides are known to dissociate in 
solution, and in this case, the metal stays in the oxidation state IIJ.33 This complex 
can bind to albumin, apotransferrin, and diferric transferrin (pointing to surface 
binding of the complex), damages nuclear DNA, alters the conformation of plasmid 
DNA aswell as inhibits DNA recognition and DNA lysis by restriction enzymes. 34 
Ru(II) polyaminocarboxylates are known to bind to the C5-C6 olefin bond of 
pyrimidines, and can span the major groove of DNA.35 
Similarly, perhaps use could be made of ruthenium's coordination chemistry with 
carbon monoxide. CO is approximately the same size as 02 and has a greater 
affinity for haemoglobin and myoglobin than 0, and tends to bind to them 
irreversibly. CO has also been linked to Sudden Infant Death syndrome,36 and 
epilepsy.37 It is also thought to play a role as a response mediator in the central 
nervous system38 and as a cardiovascular modulator.39 Ruthenium's high affinity for 
carbon monoxide suggests a possible role as a scavenger for CO. 
Although research into ruthenium drugs was originally intended to try and improve 
on the activity of cisplatin, it is now clear that due to their different effects and 
differences in mechanisms, ruthenium agents should be seen as a development of 
new drugs in their own right. 
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1.4 Ruthenium Agents 
1.4.1 Ruthenium-am(m)ine complexes 
Ruthenium-ammine complexes were the first group of ruthenium complexes to 
undergo screening for anti-tumour activity, and have been previously reviewed.40 
Examples of Ru-ammine complexes are [RuC1(N}13)5]Cl,, cis-[RuCl2(NT-13)4]Cl ,fac-
[RuC13(N}13)3] (Figure 1.2) and Ru-red, a trinuclear cation. Ru-red only exhibits 
moderate anti-tumour activity but has been shown to inhibit calcium metabolism, 
which has been linked to suppression of tumour growth.22 
H3N 
H3 N,,, 








Figure 1.2 Structures of(a)fac-[RuCI3(NT43)3 ] and (b) cis-[RuCl2(N}13)41 
Fac-[RuCI3(NH3)3] is the most active Ru-ammine complex that has been tested and 
was found to approach the effectiveness of cisplatin on P388 Leukaemia41 and has 
similar bacterial elongation properties to cisplatin.42 Unfortunately, these promising 
results were coupled with a poor solubility in saline solution4' and hence were 
deemed unsuitable for biological application. Cis- [RuCl 2(N}13)4]Cl, on the other 
hand, has quite a good saline solubility but was never considered effective enough to 
progress to clinical trials. 
Whilst not effective as an anti-tumour agent, [Ru"(H20)(N}13)5]2 serves as a simple 
model for monodentate coordination of Ru to DNA and RNA. Rapid binding is 
observed due to the attraction of the large polyanions to this cation.43 It was found 
that the N7 of guanine was the initial site of attack when exposed in the major groove 
of B-DNA. Second phase interactions probably occur due to interaction of Ru(II) 
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with new coordination sites becoming available as the nucleic acid strands separate. 
Coordination of Ru(III)-pentaammine was also observed on deprotonated exocyclic 
amines of adenosine and cytidine,44 and it has been seen to migrate over the N', N3 
and N9 donor sites of 7-methyihypoxanthine and 7-methylguanine, depending on 
pH. 
Clarke's investigations on Ru-ammine complexes led him to propose the theory of 
activation by reduction, i.e. using Ru(III) as a pro-drug.4' Indeed, Ru(II) does bind 
faster to DNA" and it has been shown that Ru-ammine complexes can be reduced by 
a transmembrane electron transport system46 and that it can be oxidised back to 
Ru(III) inside a cell, particularly in the case of abundant oxygen 4' although this 
situation is not usual in a tumour cell. 
Ruthenium am(m)ine complexes can also generate breaks in DNA. 	In 
Ru(NIII3)
5
(dGK7) the Ru(III) acts as a general acid in promoting the hydrolysis of the 
N-glycosidic bond.48  
1.4.2 Ruthenium-heterocycle complexes 
In order to address the problem of the low solubility of the Ru-ammine anti-cancer 
agents, Keppler and co-workers decided to develop Ru(III) complexes with fewer N 
ligands and more halides. These would have an improved solubility due to the ionic 
charge. The general formula of these is [HL]2[RuC15L] and [HLJ{trans-RuC14L2J, 
where L is a heterocyclic base, particularly imidazole and indazole (Figure 1.3). In 
preliminary tests the imidazole and indazole complexes were found to exhibit a 
higher activity against P388 leukaemia than cisplatin49 indicating their potential as 
anti-cancer agents. Of the two, the indazole derivative has a lower toxicity and a 
higher activity in models. Both the imidazole and indazole [HL][trans-RuC14L2] 
bind covalently to calf thymus DNA and also to the double strand polymers 
poly(dG-dC) and poly(dA-dT), with a preference for(dG-dC)30. In low chloride 
concentrations the imidazole binds the fastest of the two and, in a reaction ratio of 
10:1 nucleotide:[Ru] , after 8 h the imidazole complex was found to be 75 % bound 
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to (dG-dC) and DNA. Unlike the indazole derivative, the imidazole complex is 
stable in solution and hence the majority of in vitro tests were performed on it. 
The original synthesis of [HIm][trans-RuCl4Im,] dates back to the early 1960' S. 51 
This was further developed by Keppler and co-workers,52 who recognised the anti-
tumour activity and confirmed the structure by X-ray analysis. This complex has a 
solubility in blood plasma of 10 mM. The (1-methyl), (2-methyl) and (4-methyl) 
derivatives were also synthesised and specific tumour tests on P388 leukaemia, 
Walker 256 carcinosarcoma and sarcoma 180 indicated greater effectiveness than 5-
fluorouracil in all cases and comparable activity to cisplatin, with the methyl 
derivatives being the less active of the series. Promising results were also obtained 
from tests against autochthonous colorectal tumours in rats, reducing tumour volume 
by up to 90%. These type of tumours are not currently treatable with chemotherapy. 
çNH 
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(a) 	 (b) 
Figure 1.3 Structures of (a) trans-[RuCI4Im2] and (b) trans-[RuC14Ind2] 
It was observed that aged aqueous solutions (>20 h) reacted rapidly with DNA and 
fresh solutions did not.53 This would imply the necessity of an initial aquation step, 
similar to cisplatin, to be activated towards DNA. Studies of the process" found 
stepwise aquation with first order kinetics. Initial replacement of a chloride occurs, 
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and then a second chloride is replaced in either the cis or trans position. This 
appeared to occur equally despite the greater trans effect" associated with oxygen 
compared to chloride. The half-life of the aquation process was found to be t,12=  3.4 
h at 310 K. [RuCl5Im]2 undergoes fast aquation 56  to [RuC14(H20)Im]. When 
dissolved in D,O the initial NMR spectrum shows only this and not [RuC15Im]2 , the 
species present in the solid. 
The interactions of trans- [RuCl4Im2 ] and [RuC15Im]2 with imidazole and N6,N6- 
dimethyladenine (Figure 1.4) have been studied.56 Imidazole is good for studies on 
potentially bioactive molecules as the moiety is present in biology in purine 
nucleotides and molecules such as histidine. Also, it has several protons available 
for monitoring reactions by NMR. Dimethyladenine was used to simulate binding 
of a purine unit, but the 6-Nv1e-, creates steric hindrance, and therefore should force 
binding as the N7-H tautomer via N9, and prevents formation of multiple monomeric 
and polymeric complexes. 
NMe2 
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(a) 	 (b) 
Figure 1.4 Structures of (a) imidazole and (b) N6,N6 -dimethyladenine 
In a 2:1 ratio of imidazole: complex, trans-[RuCl4Im2] forms [Ru(OH)2Im41_ which 
precipitates as a crystal in coexistence with [RuCl4Im-,]. In the presence of excess 
imidazole the reaction proceeds to [RuIm6]3 .56 The reaction proceeds slowly at the 
start, and higher complexes begin to appear at roughly the rate of the first aquation 
step. The first aquation step is never observed, as the aquated complex is likely to 
be a short lived intermediate. The rate accelerates after the first reaction with 
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imidazole. This probably occurs via a base-catalysed process. With excess free 
imidazole the pH is high so this process is feasible. This implies a reasonable 
reaction with DNA, showing potential for inter/intra-strand binding. 
The mono-imidazole complex [RuCl5Im]2 exhibits a very high affinity for 
imidazole, even if the [HIm] counter-ion is the only source.56 Once the bis-
imidazole complex is formed it does not revert back to the mono-form due to the 
inertness of the Ru-N bond. To confirm the inertness of the Ru"-N bond, (C-2) 
deuterated imidazole was added, but the 'H-NMR signal for H-2 did not disappear. 
It would have been removed had the Ru-N bond been labile. The bis-imidazole 
complex was formed in both the cis and trans configurations and these then 
underwent successive substitutions of imidazole up to [RuIm6]3 , indicating a high 
affinity for N bases and therefore probably for DNA. 
[RuCl4lm1]2 has been found to react in a 1:1 ratio with dimethyladenine,' although 
the reaction never reaches completion. Coordination was probably via the N7-H - N9 
tautomer (normally the first site of coordination of a metal57) with retention of the 
trans configuration of the imidazoles, although no conclusive proof was found. The 
bis- dimethyladenine -Ru complex was formed in small quantities only when fifteen 
equivalents of dimethyladenine was used. 
Both imidazole and indazole complexes bind to human serum albumin and human 
serum apotransfernn,17 and are released by acidification and complexation by citrate. 
This is important due to the low pH in the endosomal compartment in cells in which 
transferrin releases its bound iron. Transferrin is potentially a very useful drug 
delivery system. Circular dichroism spectroscopy has shown both [RuCl4lm,]2 and 
[RuCl4Ind1] complexes bind specifically around the Fe(III) binding sites of 
apotransferrin, and that the presence of bicarbonate is necessary. An X-ray crystal 
structure analysis of the adduct of the indazole complexes with human 
apoIactoferrin' 7 has demonstrated that the Ru(III)-indazole complex coordinates to 
a histidine residue at the unoccupied binding sites, specifically His 253 in the N-lobe 
and His 597 in the C-lobe, and with lower affinity sites at surface exposed His 
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residues, primarily His 590 and His 654. The N-heterocycles remain attached to the 
ruthenium. On binding to HSA the imidazole complex was found to significantly 
alter the protein's structure, and deleteriously effect the binding of molecules such as 
warfarin and heme.58 This binding to transferrin may lead to controlled transport of 
the ruthenium around body, and hence a high selectivity for tumours. 
Anti-proliferative efficacy studies" against human colon cancer cell lines have been 
performed using the free complex, and transferrin and apotransferrin-bound forms of 
[RuCl4Im-,] and [RuCl4Ind,]. Cisplatin bound to plasma proteins exhibits no 
significant anti-tumour activity. The apotransferrin bound form of [RuCl4Ind2] is 
not as active as the free complex, but the apotransferrin bound form of [RuCl4Im,] 
is. 	This is possibly due to the difference in configurations of the bound 
apotransferrin due to the different sized heterocycle ligands. The protein-complex 
with imidazole ligands has the closer configuration to when Fe(III) is bound to 
transfemn, therefore the transferrin receptors on the cell membrane would be more 
likely to recognise it. 
The speed of binding of [RuC14Ind,] to human serum albumin and human serum 
transferrin is much faster (on a timescale of a few minutes) than cisplatin, whereas 
the [RuCl4Im2] binds at a similar rate to cisplatin (a few hours)". This is a possible 
explanation for the greater toxicity of the imidazole complex as compared to the 
indazole. 
[HIm][trans-RuCl4(DMSO)Im] is a ruthenium complex that has shown excellent 
anti-metastatic activity.' It contains both a heterocyclic ligand and a DMSO 
molecule. This is further discussed in Section 1.4.3. 
Spectroscopic and structural studies" have indicated imidazole as a moderate it-
donor ligand to Ru(III). This effect is not seen with Ru(II) due to the low spin d6 
electron configuration preventing the metal from accepting it—electron density from 





ruthenium also suggest that imidazole may also serve as a significant ic-acceptor 
ligand in the presence of anionic ligands. Cis-[(Im)7(NH3)4Ru'11]C13 and 
[(Im)6Ru]C13 (Figure 1.5) have been shown to have excellent immuno suppressive 
properties, and this may well be due to the imidazole ligands tuning the RuhlW 
reduction potentials to a range optimal for biological activity, whilst still being small 
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Figure 1.5 Structures of (a) cis-[Ru(NH3)4Im,]3 and (b) [RuIm6]3  
1.4.3 Ruthenium sulfoxide Complexes 
The ruthenium- sul fox ide complexes that have received the most attention from a 
biological point of view are cis- and trans- {RuCl2(DMSO)4] (Figure 1.6) The anti-
tumour properties of cis-[RuCI,(DMSO)4] were noticed early on by Giraldi et al in 
197761. This complex was obviously selected for its structural similarity to cisplatin 
and its overall neutrality. An advantage for these complexes is their ease of 
synthesis.62 Refluxing RuC13.3H2O in dimethylsulfoxide in air for five minutes, 
followed by addition of acetone, precipitated the cis isomer. From there an 
equilibrium to the trans isomer is easily set up. 
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hv 
cis-[RuCl2(DMS0)4] 	 - trans-[RuCl2(DMS0)4] 
A 
Other than the configuration of the chlorides, a significant difference between the 
two isomers is the presence of one oxygen bonded DMSO in the cis form, whereas 
all four DMSOs are sulphur bonded in the trans.67 
O-DMSO 





DMSO-S,,,,, I S-DMSO 





Figure 1.6 Structures of (a) cis-[RuC],(DMSO)4] and (b) trans-[RuC12(DMSO)4] 
Both cis- and trans-[RuC12(DMSO)4] have been the focus of much testing. In 
general both have quite a low toxicity, LD50 values of up to I -/kg, but this is 
countered by the need for high therapeutic doses.4° They have been shown to be 
mutagenic63, react in vitro with DNA forming covalent bonds, particularly with 
guanine64, and have a significant effect on metastasising murine tumours25, which are 
cisplatin-resistant. Both show only slight activity against the Lewis lung carcinoma 
primary tumour, but both are significantly active against its metastases, 65  with the 
trans isomer being the more effective. The cis isomer has a similar effectiveness 
against MCa mammary carcinoma '25  while the trans isomer inhibits both tumour 
growth and metastases of B16 melanoma in mice. Both are also active against 





A possible explanation for the greater effectiveness of the trans over the cis isomer 
can be seen from the difference in their chemical behaviour in aqueous solution 
(Figure 1.7). The steps were followed by conductivity measurements and repetitive 
electronic absorption scans.67 
O-DMSO 
	
OH2 	 OH2 
DMSO-S,,,,, 	 - DMSO 	DMSO-S,,,,, 	 - ci 	DMSO-Si,,,, 
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SLOW DMSO-S**" H "'OH2 
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Figure 1.7 Aquation steps of cis- (upper) and trans-RuCI,(DMSO)4 67 
The first step for cis-[RuC12(DMSO)4] when dissolved in water is dissociation of the 
weaker bound 0-coordinated DMSO, followed by the slow dissociation of a C1 
anion, to leave a cationic cis-diaqua species. The equilibrium was found to be 
inhibited by a 150 mM concentration of NaCl, simulating extracellular conditions, 
but unaffected in 3 mM NaCl, simulating internal cell conditions. 
The trans isomer shows quite different behaviour. On dissolving in H70, two cis 
DMSOs are released to form trans, cis, cis-[RuCl,(DMSO)2(H1O)]. This also 
slowly releases a chloride ion to give a cationic fac-triaqua complex. This 
equilibrium is again inhibited by physiological NaC1 concentration. 
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Therefore, under physiological conditions, the cis form has only one coordination 
site readily available, whereas the trans has two sites open in cis positions. The 
significance of the chloride concentration is that as neutral complexes outside the 
cell, they should be able to cross the cell membrane, and then slowly open another 
coordination site due to the low [Cl-] in the cell. The expected increased activity for 
the trans isomer is backed up by it being twenty times more toxic than the cis. 
The corresponding bromo analogue was also tested, and found to be isostructural, 
but the chloro version was far more active, pointing to the influence of the halogen. 
It is unlikely that the mechanism of anti-metastatic attack of these complexes is the 
same as their anti-primary tumour attack. Metastases differ from the primary tumour 
in their drug sensitivity, antigenicity and clonogenic capacity. This led Sava" to 
hypothesise that the host's immune system plays an important part in the anti-
metastatic effect. He proposed that the compound has an antigenic effect on the 
extracellular part of the tumour cells, and in this way induces the host's immune 
system to kill the tumour. This is only a hypothesis and it must be considered that 
trans-[RuC1-,(DMSO)4] shows similarities in its DNA chemistry to cisplatin. Both 
bind in vitro to plasmid DNA and inhibit the restriction enzymes that would 
normally cut the DNA at guanine rich sites. 
Henn and co-workers" have investigated reactions of cis- and trans-
[RuCl7(DMSO)4] with the monodentate nitrogen ligands NH3, imidazole and 
benzimidazole. They concluded, particularly from the benzimidazole derivatives, 
that the complexes should react quite easily with nitrogen bases. The inertness of 
the disubstituted derivatives leads to the possibility of long-lived DNA adducts in 
the absence of efficient repair systems. However, they will be in a variety of 
environments and they may also react with all such nitrogen ligands present, such as 
amino acids and proteins, and so large amounts may be deactivated without reaching 
the target. 
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Alessio et a!7° reacted trans-[RuC12(DMSO)4] with 5'-dGMP and found the 
formation of two diastereomeric monoadducts. The N7 of the guanine moiety and 
the cc-phosphate group (coordinating through an oxygen) form a chelate to the metal 
centre. This had only previously been seen in Pt(H)7' and metallocene72 chemistry. 
This relatively favourable coordination precluded formation of bis-nucleotide 
complexes at pH 7, even with a two-fold excess of 5 '-dGMP present. This differs 
from Pt(II) drugs where excess drug is required to prevent the formation of bis-
purine nucleotide complexes. 
The phosphodiester groups in DNA should bind to Ru(II) much less strongly than 
the phosphate monoester groups in nucleotides. Cauci73 et al investigated the 
reaction of trans-[RuCl2(DMSO)4] with 2'-deoxyguanosine as a more realistic model 
of interaction with DNA. They found two diastereomeric monoadducts were formed 
and one bisadduct, showing the possibility for cis coordination of two purine bases 
in an octahedral transition metal complex. All products were found to coordinate via 
N7 of the guanine moiety. 
As well as kinetic and thermodynamic factors, the chelate effect appears to be very 
important as the trans isomer reacts irreversibly with d(GpG), forming N7-N7 
adducts, whereas the monoadducts are reversibly bound." interestingly, studies7 ' 
using 5 '-AMP have found binding by trans-[RuC1,(DMSO)4] to occur only through 
the phosphate group. No binding to the adenine moiety was observed. However 
recent investigations" into the binding to the dinucleotides GpA, ApG, dGpA and 
dApG found that bifunctional N7,N7 macrochelates were formed in each case, and 
that chiral N7,N7 bifunctional adducts were formed on reaction with an eight 
nucleotide strand of DNA. 
The chirality of metal complexes has been used to probe nucleic acid structure and 
biochemistry,77 and chiral complexes could bind more selectively to DNA. There 
has been some success so far,78 but most studies have been on pseudo square-planar 
platinum complexes. 11'79 The chirality for octahedral complexes, however, will be 
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located on the metal centre, and is potentially more important77 than the square-
planar complexes where the chirality is on the non-leaving ligand. 
The first fully characterised chloride, dimethylsulfoxide ruthenium(III) complexes 
were published by Alessio et al in 1991,80  [(DMSO)H][trans-RuC14(DMSO)2] and 
,ner-[Ru(DMSO)3C13]. The former is isostructural to the Ru(III) complex with 
known anti-tumour properties, [HIm][trans-Ru(Im)2Cl4]1  which shows very good 
activity toward chemically induced colorectal murine tumour (cisplatin resistant)." 
A series of work has been published involving the synthesis and characterisation of 
new classes of ruthenium(III) chloride-sulfoxide derivatives and their rhodium 
analogues82. These include derivatives containing a nitrogen ligand", of the form 
Na[trans-RuC14(R2SO)(L)] 	and 	mer, cis- [RuC13(R2SO)(R,SO)(L)]. 	Also 
synthesised and characterised are the first examples of Ru(III) chloride-(DMSO)- 
carbonyl complexes.84 	In common with carbonylation of cis- and trans- 
[RuC1,(DMSO)4],85 coordination of carbon monoxide induces the selective 
isomerisation of the DMSO trans to it from S- to 0-bonding. That leaves the 
DMSO trans to CO weakly bonded and easily replaced by a nitrogen donor ligand. 
Ru(III) sulfoxide complexes containing a planar N-ligand" have also been reported: 
mer, cis-[RuCl3( 1 Me-Im)2(DMSO-S)] and [4Et-PyH] [trans-RuC14(4Et-Py)(DMSO-
S). 
Mer-[RuC13(DMSO)2(NR3)] has been tested in mice bearing solid metastasising 
tumours.87 In mice bearing the Lewis lung carcinoma, results were achieved that 
were as effective as cisplatin on primary tumour growth and more potent than it on 
prolongation of host survival time. Combined treatment with cisplatin provides 
better results than either complex alone. Slightly lower effects were found for mice 
bearing MCa mammary carcinoma as compared to cisplatin, but had an equivalent 
effect in terms of host survival time. Comparisons with [HIm][RuIm2Cl4] were 
favourable independent of tumour system used. 
Na[trans-RuC14(DMSO)Im] (NAMI) and its indazole analogue" (Figure 1.8) are 
two mixed ligand complexes that are exhibit promising cytotoxic effects and have 
25 
Chapter 1 	 Introduction 
good water solubility, particularly the indazole complex. 	Na[trans- 
RuC14(DMSO)Im] is particularly effective against solid tumour metastases26 
although it requires a relatively high concentration (> 100 .iM) for cytotoxic effects 
and this depends on the presence of serum and plasma proteins.89 NAMI is virtually 
devoid of effect on DNA, yet 80-90 % binds to calf thymus DNA in solution within 
24 h at 370  C.90 It is active against a broad range of tumours, including Lewis lung 
carcinoma, B16 melanoma and MCa mammary carcinoma.9' When tested in 
combination with 5-fluorouracil,92 it combined its effects against both a solid 
metastasising tumour, MCa Carcinoma, and a lymphoproliferative type tumour 
without reducing the activity of the other drug. 5-Fluorouracil was chosen due to its 
common clinical use against cob-rectal cancers, a type against which ruthenium 
drugs are seen as being most promising. 






(a) 	 (b) 
Figure 1.8 Structures of (a) trans-[RuC14(DMSO)Im] and (b) trans- 
[RuCl4(DMSO)Ind] 
It is interesting to note that at levels that cause a significant reduction in lung 
metastases, NAMI greatly alters the ratio between the mRNAs of MMP-2 (a 
metalboproteinase capable of degrading the extracellular matrix) and TIMP-2 (the 
specific tissue inhibitor of this enzyme)." This corresponds with a pronounced 
increase of extracellular matrix components in the tumour parenchyma and around 
tumour blood vessels which probably hinders metastasis formation and blood flow 
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to the tumour .94  Overall, NAMI down regulates type-TV collagenolytic activity and 
the metastatic potential of MCa mammary carcinoma.95 
NAMI has possibilities for "activation by reduction" to the more active Ru(II) form 
as it may be readily reduced in vivo (E,12= -0.001 V). Its reduction potential is 
strongly pH dependent and the reduction is favoured at acidic pH values.83 The 
complex hydrolyses at a similar rate to cisplatin, with a t,1-, value of ca. 3 h at 310 K. 
Like cisplatin, aquation appears to be a necessary preliminary step for DNA 
binding.50 Both analogues hydrolyse in a two step process, involving loss of a 
chloride followed by successive hydrolytic steps. 
The potential of transferrin as a drug delivery system for Na[trans-
RuCI4(DMSO)Im] and Na[trans-RuC14(DMSO)Ind] has been investigated.96 The 
first hydrolysis step of the complexes was not significantly affected by the presence 
of apotransferrin, although the rate was enhanced. The hydrolysis products do react 
with apoTf and this interaction occurs concomitantly with the second hydrolysis 
step, with a 2:1 drug:apoTf stoichiometry. 	Circular dichroism spectroscopy 
indicated a tight interaction between the Ru(III) chromophore and the chiral 
macromolecule, but this is reversible on addition of excess citrate at low pH. 
The water solubility of the DMSO/heterocycle complexes along with their cytotoxic 
activity renders this type of compound attractive for future application, and indeed, 
after changing the sodium counter-ion of Na[trans-RuCl4(DMSO)Im] to [HIm]*, 
NAMI-A, as it is now known, has become the first Ru" anti-metastatic agent to be 
introduced into clinical trials.97 It was found to have improved pharmacological 
properties over NAMI, and is more stable and reproducible.98 NAMI-A has been 
found to be virtually devoid of cytotoxicity against in vitro cell lines but causes a 
marked reduction in lung metastases in vivo.99 It has also been found to be rapidly 
cleared from the blood by the kidneys'°° and rapidly distributed to the body with 
only 10 % of the initial dose remaining in the blood after 5 mm. NAMI appears to 
be much less toxic to healthy tissues than cisplatin at equieffective doses, does not 





premitotic G2/M phase, whereas cisplatin causes a dose dependent disruption of cell 
cycle phases and reduces cell proliferation.99 
Currently, binuclear ruthenium complexes based on NAMI are being developed.10 ' 
The 	dimers Na2[ {trans-RuCI4(DMSO-5) } 7(t-L)] and { {mer, cis-RuCl3(DMSO- 
S)(DMSO-O)},(V-L)], where L is pyrazine, pyrimidine, 4,4'-bipyridine, 1,2-bis(4- 
pyridyl)-ethane and 1,3-bis(4-pyndyl)-propane have been synthesised with the aim 
to investigate their neoplastic ability. They have been found to hydrolyse slowly and 
maintain their dimeric structure in solution, indicating possible interstrand linking 
over larger distances than before. 
1.4.4 Ruthenium polypyridyl Complexes 
Another type of ruthenium complex that has received attention recently is the 
ruthenium polypyridyl complexes. Although the complexes {Ru(bpy)2(ox)] and 
[RuCl,(phen)2]C104 (ox = oxalate, phen = 1,10 phenanthroline) have previously been 
shown to be inactive as anti-cancer agents,4 ' interest has been retained in these 
complexes, particularly in their inert covalent binding to DNA. 
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Figure 1.9 Pyridyl ligands cited in the text 
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Ru(II) polypyridyl complexes have a unique combination of chemical stabilities, 
redox properties, luminescence emissions and excited state lifetimes"' that makes 
them useful. Ruthenium polypyridyl complexes have been used to probe the tertiary 
structure of nucleic acids, 77° " '°3"°4°5 binding and hybridisation,""" achieving and 
probing photosensitised DNA cleavage,"' and for probing DNA mediated electron 
transfer. 109 
Ru-polypyridyl complexes show surface binding within a DNA groove,WlH  and in 
favourable cases a partial intercalation' 2 "3 of an extended, fused' 4 aromatic ligand 
between the stacks of nucleotide bases. Full insertion of the intercalating ligand is 
prevented by the two ligands ancillary to the phosphodiester backbone. Both 
covalent and intercalating modes probably result from the different types of 
processes responsible for a decrease in the free energy of the system, such as 
electrostatic interactions, hydrophobic interactions and hydrogen bonding. Ideally, 
an intercalating ligand should be attached to a positively charged moiety to "lock" it 
into place via interactions with the negative phosphate backbone of DNA. Hence, 
appropriate Ru(II) and Ru(III) complexes are ideal candidates as intercalators. 
In 1985 Barton and Lolls") reported the enantiomeric selectivity for the A isomer of 
cis-[RuC12(phen)2] in covalent binding to B-DNA. The chiral selectivity for 
intercalative binding shows a preference for the A isomer. This gave the compounds 
special curiosity value. It is possible that new metal based drugs may be designed 
through understanding the selectivity of DNA-metal binding. 
This enantioselectivity for the A isomer in covalent binding is backed up by Grover 
et al' 5 who extended the study to a group of seven mono- and diaquapolypyridyl 
complexes of Ru(II), cis-[Ru(bpy)2(H,0)2]2 , cis-[Ru(L-L)7(py)(H,0)J2 , 
{Ru(terpy)(LL)(H2O)]2*, L-L= bpy, phen, (py=pyridine, bpy=2,2' bipyridine, 
terpy=2,2:6 ,2' - terpyridine). They found covalent binding to B-DNA, and, by 
circular dichroism spectroscopy determined the preferential binding of the A form of 
the complexes. However they found a very low ratio of [bound-metal]:[DNA- 
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nucleotidephosphate], r,, ca 0.01-0.02, as compared with that of cisplatin, 0.20116 
This low rb  is probably due to the higher steric constraints imposed by the octahedral 
geometry of the ruthenium complexes and the ligands. This is backed up by the 
finding that the smallest sized complex they tested had the largest r,,. 
In further work"' they found that the monofunctional complexes [Ru(terpy)(L-
L)(H2O)]2 (L-L=bpy, phen) cannot be oxidised to oxo-Ru(IV) after covalent binding 
to B-DNA. This suggests that similar to cisplatin, the initial step for covalent 
binding is the displacement of the aqua ligand. Monofunctional adducts of 
[Ru(terpy)(L-L)(H2O)]2 and cis-[Ru(L-L),(py)(H 2 O)]2 with calf thymus DNA were 
indicated by thermal denaturation studies."8 
On the assumption that purine bases, adenine and guanine, of B-DNA are possible 
targets for ruthenium compounds, and in particular the N7 sites which have a 
nucleophilic character and are available for metal-complex binding when located in 
the major groove, Van Vliet and co-workers took a variety of pyridyl complexes of 
ruthenium and tested them for binding to purine DNA-base derivatives. It was 
found that the reaction of cis-[Ru(bpy)2Cl.,] with 9-methyihypoxanthine (9-mhyp) 
and 9-ethylguanine (9-egua),"9 both of which are alkylated 6-keto-purines, formed 
only N7 monoadducts, and the crystal structure of cis- [RuC1(bpy)7 (9egua-
KN)]Cl.  1 •5H-,O was solved. This X-ray structure showed the likelihood of weak 
interactions between the lone pairs of electrons on guanine carbonyl group with the 
pyridyl 71-systems through space. Although it has been shown before in organic 
compounds, this is the first example of such an interaction in a coordination 
compound. This could be important for DNA-(metal-complex) interactions. 
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Figure 1.10 Structures of 9-methyihypoxanthine (9mhyp) and 9-ethylguanine 
(9egua) 
Other work includes the reaction of cis-[RuC1-,(bpy)(biq)], (biq = bisquinoline), 
binding to imidazole derivatives. Imidazoles are present as fragments in 
biomolecules like histidine, guanine and adenine. It was found that substitution of 
one chioro ligand in cis-[RuC1,(bpy)(biq)] by an imidazole derivative occurred, and 
that this takes place at the coordination site opposite to biq, with considerably slower 
substitution of the second chioro ligand. This implies that biq has a stronger 
electronic trans influence than bpy, and that the steric constraints imposed by biq do 
not inhibit the approach of an entering ligand. Potential coordinative properties 
towards certain biomolecules is indicated. 
The N7 site of guanine appears to be the preferred site of attack for Ru(II) in its 
interactions with DNA. This has been confirmed for trans-[Ru(S03)(N1-13)4(H20)] 
'0 with a gua-N7  lade-N7  binding ratio of 95. - This is even more extreme for the 
pyridyl complex cis-[RuCI,(bpy),], which reacted only with guanosine at pH 7 and 
elevated temperature, and not with adenosine, cytosine or thymine. 
While the coordination to gua-N' at neutral pH has been observed for metals with 
fast ligand-exchange kinetics, 121  for metals with slow ligand exchange kinetics, like 
Pt(II), mononuclear N1 coordination in guanine is observed only at high pH, 122 or 
when the basicity of N is lowered after prior binding to N 7. ''1 -)3 However, NI 
coordination for ruthenium has only been observed for cis-[RuC12(biq)2]1  which was 
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found to bind at neutral pH to guanosine and 9-substituted guanine bases in a 1:1 
ratio. 114 
Mer-[Ru(terpy)Cl3 ] exhibits antitumour activity in the L1210 cell line"' midway 
between that of cisplatin and carboplatin and is active against human cervix 
carcinoma HeLa and murine L1210 tumour cell lines. It also exhibits in vivo 
activity against the murine lymphosarcoma LS/BL.'26 It was found in model 
reactions that with 9-methylhypoxanthine and 9-ethylguanine, two bases coordinate 
in the trans configuration. No other configuration was observed. This indicates the 
possibility for interstrand crosslinks in DNA, and indeed, it was found to form -2 % 
interstrand adducts when reacted with calf-thymus DNA at pH 7, 37°C in the dark. 
Figure 1.11 Structure of mer-[Ru(terpy)C13 ] 
Gupta and co-workers synthesised DNA cleavage agents based on oxo-ruthenium 
(IV) complexes' 5 "7 by electrochemical oxidation of aqua-ruthenium(II) forms of 
[Ru(terpy)(L)OH,]2 , where L= i12-tpt, phen, dppz, tmentpt = 2,4,6- 
tripyridyltriazine, dppz 	dipyridophenazene, tmen = N,N,N,N- 
tetramethylethylenediamine. All oxidised via Ru(II)(OH2)2 -> Ru(III)OH2 - 
Ru(IV)02  and cleaved DNA. It is possible to study the mechanistic aspects of the 
cleavage reaction from the point of view of the metal complex with these agents. 
DNA cleavage was demonstrated by electrocatalytic cleavage upon electrolysis in 
the presence of the Ru(II)OH, forms. The electrochemical activation procedure may 
offer a means of binding functionalities (i.e. oligonucleotides) that would ordinarily 
undergo self-oxidation. 
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Although polypyridyl complexes are unlikely to yield a successful anti-cancer agent, 
they are useful as models of binding to DNA and for probing oligonucleotide 
structures, and therefore should not be eliminated in the continuing search for 
effective agents. 
1.4.5 Outlook 
The success of cisplatin and the continuing need for new and improved agents in the 
fight against cancer is an inspiration to scientists all over the world. The more we 
are learning about cancer, its root causes and developmental biochemistry, the more 
avenues for drug design and creation are being opened. Ruthenium is an excellent 
candidate for a future clinical treatment, as can be seen from the results achieved so 
far in a relatively short time, and there is every reason to be optimistic for a bright 
future for ruthenium agents. 
1.4.6 Aims of this thesis 
The aim of this thesis is to synthesise Ru(II) complexes with a view to developing 
effective anticancer agents. There is no general consensus on which the anticancer 
active oxidation state of ruthenium is, there are many examples of Ru(II), Ru(III) 
and Ru(IV) complexes in the literature. Bearing in mind the hypothesis that Ru(III) 
drugs are thought to be reduced to an active Ru(II) form in vivo, this work deals 
specifically with Ru(II) complexes 
In Chapter 3 a series of aminophosphine ruthenium complexes are synthesised and 
examined for their potential activity. Chapter 4 describes the synthesis of a range of 
water soluble Ru(II)arene complexes and Chapter 5 deals with one arene complex 
specifically and investigates its reactivity with mononucleotides and a I4mer 
oligonucleotide with the aim of elucidating how the complex would interact with 
DNA. Chapter 6 deals with some preliminary cytotoxicity tests of Ru(II)arene 
complexes against a human ovarian cancer cell line. 
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2.1 Method theory 
2.1.1 Nuclear Magnetic Resonance Spectroscopy 
Most elements have at least one naturally occurring magnetic isotope. Nuclear 
magnetic moments are very sensitive to their environments, and yet interact only 
weakly with them, and this makes them ideal candidates for analysis. Historically, 
the first NMR signals were independently observed by two separate physicists back 
in 1945 for which Bloch and Purcell were jointly awarded the Nobel prize for 
Physics in 1952.12  The phenomenon of chemical shift was discovered in 1950 and 
the first commercial NMR spectrometer (a continuous wave, CW, spectrometer) was 
produced in 1953. In 1970 Fourier Transform (FT) was introduced. Nowadays 
NMR signals of almost any magnetic nucleus can be routinely detected. A number 
of textbooks have been published recently explaining the theory of NMR and its 
application for chemists.3'456'7 and can be referred to for a more in-depth look at 
NMR. A simplified schematic of an NMR machine is shown in Figure 2.1. 
Sample 
Magnet 




Recorde r chart 
Figure 2.1 Schematic of NMR machine 
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Nuclear Magnetism 
Nuclei possess a spin quantum number I, where I = 0, 1/2. 1, etc., with I> 4 being 
very rare. Protons, neutrons and electrons all have I = ½, and the protons and 
neutrons determine the I value for a nucleus. A rule of thumb for calculating the I 
value for individual nuclei is given in Table 2.1 below: 
PROTONS NEUTRONS I 
even even 0 
odd odd 1,2,3... 
even odd 1/2, 3/2, 5/2... 
odd even 1/2, 3/2, 5/2... 
Table 2.1 Rule of Thumb for Calculating I Value 
It needs to be noted that this rule is not infallible, due to interactions of the protons 
and neutrons. 
The properties of the nuclei studied in this thesis are given in Table 2.2. 
Nucleus Spin % Natural 
Abundance 
Magnetogyric Ratio 
y / iO rad T' s' 
NMR Frequency 
at 2.35 T 
(MHz) 
1 H V2 99.98 26.75 100.00 
31 P 
1/2  100 10.80 40.48 
15 
V2 0.37 -2.71 10.13 
Table 2.2 NMR Properties of nuclei studied in this thesis 
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Chemical Shift 
The frequency a nucleus resonates at is primarily dependent on the nucleus' 
magnetogyric ratio, y, and the applied magnetic field, B0, it is also dependent on the 
local electron distribution. It is this what distinguishes between different locations of 
the same nuclei and is what makes NIMR so attractive to chemists. The field 
experienced by individual nuclei, B, is less than the applied field, B0. This is because 
the external field causes electrons to circulate in their orbitals, generating a local field 
B' in the opposite direction to 130. This shields the nucleus from B0. 
B=B0 -B'=B0(1-c) 





It is common practise to define the chemical shift in terms of the difference in 
resonance frequencies between the nucleus of interest, v, and a reference nucleus, V ref, 




Dividing by V ref means that 8 becomes a molecular property independent of the 
magnetic field, 106  scales the value to a more convenient size, and 8 values are 
quoted in parts per million, ppm. The 6 scale increases from right to left by 
convention. The left-hand side is known as lowfield (downfield) end or the high 
frequency end of the spectrum. The opposite is true for the right-hand side. 
Integration 
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The intensity of the signal is generally proportional to the number of protons 
resonating at that frequency with the result that the area under the peak is 
proportional to the number of protons being detected. This area is measured by 
integration. 
Spin-spin coupling 
Spin-spin coupling causes NMR resonances to split into a small number of 
components with characteristic relative intensities and spacings. It arises when 
neighbouring nuclear spins interact with each other due to the tiny magnetic field of 
one nucleus affecting the other. If the spin of the neighbouring nucleus is aligned 
with the field, the total effective field at the neighbouring nucleus is slightly larger 
than it would be otherwise. Therefore the applied field necessary to cause resonance 
is less. Conversely, if the spin is aligned against the field, the applied field necessary 
to resonate is more. The consequence of this coupling is that the nucleus comes into 
resonance at two slightly different values of the applied field. These splittings are 
separated by the coupling constant, J, which is measured in Hz. 
Relaxation 
Once a physical system is perturbed from its equilibrium condition, and then the 
perturbing influence is removed, the system will return to its original equilibrium 
condition in a finite time. The system is said to relax. Spin-lattice relaxation occurs 
when nuclei in the higher energy state transfer energy to the surrounding lattice. This 
results in a net loss of energy from the system. Spin-spin relaxation does not result 
in a net loss of energy from the system, but in loss of phase coherence. 
Two-dimensional NMR 
2D NMR allows for the collection and presentation of a lot more information than 
1D spectra. A 2D spectrum is essentially a contour map, with the two axes being J- 
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resolved or shift correlated. J-resolved is the separate presentation of chemical shift 
and coupling information. The chemical shift is plotted on one axis and the 
multiplicity on the other. A shift-correlated 2D spectrum allows you to establish 
which nuclei are coupled. The coupling can be either homonuclear or heteronuclear. 
COrrelation SpectroscopY (COSY) 
In proton spectroscopy it is often valuable to identify all the couplings and 
connections present in a molecule. Difference decoupling can be a very useful tool 
for this, but in complicated systems it is difficult to carry out all the necessary 
decoupling experiments for all the possible connections. Furthermore, when two or 
more chemical shifts are similar it is impossible to tell what is coupled to what. 
COSY can reveal all the coupling relationships present in a molecule, or hide them, 
in a single experiment. Application of a suitable pulse sequence and processing 
results in a 2D plot, with the conventional ID spectrum along the diagonal, and 
crosspeaks identifying nuclei that are coupled to each other. 
Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) 
This is a form of 2D NMR where the interactions between two different types of 
nuclei are studied. Two types are used in this thesis. One is ['H, 31P] HSQC, where 
the coupling between phosphorus nuclei and protons is observed and presented in the 
form of a 2D map. The other type is ['H, ' 5N] HSQC. Direct studies of M-N-H 
studies in aqueous solution has previously proved difficult.' Using ' 5N-edited, either 
by high concentration (natural abundance) or '5N isotope enriched samples, N-H 
proton signals are selected and separated according to their 15N chemical shifts. 
Ruthenium NMR 
Although not a technique utilised in this thesis, it is interesting to pay passing regard 
to ruthenium NMR. There are two NIMR active isotopes of ruthenium, 99Ru (natural 
abundance = 12.7 %) and '°'Ru (natural abundance = 17.1 %). Both isotopes have an 
I value of 5/2, but 99Ru has a much slower spin-spin relaxation rate than '°'Ru9 and 
hence gives narrower spectral lines. This favours its use over '°'Ru, despite the 
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latter's higher receptivity. 99Ru is considered a promising nucleus for chemical 
studies," with the nucleus being sensitive to the environment around the metal 
centre." It is particularly useful for solid state NMR, 12  for example, for investigating 
magnetic properties of ruthenium oxides.'3 Solution 99Ru and '°'Ru NMR was first 
reported in 1981' and since then it has been used to investigate organometallic 
Ru(II) complexes, both for structural analysis and for distinction of isomers in 
enantiomeric mixtures." 
2.1.2 Electrospray lonisation Mass Spectrometry 
Atmospheric Pressure lonisation (API) involves the formation of ions from a liquid 
flow introduced into a source region maintained at atmospheric pressure. There are 
three main types of API: electrospray, ion-spray," and a heated nebuliser with a 
corona discharger.' 7 The electrospray technique was pioneered by Dole et al" in 
1971. It is based on the desorption of ions from small droplets with virtually no heat 
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Figure 2.2 Schematic of electrospraying.'9 The capillary sprays onto a counter 
electrode (HV lens) which is also at atmospheric pressure. Ions are transported into 
the high vacuum system of the mass spectrometer by use of a nozzle-skimmer 
arrangement. 
An electric field is generated by applying a high (several kV) voltage directly to the 
spraying capillary, (see Figure 2.2) with a counter electrode located a few mm away. 
The emerging liquid assumes an equilibrium conical shape (a "Taylor" cone) with a 
sharp tip from which a stream of droplets is ejected. 	These droplets are 
electrostatically charged and a partial separation of positive and negative ions occurs 
near the capillary tip, allowing detection of either type of ions. Therefore the 
electrosprayed droplets contain excess ions of one charge. As the solvent evaporates, 
the electrostatic repulsion produces smaller and smaller droplets until the 
macromolecule is "expelled" saturated with charges .2' The formation of multiply 
charged ions makes the analysis of high molecular weight analytes more accessible 
to instruments with a limited m/z detection range, e.g. a quadrupole analyser. This 
means that a large molecule can contain multiple charges. A protein can bear a 
proton for every 5-17 amino acid residues, thereby yielding peaks at m/z = 600 - 
2000, even for 200 kDa proteins. In a similar manner, polynucleotides can yield 
negative ions of such m/z values by losing a proportionate amount of protons. 
in 
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\ J 	Droplet 	 As droplet evaporator., the 
containing ions 	electric field Increases and 
Capillary 	 ions move towards the surface 
+4kV 
Figure 2.3 Ion evaporation mechanism" 
Another advantage of ES is that it allows use of solvents such as H20 or acetonitrile 
which provide spectra that are relatively free of matrix peaks, and hence improved 
detection is achieved. 
Electrostatic spraying takes place in stages. As the voltage at the capillary increases, 
the liquid begins to emerge as a succession of large droplets, at which time no ions 
can be observed. At high voltage, a continuous cone-shaped spray pattern is 
observed at the needle tip which emits an expanding fog of very small droplets. This 
stage is influenced by the nature of the solvent, the potential difference and the flow 
rate. Only a certain volume of liquid can be removed from the tip of the cone by 
electrical shear force so electrospray flow rates are limited to a few microlitres per 
minute. At this stage a flow of drying gas, usually warm (60 °C) N7, is introduced, 
flowing in the opposite direction between the spraying tip and the sampling orifice. 
This is to minimise the flow of neutral solvent molecules into the vacuum chamber 
and aid desolvation of the charged droplets. 
Although the electrospray ion formation process is not completely understood,2' the 
ions detected in the gas phase are thought to reflect the ions present in solution. 22,23 
However it is possible that gas phase reactions can contribute to the ion formation 
process of electrospray ionization. 
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A proposed mechanism of gas phase ion formation is field desorption. The radius of 
the droplet decreases as solvent evaporates resulting in a concurrent build up of the 
electrical field at the droplet surface. An analyte molecule that has accumulated 
sufficient charge is then able to evaporate or desorb, from the charged droplet either 
alone, or associated with one or more solvent molecules. 




where E. is the permittivity of free space. 
If the field needed for ion desorption is E0, then the limiting charge, q0, above which 




Another mechanism of ion formation is Rayleigh Fission. The Rayleigh limit occurs 
when charged droplets evaporate until the increased surface charge density confers 
instability. The maximum charge that can be obtained at the Rayleigh limit, q, is 
given by: 




However, due to local disturbances at the surface of the droplet it may not be 
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In summary, electrospray ionisation is a convenient atmospheric pressure, moderate 
temperature method of analysing macromolecules, such as biomolecules, in solution 
conditions and within a reasonable detection range. 
2.1.3 High Performance Liquid Chromatography (HPLC) 
High Performance Liquid Chromatography (HPLC) is the generally accepted name 
for the liquid analogue to gas chromatography. The stationary phase, a solid surface, 
a liquid, an ion-exchange resin or a porous polymer, is held in a metal column and 
the liquid mobile phase is forced through under pressure. Numerous textbooks are 
available describing the principles of HPLC.2425,26 
The emergence of HPLC is considered to have begun with Hubert and Hulsen27 in 
1967, and nowadays modern HPLC analyses are routinely fast and efficient with 
detection levels as low as 200 pg. As well as at an analytical level, HPLC can also 
be used on a preparative scale. HPLC also has the advantage of being able to be used 
"on-line" with various other techniques such as mass-spectrometry. A block diagram 
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2 	3 
Figure 2.4 Block diagram showing the components of an HPLC system. The 
labelled parts are explained below. 
A mobile phase: this is the solvent, or mixture of solvents, used to carry the 
sample through the system. Mixing chambers are present to allow variations in 
mixture composition during the course of a run. This results in solvent gradients 
(constant composition = isocratic) that can be used to draw strongly retained 
molecules from the column and cut down on time. 
A pump system: the pump system forces the mobile phase through the system 
under pressure. Varying the flow rate of the pump varies the pressure. 
Injection system: The mixture to be analysed is dissolved in a suitable solvent 
and introduced at this point ("injected") and carried through the column by a 
continuous flow of the mobile phase. Exact amounts can be controlled by 
injection size and loop size (20 j.il - 2 ml). 
A column: this is where the separation takes place. The stainless steel column is 
packed with the "sorptive" particles of large surface area . This is known as the 
stationary phase. 	In normal phase chromatography this is traditionally 
hydrophilic or polar resulting in the retention of ionic or hydrophilic molecules in 
the column. 	In reverse-phase chromatography, the stationary phase is 
hydrophobic or non-polar and typically consists of hydrocarbon chains, e.g. C-8 
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through the column under continuous flow and the different components are 
separated due to their varying interactions/affinities with the stationary phase. 
5. A detector: this is usually a U'V/Vis detector set to a specific wavelength 
depending on the substance being analysed. As the sample components emerge 
from the column the resulting signals are plotted in a chromatogram. The 
chromatogram is a record of the detector's response as a function of time and 
indicates the presence of the components as peaks. The eluted components are 
identified by their retention time (tr),  i.e. time taken for component to elute from 
the column. 
To achieve a separation, it is necessary to manipulate the experimental variables that 
hae the greatest influence on the equilibrium distribution: the composition of the 
mobile phase, the nature of the stationary phase and, less importantly, the 
temperature. The forces responsible for solute interactions between the two phases 
are those that explain solubility: electrostatic, dipole and dispersive (Van der Waals) 
forces. The mobile and stationary phases are usually chosen to have contrasting 
polarities. 
An explanation of some important terms is given below, and a variety of text-books 
are available. 21.25.26 
Capacity factor k' 
This is a measure of the retention of a compound on a column. It is measured in 
terms of the number of column void volumes (the total volume of the mobile phase 
in a packed column) it takes to elute the centre of the peak. 
k' also defines the distribution of a solute between two phases: 
amount of solute in the stationary phase 
k' = 
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The k' value is a relative retention measurement which can be calculated from 
experimental values. 
Selectivity 
Selectivity is the ability of the column to discriminate between two components. 
Column efficiency 
This is the measure of the broadening which a solute band experiences during its 
migration through the column. Generally the efficiency of HPLC columns increases 
as the particle size of the column decreases. 
Resolution 
This is the separation between two solute bands. It is defined in terms of the 
retention times and peak widths: 
R = 2(tR2 - tR/Wl + w,) 
The values of t and w can be measured in volume (ml), distance (cm), or time units 
(s). It has been shown 21  for column chromatography that the resolution (R) can be 
related to the capacity factor, selectivity, and efficiency. 
The main mode of HPLC used in this body of work is reverse-phase HPLC. 
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2.2 Experimental 
2.2.1 High Performance Liquid Chromatography 
The following equipment was used: A Hewlett-Packard Series 1100 Chemstation, 
HP 1100 series quaternary pumps, HP 1100 series vacuum degasser, HP variable 
wavelength D, lamp UV/Vis detector, HP enhanced integrator, Rheodyn sample 
injector with 25 - 100 il loops, Hamilton microlitre syringes. All water for HPLC 
was purified using a Millipore Elix 5 system, followed by an Elgastat U}IQ II 
deioniser, and filtered using PK50, 0.45, 47 mm nylon 66 membranes from 
Anachem. The data were analysed using HP chemstation for Windows '95. The 
column and mobile phase used was dependent on the system being studied and is 
noted in the relevant chapter. 
2.2.2 Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were recorded on Bruker DMX 500 MHz or Varian Inova 600 MHz 
spectrometers using 5 mm tubes. The 'H chemical shifts were internally referenced 
to either TSP (TSP = sodium 3-trimethylsilyipropionic acid) or dioxane (3.767 ppm 
to TSP). The ' 5N chemical shifts were externally referenced to 1 M 'NH4C1 in 1.5 M 
HC1, and the "P chemical shifts were externally referenced to 30 % H3PO4. Typical 
acquisition conditions for 'H NMR one-dimensional spectra were as follows: 45-60° 
pulses, 16-32 K data points, 2-3 second relaxation delay, and collection of 32-128 
transients. Water resonance was suppressed by presaturation. The two-dimensional 
gradient selected 'H, 'H-COSY and TOCSY (mixing time of 0.12 s) experiments 
were carried out using standard sequences. Data sets with 2048 x 512 points were 
acquired with frequency widths of 8000 Hz in both dimensions and 16 scans per t, 
increment. The t, dimension was zero-filled to 2048 data points, and the spectrum 
was processed with a combination of exponential and Gaussian weighting functions. 
The two-dimensional ['H-3 'P] HSQC spectra were recorded using standard sequence 
and the 31 P spins were decoupled by irradiation with the GAR-P-1 sequence during 
acquisition. 
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Some NMR spectra were also recorded at the NMR Service, University of 
Edinburgh. 
2.2.3 Electrospray Mass Spectrometry 
Negative and positive ion electrospray mass spectrometry was performed on a 
Platform II mass spectrometer (Micromass, Manchester, U.K.). The samples were 
infused at a flow rate of 0.48 ml h and the ions produced in an atmospheric pressure 
ionisation (API)/ESI ion source. The temperature was 363 K and the drying gas flow 
rate 300 L h'. The acquisition and deconvolution of were was performed with a 
Mass Lynx (V. 2.3) Windows NT PC data system using the Max Ent Electrospray 
software algorithm and calibrated versus a NaT calibration file. ESI-MS was used to 
detect the hydrolysed ruthenium complexes and its adducts with a 14mer 
deoxynucleotide DNA strand. 
2.2.4 X-Ray Crystallography 
X-ray crystal structure analyses were performed by Dr. Simon Parsons at the 
University of Edinburgh. 
2.2.5 Ultraviolet and Visible Spectroscopy 
Ultraviolet and visible spectra were obtained on a Perkin-Elmer ? 16 UV-Vis 
recording spectrophotometer using 1 cm path length quartz cuvettes. 	The 
temperature was controlled using a PTP1 Peltier Temperature Programmer. Spectra 
were normally referenced to solvent alone. Spectra were processed with UVWinlab 
for Windows '95. 
DNA melting-point UV-Vis spectra were recorded on a Perkin Elmer X 20 UV/Vis 
Spectrometer using a UV quartz cell with a path length of 10 mm. The temperature 
was controlled using a PTPI Peltier Temperature Programmer. The data were 
54 
Chapter 2 	 Materials and methods 
analysed using UV Winlab and PE Templab software for Windows '95 from Perkin 
Elmer. 
2.2.6 Inductively Coupled Plasma Mass Spectrometry 
ICP-MS investigations were performed using a PlasmaQuad 3 inductively coupled 
plasma mass spectrometer from VG Elemental (Winsford UK). The instrumental 
apparatus included a high efficiency interface (S-Option TM),  which improves 
sensitivity by increasing the efficiency of the extraction of ions in the plasma through 
to the mass spectrometer itself. 
2.2.7 CHN Analysis 
CHN analyses were performed by the CHN Service at the University of Edinburgh 
2.2.8 pH Measurements 
All pH measurements were made using a Corning 240 meter equipped with an 
Aldrich microcombination electrode calibrated with Aldrich buffer solutions pH 4, 7 
and 10. Meter readings from D20 were not corrected for deuterium isotope effects 
and are termed pH*. 
2.2.9 Lyophilisation 
All samples for lyophilisation were frozen in liquid nitrogen and lyophilisation 
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2.2.10 Centrifugation 
Centrifugation was carried out using a Sanyo MSE Microcentaur for small volumes 




When anhydrous solvent is specified, the solvent was dried in the manner described 
in Table 2.3. 
SOLVENT DRYING METHOD 
ethanol, methanol, propan-2-ol distilled over Mg/I, 
benzyl alcohol, ethylene glycol distilled over Na 
tert-butyl alcohol distilled over calcium hydride 
chloroform, dichioromethane, distilled over P,05 
acetone distilled over K,CO3 
acetonitrile pre-dried with K,CO3 followed by 
distillation over CaH, 
benzene, toluene distilled over P,05 
diethyl ether distilled over Na 
THF distilled from Na!benzophenone ketyl 
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2.3.2 Reagents 
The reagents used in this work, and their sources, are shown in Table 2.4. 
REAGENT COMPANY 
AgB F4, NH4PF6, isonicotinamide, 4-biphenylcarboxylic acid, 
1 ,4-cyclohexadiene, a-terpinene, NaBH41  
Acros 
LiAIH4, Li wire, Bz2NCH,CH,C1.HC1, H7NCH,CH2C1.HC1, 
Me,NCH,CH,CI.HC1, KOtBu, Ru ICP standard 
Aldrich 
benzoic acid, biphenyl BDH 
TEAA buffer Fluka 
RuC13.3H2O Johnson Matthey 
Bz(H)NCH-,CH20H, C6H11 (H)NCH.,CH2OH PCi5, Lancaster 
ethylenediamine Prolabo 
nuclease P1 Pharmacia Biotech 
9-ethylguanine,, 5'-AMP, 5'-CMP, 5'-GMP 5'-TMP, 
phosphodiesterase I (5'-VPD), phosphodiesterase II (3'-SPD) 
Sigma 
HPPh2 Strem 
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3.1 Introduction 
Aminophosphines are bidentate mixed donor ligands containing one soft phosphorus and 
one hard nitrogen donor. They can act as chelating or pendant ligands in metal 
complexes. 
There are many previous reports relating to the potential use of aminophosphine 
complexes, mainly with regard to catalysis.' 	However very few studies2 have 
investigated the biological activity of the complexes even though they contain cis amine 
ligands, a feature found in many active platinum anti-cancer agents3 and two cis 
phosphines. Anticancer activity in diphosphines such as 1 ,2-diphenylphosphinoethane 
complexes of Cu(I),4 Ag(I)5 and Au(I)5 has been detected. Monophosphine complexes of 
Au(I) have found use in the treatment of arthritis and auranofin, a PEt3 complex of gold, 
is in clinical use.' Aminophosphine complexes also possess lipophilic-cationic character 
and could possibly act by disrupting mitochondrial function.7 
With metals such as Ru(II), Pt(II) and Pd(II) the hard nitrogen atom would be expected to 
bind more weakly than the soft phosphorus, offering the possibility of chelate ring-
opening and the availability of extra coordination sites. This would be especially 
pronounced when the P is trans to N as the phosphorus exerts a high trans influence.' 
This could be particularly useful for the d6 Ru(II) as the octahedral geometry offers more 
potential reaction sites than the square-planar d8 Pt(II) and Pd(II). In addition, M-N bond 
strength is affected by steric factors to a greater extent than the corresponding M-P bond.' 
Thus, with the appropriate choice of nucleophiles and under a given set of conditions 
such as pH, [CL] and steric restrictions, equilibria involving the dissociation of the amino 
groups can occur resulting in ring-opened complexes with a potential binding site on the 
metal centre, thereby increasing its inherent biological or catalytic activity. A schematic 
for chelate ring-opening in a coordinating solvent is shown in Figure 3.1. 
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Figure 3.1 Schematic for chelate ring-opening of a bischelated ruthenium aminophosphine 
complex in a coordinating solvent 
It has recently been established that chelate ring-opening reactions of Pt(II) 
aminophosphine complexes with a two-carbon backbone can be controlled under 
conditions of biological relevance, and that they readily bind reversibly to the DNA base 
guanine.'° It was also shown that complexes of this type can bind rapidly and strongly to 
thymine, as well as the RNA base uracil, under physiological conditions, in contrast to 
platinum am(m)ine anti-cancer complexes." The three carbon backbone complex 
[PtC12(Me2N(CH2)3PPh2 - P)2] also gave interesting results. 12  In comparison to cisplatin, 
it was found to coordinate faster to DNA, induced conformational alterations in DNA that 
were distinctly different from cisplatin, and formed adducts with adenine more frequently 
than cisplatin. It was reported that both of the above complexes exhibited activity against 
tumour cells, including those resistant to cisplatin, and this suggests that the mechanism of 
action of Pt-aminophosphine complexes is different from that of cisplatin and related 
analogues. 
The catalytic activity of ruthenium aminophosphine complexes has been of interest. The 
idea of using chelating ligands for synthesising complexes for use in homogenous catalysis 
came about as platinum group metals with phosphines have been found to be good 
catalysts in a number of reactions.'3 Chelating multidentate phosphine based ligands 
provide better control over the coordination number and stereochemistry of the resulting 
complexes, increase basicity at the metal centres and slow down intra- and inter-
molecular exchange processes. 14  In particular, ruthenium complexes with chelating P-N 
ligands have been shown to form dihydrogen complexes. 15,16,17  [RuC12(PPh3)(DPBA)], 
where DPBA is bis(2-diphenylphosphino)ethyl)benzylamine, has shown in tests to have 
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where P-,N,C,H4 is N, N' -bis [o-(diphenylphosphino)benzyl] ethylenediamine has been 
reported to have excellent activity for the hydrogenation of acrylic acid to propionic 
acid.'9 
The interactions of ruthenium aminophosphine complexes with H-,S have invoked interest 
because of the involvement of H7S in the biological sulphur cycle, the formation of ores, 
hydrodesuiphurisation catalysis and as a source for H2 and elemental sulphur .2' The 
complex RuC1,(o-Ph7PC6H4NMe,)(P(p-tolyl)3)(SH,) has been isolated and fully 
characterised, which is unusual as the H,S was not oxidised, and low temperatures were 
not required for stability. 
Although some Ru-aminophosphine complexes have been synthesised previously'62 ' 
there are very few crystal structures in the literature. Ones that have appeared include the 
five coordinate complex dichloro(o-diphenylphosphino-N, N-dimethylani line)- [tris(p- 
tolyl)phosphine]ruthenium(II)' 6, 	 trans-dichloro-N, N '-bis [(o-(di- 
phenylphosphino)benzylidenejethylenediamine-ruthenium(iI) where the aminophosphine 
ligand is tetradentate22 and the dimeric structure of [Ru,C12(P-N)4], where P-N is 1-
(diphenyl-phosphino)-2-(2-pyridyl)ethane.23 A recent paper from this group24 reported 
the synthesis and characterisation of the Ru(II) complex cis, trans-
[Ru(Me,NCH,CH2PPh7-P,N)2C1,]. It was found that this complex underwent a two step 
reaction in methanol which involves chloride dissociation followed by P-N chelate ring-
opening. Chloride inhibited the solvolysis process, and chloride release appears to be 
necessary for the chelate ring-opening reaction, although it has been found in a Cp*Ru 
complex of an aminophosphine ligand that CO(g) caused the ring-opening reaction to 
occur. 35 
This chapter is concerned with the synthesis and crystal structures of some Ru(II) 
aminophosphine complexes using the ligands shown in Figure 3.2 and with their potential 
chelate ring-opening reactions. and hence their possible biological applications. 
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Figure 3.2 Schematics of the ligands used in this section for the synthesis of 
Ru(II)aminophosphine complexes. DHAP = dihydroaminophosphine, DMAP = 
dimethylaminophosphine, DPEBA = diphenylphosphinoethanebenzylamine. 
3.2 Experimental 
For materials and UV-Vis see Chapter 2 Materials and methods. 
The 'H and 3 'P {'H} NMR spectra were recorded at 298 K on Brüker DMX500 (1H 500 
MHz; 31P 202 MHz) and Varian-Inova 600 spectrometers ('H 600 MHz), using 5-mm 
NMR tubes. The chemical shift references were as follows: 1H, (internal, TSP), 31P 
(external, 30% H3PO4). The 2D Gradient-Selected 'H,'H-COSY and TOCSY (mixing 
time of 0.12 s) experiments were carried out using standard sequences. Data sets with 
2048 x 512 points were acquired with frequency widths of 8000 Hz in both dimensions 
and 16 scans per t1 increment. The t1 dimension was zero-filled to 2048 data points, and 
the spectrum was processed with a combination of exponential and Gaussian weighting 
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functions. The 2D [1  H,31 P] HSQC NMR spectra were recorded using standard sequence. 
The 31P-spins were decoupled by irradiation with the GARP-1 sequence during 
acquisition. 
Cyclic voltammetry experiments were carried out in CH3CN/[n-Bu4N][BF4] (0.4 M), with 
an Autolab PGSTAT20 potentiostat equipped with GPES 4.2 software. The working 
electrode was a platinum microdisc of diameter 0.5 mm and the potential reported is 
quoted relative to a Ag!AgC1 reference electrode via FeCp2/FeCp2 (0.375 V). 
3.2.1 Preparation of ligands 
3.2.1.1 Preparation of H2NCH2CH2PPh2 (DHAP) 
PPh,H (5 ml, 5.35 g, 28.76 mmol) was added via syringe under argon to a stirred 
suspension of ButOK (8.5 g, 76 mmol) in freshly dried THF (100 ml). This was stirred at 
ambient temperature for 40 min after which time H,NCH,CH7C1.HC1 (3.24 g, 28.17 
mmol) was added in one portion. The reaction was heated to reflux for 20 h during 
which time the deep red solution turned almost colourless. The solvent was removed in 
vacuo and the residue taken up in 10 % HC1 solution. The solution was washed with 
benzene and made alkaline with 10 % NaOH solution. The product was extracted into 
benzene (3 x 50 ml), washed with brine and dried over 
MgSO4. This was filtered and the solvent removed on the 
H2N 
rotary evaporator leaving a colourless oil. This was 	
/ 	
\ 
dissolved in ether and purified on a short column of 
alumina. 
Yield: 3.39 g, 14.8 mmol, 52.4 % 
'H NMR (CDC13): 6  1.51 (2 H, br, s, H,N), 2.26 (2 H, m, P-CH,), 2.86 (2 H, in, N-CH,), 
7.1-7.4 (10 H, m, 2 Ph) 
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31 P{'H} NMR (CDC13): -21.5 
3.2.1.2 Preparation of Me2NCH2CH2PPh2 (DMAP) 
This was prepared in an analogous procedure to that described Section 3.2.1.1, replacing 
ftNCHCH1C1.HC1 with Me2NCH2CH2C1.HC1 
Yield: 4.28 g, 16.4 mmol, 41.3 % 
'H NMR (CDCI3): 8 2.24 (6 H, s, N-CH,), 2.26-2.28 (2 H, m, P-CH2), 2.38-2.44 (2 H, in, 
N-CH.), 7.31-7.34, 7.36-7.48 (10 H, m, Ph) 
31 PI'H NMR (CDC13): 8 -19.07 






This was prepared by a procedure analogous to Section 3.2.1.1, 
replacing H2NCH2CH,CI.HC1 with H(Bz)NCH1CH,C1.HC1 and with a modification to the 
work-up. After the THF was removed in vacuo, 20 % HC1 solution was added, leaving a 
whitish precipitate. This was filtered, redissolved in CHC13 and filtered to remove any 
undissolved particles. The solvent was removed on a 
rotary evaporator to leave a white powder which was 
recrystallised from methanol/ether to give shiny white 
crystals. 
Yield: 5.31 g, 19.4 mmol, 84 % 
C,H24C1,NP (392.3) Calc. %C = 70.68 %H = 6.45 %N = 3.92 
Found %C=70.41 %H= 6.44 %N=4.14 
'H NMR (CDC13): 6 2.59 (m, 4 H)), 2.82 (s, br, 2 H), 7.24-7.62 (m) 
31P{'H} NMR(CDCI3): 6-20.33 
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3.2.2 Preparation of ruthenium complexes 
Cis- and trans-[RuC1,(DMSO)4],5° [(COD)RuCl21, 25 and [( 6-C6H6)Ru(CH3CN)2Cl][PF6] 
26  were synthesised according to the published procedures. 
3.2.2.1 Synthesis of trans, cis-[RuCl2(H(Bz)NCH2CH2PPh2-N, P)2] I 
cis-[RuC17(DMSO)4] (0.24 g, 0.5 mmol) was stirred in acetone (10 ml) and the ligand 
DPEBA (0.36 g, 1 mmol) added in one portion. This was sealed and the reaction stirred 
overnight at ambient temperature. Ether was added to induce precipitation of a pink solid 
which was collected and recrystallised from acetone/ether. 
Yield: 4 mg, 4.9 x iO mmol, 1 % 
C47H44C17N.,P,Ru (810.75) 	Calc. %C = 62.22 %H = 5.47 %N = 3.46 
Found %C=61.63 %H5.80 %N3.71 
3.2.2.2 Synthesis of trans, cis-[RuCl2(Me2NCH2CH2PPh2-N, P)2 ] 2 
The ligand DMAP (0.36 g, 1.4 mmol) dissolved in benzene (5 ml) was added to a stirred 
suspension of [Ru(COD)C1,] (0.39 g, 1.4 mmol) in benzene (10 ml). The reaction was 
refluxed for 24 h and filtered while hot to remove unreacted ruthenium starting material. 
The red filtrate was evaporated to dryness and recrystallised from toluene. 
Yield: 0.33 g, 0.48 mmol, 34.6 % 
C32H40C12N,P,Ru (686.57) 	Calc. %C = 55.98 %H = 5.87 %N = 4.08 
Found %C=55.53 %H=5.63 %N=3.92 
31P{ 'H} NMR (d8-toluene): 6 57 
3.2.2.3 Synthesis of trans, cis-[RuCl2(H2NCH2CH2PPh2-N, P)2 ] 3 
The ligand DHAP (1.15 g, 5 mmol) was added in one portion to a stirred suspension of 
[Ru(COD)Cl,] \ (0.7 g, 2.5 mmol) in benzene (40 ml) and the mixture refluxed under 
argon. After 4 h, a yellow precipitate had formed. This was collected after cooling and 
recrystallised from CH2C17/ether. 
Yield: 0.20 g, 0.32 mmol, 12.8 % 
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C28H32CI-,N-,P,Ru (630.53) 	Caic. %C = 53.34 %H = 5.12 %N = 4.44 
Found %C=53.95 %H=5.16 %N=3.07 
3 P{'H} NMR (d6-DMSO): 6 60.7 (d, J = 24.6 Hz), 45.7 (d, J = 24.6 Hz) 
3.2.2.4 Synthesis of trans, cis-[RuCl2(DMSO-S)2(H2NCH2CH2P(0)Ph2-N, 0)] 4 
Trans-[RuC1,(DMSQ)41 (0.06 g, 0.13 mmol) was set stirring in freshly dried ethanol (10 
ml). DHAP (0.03 g, 0.13 mmol) was added in one portion and the yellow solution stirred 
overnight. An orange precipitate formed during this time. This was collected and 
recrystallised from ethanol/ether. 
Yield: 6 mg, 9.5 x i0 mmol, 7.32 % 
3 P{'H} NMR (CDC13): 651.6(s) 
3.2.2.5 Synthesis of [( 6-C6H6)Ru(PPh2CH2CH2NMe2-N, P)CI][PF6] 5 
DMAP (0.077 g, 0.23 mmol) dissolved in dry acetonitrile (2 ml) was added in one 
portion to a solution of [( 6-C6H6)Ru(CH3CN)7Cl][PF6] (0.102 g, 0.23 mmol) in dry 
acetonitrile (8 ml). The mixture was stirred at ambient temperature for 10 h in a sealed 
flask with no special precautions to exclude air. The orange solution was evaporated to 
an orange oil which was taken up in 2 ml CHC13. Ether was added to induce precipitation 
and the orange solid was collected, washed with ether and recrystallised as the 0.5 
CH3CN solvate by slow diffusion of ether into an acetonitrile solution. 
Yield: 0.085 g, 0.13 mmol, 57.8 % 
C23H77 ClF5N, 5P2 Ru (637.43) 	Caic. %C = 43.30 %H = 4.35 %N = 3.29 
Found %C = 43.05 %H = 4.40 %N = 3.03 
'H NMR (CD3CN): 6 5.68 (d, 6H), 3.19 (s, 3H), 3.11 (s, 3H) 
31p{ 'H} NMR (CD3CN): 6 57.9 (s) 
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3.2.2.6 Reaction of complex 5 with carbon monoxide 
Complex 5 (0.064 g, 0.1 mmol) was dissolved in dry and degassed CH3CN (5 ml). CO(g) 
was bubbled through the solution for 15 mm, the flask sealed under positive pressure and 
the reaction stirred for 24 h. Ether (50 ml) was added and the precipitate was collected 
and dried in vacuo. 
3.3 Results and Discussion 
3.3.1 Preparation and properties of ligands 
The ligands were prepared by the method of Habtemariam.27 A number of methods have 
been reported in the literature for the preparation of aminophosphine ligands.' The 
method utilised here has the amino alcohol as the convenient starting material. A large 
number of aminoalcohols are available commercially or can be prepared from the 
reduction of amino acids .2' The chlorination of the amino alcohol, followed by the 
reaction with the diphenylphosphine anion which was formed in situ by the reaction of 
tert-potassium butoxide and diphenylphosphine in THF under argon, afforded the ligand. 
The ligands were obtained as viscous oils (DMAP and DHAP) or the hydrochloride salt 
(DPEBA). The oily ligands were easily purified by passing an ether solution through a 
short column of alumina or reduced-pressure distillation. The DPEBA was recrystallised 
from methanol/ether. 
The mixed donor ligands DMA-P, DHAP and DPEBA are soluble in almost all organic 
solvents. The 'H NIMR spectra of the ligands in CDC13 showed the expected peaks with 
the backbone -CR,- giving multiplets and the -NH7 a broad peak at ö 1.5 (DHAP). The 
31P{'H} NMR showed singlet resonances in the region of 6 -19 to -22. 
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3.3.2 Ruthenium(II) complexes 
The ruthenium(II) complexes 1-5 were prepared from four different starting materials. 
Cis-[RuC1,(DMSO)4] is a very versatile reagent that is known to provide a very good 
entry point to Ru(II) chemistry. A large number of Ru(II) complexes have been 
synthesised from it" including the chelate-ring opening aminophosphine complex 
[RuC1,(DMAP)2].24 The easily displaced DMSO ligands make possible the formation of 
Ru(II) chloride complexes with a variety of ligands. 
Trans-[RuCl2(DMSO)4] is easily obtained by light catalysed isomerisation from the cis 
form.5° Although not usually used for synthesis, it was hoped that this compound would 
facilitate the replacement of only two DMSO molecules by one aminophosphine ligand. 
Hence, a more water soluble complex may be formed. 
The third starting material utilised is [(COD)RuC12 ],(. This is a brown, reasonably 
insoluble material that is not very well characterised but assumed to be oligomeric. 
Initially this was used in the hope of making a Ru(II) complex with a coordinated COD 
ligand as well as an aminophosphine. However the COD proved to be too labile under 
the conditions used and the ligands were able to replace it. This proved to be a successful 
starting material, with complexes 3 and 4 being produced from it in low but workable 
yield. 
It was also decided to investigate the possibility of synthesising arene ruthenium 
aminophosphine complexes. 	The starting material utilised was 
C6H6)Ru(CH3CN)2Cl][PFJ and was prepared according to the published procedure .21  It is 
potentially a very useful entry point to Ru(II) arene complexes.3° 
3.3.2.1 trans, cis-[RuCl2(H(Bz)NCH2CH2PPh2-N, P)2] I 
The reaction of cis-[RuCl2(DMSO)4] with DPEBA as its hydrochloride salt in a 1:2 molar 
ratio, in acetone, gave rise to complex 1. The extremely low yield took the form of a few 
crystals which were suitable for X-ray analysis and the structure was solved. The 
remaining few crystals were used for elemental analysis. Although cis-[RuC12(DMSO)4] 
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is insoluble in acetone, the product should be soluble in acetone and therefore separable 
from starting material. Attempted preparation in CH2C12 (c. f. Guo et a124) resulted in an 
air-sensitive, uncharacteri sable reddish solid, and the initial crude material from the 
acetone reaction was similar. However, the attempt to recrystallise the crude product 
gave only ca. -4 mg of product. Repeated attempts to synthesise more of the compound 
all failed. 
3.3.2.1.1 X-ray crystal structure of complex I 
Single crystals of complex 1 suitable for X-ray analysis were grown from an 
acetone/ether mixture. Compound 1 crystallised in the space group P1 with two 
molecules in the unit cell. In the molecule the ruthenium is in the formal oxidation state 
of +2 and is situated in a distorted octahedral coordination environment with two Cl 
ligands in mutually trans positions and two chelated P-N ligands in cis positions. The 
structure can be seen in Figure 3.3. This arrangement seems to be sterically crowded, but 
is apparently preferred to that in which the two P atoms are mutually trans because of 
their strong trans effects! This is in agreement with the previously reported structure of 
trans, cis-[RuCI,(DMAP)2].24 There are no strong intermolecular interactions involved in 
the crystal packing. A summary of crystal data can be found in Table 3.1 and selected 
bond-lengths and angles are found in Table 3.2. 
The Ru-P (2.247(4) and 2.252(4) A) and Ru-Cl (2.401(4) and 2.410(4) A) bond lengths 
are within the range of values typical for Ru(II) complexes. 24,31 
It was found in trans, cis-[RuCl,(DMAP),] by Guo et a124 that the Ru-N bond lengths 
(mean = 2.391 A) were considerably longer (0.2 A) than values for P-N chelated Ru(II) 
complexes previously reported, for example, N trans to P in complexes such as trans-
dichloro-bis(diphenylphosphino)pyridineruthenium(II) (2.13 and 2.06 A),32 trans-
dichloro-N, N-bis- [o-(diphenylphosphino)benzylidene] (ethylenediamine)ruthenium(II) 
(2.17 	and 	2.16 	A)22 	and 	dichlorotetra(1-(diphenylphosphino)-2-(2- 
pyridyl)ethane)diruthenium(II) (2.152 and 2.157 A).33 This lengthening of the Ru-N 
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bond presumably results from the trans influence of the P and the steric effects of the 
methyl substituents on the nitrogen. This increased length indicates a weaker Ru-N bond 
which would be expected to facilitate chelate ring-opening under certain conditions, a 
major part of our rationale for investigating Ru(II) aminophosphines. However this effect 
is not seen for complex 1, despite the similar geometry and having the potentially more 
bulky benzyl group on the nitrogens. It is possible that having H as the second 
substituent on N allows sufficient space to reduce the steric effects. The benzyl groups 
point away from each other, much like a crab's claws reversed, thereby greatly reducing 
the steric hindrance. The crystal structures of Pd(II) and Pt(II) complexes with the same 
ligand (DPEBA) do not contain any metal-N bonds probably because the benzyl groups 
are too sterically crowding and prevent chelation in these square planar structures. 
The less than 180° bond angle for Cl-Ru-Cl (166.98(1 l)°) probably results from crowding 
caused by the phenyl substituents on phosphorus. This is less than was found by Guo et 
a124 for {RuCI7(DMAP)2] (172°). Having the benzyl group as a substituent means that the 
phenyl ring is one atom removed from nitrogen and hence there is more space for the 
chloride ligands and therefore the Cl-Ru-Cl angle is able to distort from 1800,  as opposed 
to cis, trans-[Ru(DMAP)7C1,]. Cl-Ru-Cl bond angles have been reported in the literature 
as 	low 	as 	165.4° 	for 	trans-dichloro-N,N-bis-[o- 
(diphenylphosphino)benzylidene] (ethyl enedi amine) ruthenium(II).22 
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3.3.2.1.2 Conclusions 
Complex 1 proved to be an elusive compound, and only a few crystals were obtained 
despite considerable synthetic effort. The X-ray structure was solved and the complex 
adopted the expected distorted octahedral geometry with two trans chlorides and two 
aminophosphine ligands chelating in a cis configuration. However, the structure did not 
show the hoped for elongated Ru-N bond length exhibited by cis, trans-
[Ru(DMAP)2Cl-,]24  and so no conclusions can be made at this stage as to the potentially 
hemilabile nature of the chelated ligand. The lack of water solubility of the complex 
potentially limits any biological uses. 
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Complex I Complex 3 Complex 4 Complex 5 
Empirical Formula C42 H44C17 N2 P2 Ru C25H32C12N2 P7Ru C1 8 H25C12NO3PRuS2 C23H27.5C1F6N1 PRu 
Formula weight 810.70 630.47 573.47 637.43 
Crystal habit orange block orange needle orange block orange block 
Crystal size / mm 0.19 x 0.16 x 0.12 0.20 x 0.06 x 0.06 0.45 x 0.27 x 0.19 0.45 x 0.45 x 0.45 
Crystal system triclinic triclinic monoclinic monoclinic 
Space group P-i P-I P2 1 /c P21 /c 
Volume / A 1890.8(18) 1375.5(2) 2344.4(8) 2501.2(12) 
Z 2 2 4 4 
Density (calc.) / mg m 1.424 1.522 1.625 1.693 
Absorption coefficient/mm 5.700 0.901 1.162 0.921 
F(000) 836 644 1168 1284 
0 range for data collection / deg 2.86 to 59.99 2.36 to 29.46 2.52 to 22.55 2.53 to 25.06 
Reflections collected 5825 10038 5895 4618 
Independent reflections - 5540 7321 3082 4414 
Conventional R (R ) 0.0764 0.0378 0.1200 0.0369 
Table 3.1 Summary of the crystal data for complexes 1, 3, 4 and 5 
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1 3 4 5 
Ru-P(1) 2.247(4) 2.2552(6) - 2.3122(11) 
Ru-P(2) 2.252(4) 2.2565(6) - - 
Ru-N(l) 2.212(11) 2.1642(19) 2.20(2) 2.212(3) 
Ru-N(2) 2.230(10) 2.1796(18) - - 
Ru-C1(1) 2.401(4) 2.4053(6) 2.400(7) 2.3986(11) 
Ru-C1(2) 2.410(4) 2.4192(6) 2.401(7) - 
Ru-U - - 2.18(2) - 
Ru-S(1) - - 2.200(7) - 
Ru-S(2) - - 2.250(5) - 
P(1)-Ru-P(2) 101.48(14) 102.80(2) - - 
N(l)-Ru-N(2) 93.1(4) 90.73(7) - - 
Cl(1)-Ru-C1(2) 166.98(11) 164.31(8) 170.6(2) - 
P(1)-Ru-N(1) 82.5(3) 82.99(5) 81.68(9) 
P(2)-Ru-N(2) 83.0(3) 83.51(5) - - 
N(1)-Ru-0(1) - - 94.4(6) - 
Table 3.2 Selected bond lengths (A) and angles (°) for complexes 1, 3, 4 and 5 
3.3.2.2 Trans, cis-[RuCl2(Me2NCH2CH2PPh2-N, P)j 2 
The 1:1 reaction of the ligand DMAP and [Ru(COD)Cl,] in refluxing benzene produced 
the complex trans, cis-[RuC12(Me2NCH7CH2PPh,-N, P),] 2. This was not the expected 
product. It was hoped that this product would contain one coordinated ligand and an 
coordinated cycloctadiene. However, under the conditions used, the COD ligand proved 
to be too labile and was displaced by two ligands. 
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Complex 2 is a known complex. Two papers within the space of a few months24'34 
reported on the synthesis, structure and chelate ring-opening of this complex. Presumably 
because of the reaction conditions and recrystallisation solvent used (toluene), complex 2 
had different solubility properties to the previous reports. Unlike the others, this version 
had a very low solubility in chlorinated solvents, and was actually slightly soluble in ether. 
It was on attempting to solve the X-ray crystal structure of the molecule that the true 
product was discovered. With the knowledge of what the structure was, the elemental 
analysis data fitted, and also, the NMR data corresponded to the literature complexes. On 
Figure 3.4 Structure of trans, cis-[RuC12(Me2NCH2CH2PPh2-N, P)2] 
complex 2 
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literature complexes. On dissolving in methanol, the solution became green with time, 
and a new singlet arose in the 31P NIMR spectrum at 6 = 33.9, corresponding to the ring-
opened species observed in the literature.24 Unfortunately, the crystals were of a very poor 
quality and contained a lot of disordered aromatic toluene. An initial structure was 
obtained, but the quality of the crystals was such that they were only sufficient to 
determine connectivity. The structure is shown in Figure 3.4. This procedure was not 
repeated to try and improve the quality of the crystals as the complex had little new to 
offer with regards ring-opening or obvious structural novelty, and if anything, was of 
more limited use due to the restricted solubility. 
3.3.2.3 trans, cis-[RuCl2(H2NCH2CH2PPh2-N, P)2 ] 3 
The reaction of [Ru(COD)Cl2] with DHAP in refluxing benzene in a 1:2 molar ratio 
resulted in the displacement of the COD ligand and the coordination of two DHAP 
ligands. This yellow compound analysed for [Ru(DHAP)7C12] by elemental analysis and 
X-ray crystallography. Complex 3 is only reasonably soluble in coordinating solvents 
such as DMSO and acetonitrile and sparingly soluble in alcohols. It is insoluble in other 
organic solvents and water. 
3.3.2.3.1 X-ray crystal structure of complex 3 
Crystals suitable for X-ray analysis were grown by the slow evaporation of an ethanolic 
solution. The complex crystallises in the space group P1 with two molecules in the unit 
cell. Like complexes 1 and 2, the Ru has the formal oxidation state of +2 and is situated 
in a distorted octahedral environment. The two chlorides are in trans positions and the 
aminophosphine ligands chelated in the cis positions. No strong intermolecular forces 
were found in the crystal packing. The structure is shown in Figure 3.5. A summary of 
the crystal data is given in Table 3.1, and selected bond-lengths and angles are given in 
Table 3.2. 
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The lack of steric hindrance from the N-H moieties in the structure is apparent from the 
Ru-N bond lengths of 2.1642(19) and 2.1796(18) A which are the shortest Ru-N bond 
lengths of the complexes 1, 3, 4, 5, {RuC12(DMAP)2],24  [Cp*Ru(DMAP)C1]3) and 
RuHBz(DMAP). The hydrogens allow the nitrogen to be positioned closer to the metal 
as compared to bulkier substituents such as a methyl or benzyl. The bite angle of the 
chelate rings is ca. 83°, indicating a tighter chelate ring than in the other complexes. 
Also, it can be seen from the N-Ru-N angle of 90.73(7)0,  compared with 93.1(4) 0  for 1 
and 94.6(3)° for trans, cis-[RuC1,(DMAP)2]24 that the nitrogens are closer together in the 
structure than in the other bischelated aminophosphine discussed. 
The Ru-Cl bond lengths (2.4053(6) and 2.4192(6) A) are typical for octahedral Ru(II) 
complexes. The Cl-Ru-Cl bond angle of 164.30 is very low, highly distorted from 
linearity. The lowest reported in the literature for an octahedral Ru(II) complex with 
trans chlorinde ligands is 165.40.22  The distortion is caused by the phenyl groups on the 
phosphine part of the ligand pushing the chlorides away from them. The extent of the 
distortion can again be attributed to having two hydrogens on the nitrogens as their low 
steric hindrance would allow the phenyl groups to push the chlorides further away from 
them. The phenyl rings of adjacent PPh,'s are almost perpendicular, thus minimising 
repulsion between them and allowing them to pack closely together. 
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3.3.2.3.2 Cyclic voltammetry of complex 3 in CH3CN 
The reduction potential (Ru(III)/Ru(II)) of ruthenium complexes could play an important 
role in their biological activity. It has been hypothesised that Ru(III) complexes may be 
prodrugs that are activated in vivo by reduction to Ru(II). Therefore, we looked at the 
electrochemistry of complex 3. Acetonitrile was used to provide good solubility and 
allow ease of handling at various temperatures. At one stage, the temperature was 
lowered to 227 K, which would not have been possible with DMSO. 
On analysis, at 298 K and 0.1 Vs' sweep rate, there were two weak peaks. When the 
sweep rate was increased to 1 Vs-' a clearer redox couple became visible, with a 
reversible oxidation at 0.82 V (versus Ag/AgC1) in CH3CN. The oxidised species 
appeared to be unstable in solution and very quickly changed into other species, which is 
why no peak was detected using a slow sweep rate. When the sample was cooled to 227 
K, this couple was even clearer. The redox process can tentatively be assigned to the 
metal centred Ru(II)/Ru(III) couple. The value of 0.82 V is much higher than the 
corresponding value for [RuC17(DMAP)2]24 which was observed at 0.326 V, and is likely 
to be too high to be of biological relevance. 
3.3.2.3.3 NMR analysis of chelate ring-opening of complex 3 
When dissolved in DMSO, 3 undergoes an instantaneous chelate ring-opening reaction. 
A fresh solution of 3 in DMSO-d6 was monitored by NMR. The ring-opening reaction 
appeared complete by the time that the spectrometer had been prepared and the spectrum 
acquired. A one ring-open, one ring-closed conformation is strongly suggested by the 
31P {'H} NMR spectrum. Two doublets are present, one at 8 60.7 and the other at 6 45.7. 
The J(P-P) coupling constant of 24.6 Hz is indicative of two cis phosphorus nuclei.36 The 
signal at 6 60.7 corresponds to the expected value for a chelated aminophosphine ligand 
bound through both P and N.24'37 If ring-opening of a chelated ligand occurs (Ru-N bond 
breaks) the 31P signal for the phosphorus of that ligand would be expected to shift to 
M. 
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higher field. This was observed for trans, cis-[RuC12(DMAP)] by Guo et a124 and also the 
chemical shift is similar to that observed for the ring-opened Pt(II) complexes of 
aminophosphine ligands coordinated via P only.1° This phenomenon has also been 
observed for the complex [Cp*Ru(DMAP)Cl],35  for which the 31P shift of the ring-closed 
form of the complex is 6 60.9 and the ring-opened form appears at higher field at 6 38.9. 
After one week it was noted that a third signal had arisen in the 3 P spectrum of 3 at 6 
51.4. This was a singlet, indicating equivalent phosphorus nuclei in the complex. 
However, even after two months this species never became dominant and a definite 
assignment was not possible. Of the possible structures it could have arisen from, free 
ligand could be ruled out as the chemical shift of the phosphorus in the free ligand is ca. - 
20 ppm. This leaves a Ru-complex with two equivalent ring-opened ligands due to the 
second ligand ring-opening, or a Ru complex with two equivalent chelated ligands, due to 
the open ring reclosing. No free ligand was detected at all, therefore complexes with only 
one ligand, due to loss of a DHAP can be ruled out. The spectrum in CD3CN is very 
similar. Thus 3 reacts with DMSO and CH3CN to give a complex with one chelated 
aminophosphine ligand and one pendant ligand coordinated only through the P. The H 
NMR spectrum showed a variety of peaks due to the two inequivalent ligands and 2D 
NMR techniques had to be employed for complete assignment. 
2D NMR spectroscopy of complex 3 in DMSO 
2D NMR spectroscopy was utilised in order to fully assign the NMR resonances 
observed. COSY, TOCSY and [31P-'H] HSQC experiments were performed, and from 
these spectra it was possible to distinguish between the pendant and chelate ligands. The 
[31 P-'H] HSQC spectrum is shown in Figure 3.6 and the COSY spectrum with selected 
assignments is shown in Figure 3.7, and full spectra are available in Appendix 1. Each 
experiment had its own piece of the jigsaw to offer, and then by combining all the 
information obtained from them the full picture could be seen. A table of assignments is 
given in Table 3.3. 
The [3 P, H] HSQC spectrum, Figure 3.6, allowed assignment of protons coupled to 
phosphorus, thereby showing at least some of the protons that were linked with either the 
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ring-opened or ring-closed ligand. The COSY spectrum is a ['H, 'H] 2D spectrum, and 
this allowed protons which are coupled to each other to be identified, and when combined 
with the HSQC spectrum assignments could be made for the ring-opened or ring-closed 
aminophosphine. Finally, the TOCSY experiment allowed the N-H protons to be 
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NH2 X H 




Ph2 X Ph2  
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6 31 
Figure 3.6 31P-'H HSQC spectrum of complex 3 in DMSO-d after 1 week. The ring- 
open ligand is shown in red and the chelated ligand in green. 
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NH2 X H 
I X, I N 
1uc p 
Ph 2 X 	Ph., 
9 
Figure 3.7 'H-'H COSY spectrum of complex 3 in DMSO-d6 after 1 week, with selected 
couplings traced. The ring-open ligand is shown in red and the chelated ligand in green. 
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The only piece of information lacking is the identity of the ligand coordinated at the 
vacant site after ring-opening, although as DMSO is the solvent, it is likely to be this. 
Coordinated DMSO could quite possibly be hidden under the free DMSO peak or the 
peak from water present as a trace impurity. Coupling information obtainable from the 
2D NMR spectra in this regard would not be expected due to the number of bonds that 
the coupling would have to pass through: 5 bonds to the nearest N-H proton, 6 bonds to 









Chelated ligand Td  phenyl ring of 
chelated ligand / 
Pendant ligand 
N-Hz 4.97 4.23 
N-H 4.71 4.23 
H1  3.13 2.89 
H1, 2.57 1.86 
H2 3.07 2.57 
H2. 2.95 1.97 
Ha, H2. 7.78 7.36 7.89 
Hb, Hb. 7.40 - 7.48 7.27 7.40 - 7.48 
Hc 7.4 - 7.48 6.75 7.40 - 7.48 
Table 3.3 Assignment of the H NMR spectrum of complex 3 in JJMSU-d6 tor the 
chelated and pendant (ring-opened) ligand. 
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It can be seen from the assignments that the phenyl rings of the chelated ligand are 
inequivalent. This can be attributed to the pendant ligand 'dangling" to one side, hence 
creating the difference in environment for the chelated ligand. The equivalence of the 
phenyl protons for the pendant aminophosphine is another argument for being ring-
opened as it would now be possible for the Ru-P bond to rotate easily as the rigidity of 
being chelated is lost, and hence the phenyl protons could be seen as equivalent. 
Alternatively, the inequivalence of the chelated ligand may arise from the DMSO that is 
coordinated at the vacated site. 
3.3.2.3.4 Conclusions 
Hence it has been shown that the ligands present in complex 3 exhibit a hemilabile 
nature, thereby exposing an available coordination site under certain conditions, in this 
case in a coordinating solvent. Although the solubility of complex 3 limits its direct use 
in biological systems, the findings here show the potential of this style of complexes for 
use in medicine. 
3.3.2.4 Trans, cis-[RuCl2(DMSO-S)2(H2NCH2CH2P(0)Ph2-N, 0)] 4 
The 	synthesis of trans, cis- [RuCl, (DM SO-S),(H2NCH, CH, P(0)Ph.,-N, 0)], 4, was 
unexpected. From a 1:1 molar ratio reaction of trans-[RuCl,(DMSO)4] with the 
aminophosphine ligand DHAP, complex 4 was formed in very low yield. The product is 
of a similar type to that expected, i.e. a Ru complex with one chelated ligand, two Cl 
ligands and two DMSO ligands. However the P(III) had been oxidised to P(V) at some 
stage to give the aminophosphine-oxide. The reaction was performed in air, so air 
oxidation during the reaction may have occured. However since the reaction was carried 
out in ethanol, a reducing solvent, this seems unlikely. On reanalysing the batch of 
ligand used for the reaction by 31P NMR, it was discovered that instead of just one peak in 
the spectrum for the free ligand (6 -21), an extra peak was present as a minor species at 6 
32.6. This corresponds well to a P=O resonance. Ph3P=O produces a resonance at 6 = 
3 1.0.38  Therefore, the ligand had become partially oxidised while being stored, and the 
ligand used for the reaction was actually a 4:1 mixture of DHAP and DHAP(0). It is this 
Me 
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minor species that gave the product. Therefore it was to be expected that the yield would 
be low. Ruthenium phosphine oxide complexes can be difficult to isolate due to the 
lability of phosphine oxides in solution, and they are sometimes formed only as 
intermediates," for example a Ru(II)terpy complex with (0)Ph2PCH7CH1PPh,(0) quickly 
loses the P=O in solution.38 
There is interest in catalytic systems which involve ruthenium with functionalised 
phosphine-oxide derivatives.40 Currently, aminophosphine-oxides are being considered 
for ruthenium assisted enantioselective transfer hydrogenation of ketones.4' These have 
been found to give high yields of product with up to 84 % enantiomeric excess, although 
no evidence of a Ru-O bond was found. Bisphosphine monoxide ligands are also being 
used in the development of chiral ruthenium Lewis acids.42 
The 31 P NMR spectrum of complex 4 in CDC13 shows a singlet at 51.6 ppm. The 31 P 
resonance is deshielded compared to the free ligand, consistent with disruption of the 
O=P it interaction by Ru-O bonding. Up to 48 h, no other peak arises in the spectrum, 
indicating that in this case the phosphine oxide remains bound to the metal. 
3.3.2.4.1 X-ray crystal structure of complex 4 
The product was obtained as single crystals suitable for X-ray analysis by diffusion of 
ether into an ethanol solution. The structure of 4 is shown in Figure 3.8. A summary of 
crystallographic data is given in Table 3.1, and important bond lengths and angles are 
given in Table 3.2. Compound 4 crystallised in the space group P21 /c with four 
molecules in the unit cell. The ruthenium is in the formal oxidation state of +2 and is 
situated in a distorted octahedral coordination environment. The P of the ligand is P(V), 
and the ligand forms a six-membered chelate ring, binding to the Ru through the 0 and 
the N in cis equatorial positions. The two chloride ligands are mutually trans in the axial 
positions and the two DMSO ligands fill the other two equatorial sites. Both DMSO 
molecules are coordinated through sulfur, and one is trans to N and the other is trans to 
0. Sulfur is a mildly it-accepting ligand, and it is reasonable to expect two it-accepting 
Chapter 3 	 Chelate-ring opening aminophosphine complexes of ruthenium 
ligands to be located orthogonal to each other.43  There are no strong intermolecular 
interactions in the crystal packing. 
The Ru-U bond length is 2.18(2) A, similar to those in the chelated phosphine-oxide 
traits- {RuC1, {o-C6H4(PMePh).,} {o-C6H4(PMePh)(P(U)MePh)} which has a Ru-U bond 
length of 2.166(5) A,44 the arene complex [( 6-p-cymene)RuCl( 2- 
Ph,PCh,P(0)Ph1)][SbF6] 	(Ru-U = 2.154(3) A),42 and the mixed-valent Ru(IJ1III) 
binuclear compound [Ru,(t-0,CC4H3S)4(UPPh3)2] (Ru-0(P) = 2.216(7) A.45  
The Ru-S bonds in the two DMSO ligands are significantly different to each other. The 
longest is the Ru-S trans to N, 2.250(5) A, a value reasonably typical of an S-bound 
DMSO trans to a nitrogen, and comparable with 2.229(1) A for [RuCI,(9-(2-
aminoethylamino)ethyl)adenineH)(DMSU)2]Cl.46 The Ru-S trans to oxygen, however, is 
quite short, 2.200(7) A, similar to that for [Ru(DMSU)(N}13)5]2 , 2.188(3) A.47 The 
shortness of the Ru-S bond in the amine complex is attributed by the authors to an M=S-
0 component, a conclusion which can be supported by the relatively long S-U bond 
length of 1.527(7) A. Complex 4, on the other hand, has a more typical S-U bonds of 
1.48(2) A, a feature found in S-bound DMSO molecules in [Ru"C13(DMSU)3] (1.48 A 
2 mean)45  and [Ru(DMSU)6] (1.482 i mean) .41  
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A more likely explanation for the shortness of the Ru-S bond in complex 4 is that an 
bound ligand (weak ic-acceptor) trans to an 0 (strong cT-donor) would experience little 
competition for the metal it-electrons, and so would be able to back-bond more strongly 
and hence shorten the bond length. The difference in the Ru-S bond lengths may be due 
to steric interactions between the phenyls on the phosphorus and the DMSO ligand which 
is inhibiting the approach of one of the DMSOs. 
Both Ru-S bonds in complex 4 are shorter than those in cis-[RuCl,(DMSO)4] (2.267 A 
mean), its isomer trans- [RuCl,(DMSO)4] (2.352 A mean)," and [Ru(DMS0)6]2 (2.259 A 
mean). This can be attributed to less It-accepting ligands being present in complex 4 to 
compete for the available ic-orbitals and 71-electron density on the metal. The geometry of 
the coordinated DMSO ligands is distorted tetrahedral, as would be expected. The 
greater distortion is in the DMSO trans to N. This is caused by the nearby phenyl rings. 
The Cl-Ru-Cl angle of 170.6(2)0 shows distortion from the true octahedral value of 1800.  
This distortion, however, is less than in the other aminophosphine complexes 1 and 3 
described in this chapter. This is due to the oxygen being the coordinating atom rather 
than the P, and so the phenyl rings are one atom displaced away from the metal as 
compared to complexes 1 and 3, and so the distorting effect will be less. Also, there is 
only one coordinated aminophosphine-oxide ligand, and so the complex is not as 
crowded. The Ru-N bond length (2.20(2) A) is in the expected range. 22.12.11 
3.3.2.4.2 Conclusions 
The synthesis of complex 4 was a serendipitous occurrence, caused by a small portion of 
the ligand having been oxidised by air while stored. While the yield was low, it was also 
significant that a stable phosphine-oxide has been isolated and the X-ray crystal structure 
solved. The reactivity and potential biological applications are unknown just now, but 
the complex looks promising from a point of view of solubility and the groups present. 
Ru(II) molecules with DMSO ligands are known to be active, and the phosphine oxide 
offers a new approach to drug design. 
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3.3.2.5 [( 6-C6 H6)Ru(DMAP-N, P)CI][PF6] 5 
The reaction of [(16-C6H6)Ru(CH3CN)2C1}[PF6] with DMAP in acetonitrile followed by 
work up produced red crystals of the complex [(q'-C6H6)Ru(DMAP-N, P)Cl][PF6] 5 in 
moderate yield. Complex 5 is soluble in alcohols and coordinating solvents such as 
DMSO and acetonitrile, but insoluble in water or mixed solvents containing an 
appreciable (>20 %) water. 
3.3.2.5.1 NMR spectroscopy of complex 5 
The H NMR spectrum in CD3CN shows a doublet for the ic-coordinated benzene ring 
centred at 6 5.68 (J = 0.9 Hz) due to coupling to the 31 P, implying that all the protons on 
the benzene ring are equivalent and hence there is free rotation of the it-coordinated 
benzene ligand. The NMe, groups of the ligand give rise to two separate singlet 
resonances at 6 3.11 and 6 3.19, indicating that the two methyl groups are inequivalent 
when the ligand is chelated. As the complex has a piano-stool style structure it is likely 
that the coordination of the N causes one methyl group to point more towards the benzene 
ring and one to point more away from it, causing inequivalence. The 31 P NMR spectrum 
shows a singlet at 6 58, appropriate for a ring-closed structure. The '3C{'H} NMR shows 
resonances at 6 125-135 for the P-Ph. carbons. The p6-coordinated benzene ring is a 
doublet, due to coupling to the 3 P, at 6 89.3 	= 2.95 Hz), indicative of Ru in the 
oxidation state 	The N-CH,- signal appears as a doublet centred at 6 60.5 (Jcp = 2.98 
Hz), and the P-CH,- resonance is a doublet centred at 6 25.6 (Jcp = 26.66 Hz). The two 
N-CH3 signals are singlets at 6 58.3 and 6 56.5. There was no change in the NMR 
spectrum after three days incubation at 300 K, so ring-opening of the chelate-ring in a 
coordinating solvent does not occur. 
3.3.2.5.2 X-ray crystal structure of complex 5 
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Crystals suitable for X-ray analysis were grown by diffusion of ether into an acetonitrile 
solution of 5. Complex 5 crystallised as the acetonitrile solvate in the space-group P21 /c 
with four molecules in the unit cell. In the molecule, the ruthenium is in the expected 
piano-stool type geometry typical for Ru(II) arene complexes. The structure can be seen 
in Figure 3.9. A summary of crystal data is presented in Table 3.1 and selected bond 
lengths and angles are in Table 3.2. There are no unusual intermolecular reactions in the 
unit cell. 
The structure of 5 can be compared to that of [Cp*Ru(DMAP)Cl].35  The Ru-P bond 
lengths are similar, 2.3122(11) A for 5, as compared to 2.289(1) A for the Cp*  complex. 
The Ru-N bond length, however, is quite different, despite the obvious similarities in the 
complexes. In 5 it is 2.212(3) A, significantly shorter than the value of 2.260(2) A for the 
Cp* complex. The Ru-Cl bond is also noticeably shorter (2.3986(11) A as opposed to 
2.441(1) A), but in the region of Ru-Cl bonds for half-sandwich complexes of Ru(II).5 ' 
The reason for this is probably a result of two factors, the steric restrictions imposed by 
the methyl groups on the Cp*,  and also the change in the overall charge on the complex 
from +1 to 0 as the Cp*  is an anionic ligand. The P-Ru-N angle of 81.68(9)° compares 
well with that of the Cp*  complex. 
When compared to complexes 1 and 4, 5 has the longest Ru-P bond, but this is to be 
expected since the phenyl rings on the P and the benzene ring would interact. The Ru-N 
and Ru-Cl bond lengths are similar. 
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3.3.2.5.3 UV/Vis spectroscopy of complex 5 
The UVIVis spectrum of 5 in DMSO undergoes a change with time, see Figure 3.10. The 
absorbtion band at 326 nm gradually decreases with time and the band at 300 nm 
increases concomitantly, with an isobestic point at 320 nm. By following the absorbance 
decrease at 326 nm with time, assuming a first order reaction and treating the data by the 
Guggenheim method 52  a first order rate-constant of 2.03 x iO s' was obtained. This 
change can be attributed to loss of the chloride, and presumably coordination of a DMSO 
molecule as the change is inhibited by the presence of 100 mM LiCI. 
3.3.2.5.4 Reaction of complex 5 with carbon monoxide 
In order to investigate the hemilability of the chelated aminophosphine ligand in 5, a 
reaction with CO(g) was performed. A similar compound, [Cp*Ru(DMAP)Cl] has 
been reported to ring-open (Ru-N bond breaks) when saturated and stirred with CO(g). 
The ring opens, and CO coordinates. 
As well as investigating the lability of the ligand, it is interesting from a biological point 
of view to investigate whether or not CO binds to the complex. CO has a similar size to 
02, and can bind irreversibly to haemoglobin and myoglobin. CO has also been linked to 
SID (Sudden Infant Death) syndrome," and epilepsy.54 It is also thought to play a role as 
a response mediator in the central nervous system" and as a cardiovascular modulator.56 
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Figure 3.10 a) UV/Vis spectrum of complex 5 in DMSO over a period of 12 h b) plot of 
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After isolation and drying, the product of the reaction was investigated by JR and NMR 
spectroscopy. The JR spectrum (KBr disc) showed no peak appropriate to CO bound to a 
metal. A shift to lower energy compared to free C057 (2143 cm) would have been 
expected, if coordinated, due to a lowering of the C-O bond order. This is because CO is 
a 7r-acceptor ligand, and accepts electron density back into the m orbital of the C-O bond. 
The 'H NMR spectrum of the product in CD3CN showed no difference to the starting 
material. Tellingly, the methyl groups (-N(CH3)2) are still present as two singlets. If the 
chelate ring had opened via Ru-N bond breakage, we would expect to see the pendant 
methyl groups as equivalent, and hence a singlet. The '3C NMR spectrum shows no peak 
appropriate for CO. All peaks in the spectrum correspond to the original complex 5. The 
1'P NMR shows a single resonance at 8 57.9, the same value as complex 5, and 
appropriate for a ring-closed complex. Hence, we can say that complex 5 does not ring-
open in the presence of CO, and does not react it with it at all. 
3.3.2.5.5 Conclusions 
Complex S is a Ru(arene) aminophosphine complex which exhibits the typical piano-
stool type geometry. It is insoluble in water and water mixed with other solvents and 
although there is evidence of loss of the chloride ligand, none could be found to back up 
the hypothesis of chelate ring-opening. Hence, this complex does not appear to have 
much biological potential. 
3.4 Conclusions 
A range of Ru(JI)aminophosphine complexes have been synthesised in this chapter. 
These complexes were generally difficult to synthesise and the result was low yields for 
complexes 1 and 4. However, the crystal structures of all compounds were obtained, so 
the structures of them all could be unambiguously confirmed. Complex 3 was shown to 
undergo a ring-opening reaction in coordinating solvents, thereby exposing a 
coordination site at the metal. This was the rationale behind developing these style of 
complexes. It is hoped that under certain biological conditions the complexes would 
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ring-open. Unfortunately, these complexes are also insoluble in water, but if the 
synthesis of water soluble ruthenium aminophosphine complexes was developed, there is 
no reason at present why these complexes shouldn't become important biological agents. 
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4.1 Introduction 
Metal arene 7c-complexes are of considerable interest for their potential roles in 
homogenous catalysis, for example in olefin hydrogenation' and ring-opening 
polymerisation reactions,' and now, as a result of the work contained in this thesis, in 
their prospective use as anti-cancer agents. 
The first report of 7t-C6H6RuC1, was in 1967 by Winkhaus and Singer.' They presumed 
that this was a polymeric material and postulated a bidentate benzene ring, an unusual 
mode of binding for Ru(II), but well known at the time for silver(I) complexes.' It was 
analogous to the structure which had been proposed for [RuCl7(diene)]21  where diene is 
norboradiene or cyclooctadiene.5 The oxidation state of +2 was relatively high, and 
therefore interesting as most work with arene complexes up until then had been with 
zerovalent metals.6 
The synthesis of this 7t-C6H6RuC11 was taken further and developed by two independent 
groups, Bennett et a17 and Zelonka et al,' at around the same time. Both syntheses are 
based on the reaction of RuCl3 and 1, 3-cyclohexadiene in ethanol, with Zelonka et al 
claiming a wider solubility of their compound as a result of performing the reaction in 
aqueous ethanol. The complex is now formulated as being dimeric. 
It was quickly realised that monomeric Ru(II)-arene complexes could be formed by 
breaking the dimeric structure and addition of a variety of ligands such as PEt3 or 
P(OEt3).8 These syntheses have formed the foundation-stone for a large range of work as 
they act as excellent synthetic precursors and an easy entry point to arene chemistry of 
both Ru(II) and Ru(0)9. 
The complex [(p-cymene)RuC1,]2 (p-cymene = para-isopropyl toluene) was also readily 
synthesised in high yields by this method using a-terpinene as the arene precursor 
instead of the cyclohexadiene. This is frequently the reagent of choice in preference to 
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the benzene complex due to its improved solubility in organic solvents. These two 
complexes (the benzene and p-cymene) also offer a limited route to other arene 
complexes via arene substitution reactions. Possible replacements include toluene, 
ethylbenzene, cumene and o, m and p-xylene.7 p-Cymene is the most easily replaced yet 
there is no significant difference in bond length between the two.'° However, arenes 
having electron withdrawing substituents such as Cl, F or CO2Et failed completely to 
replace a coordinated arene and so an alternative method of synthesis is required to 
introduce variety on the arene ring. 
Ru(arene) complexes were attractive to us for a number of reasons. They are known to 
keep the metal in the oxidation state of 2+. This is an advantage as it is unknown which 
is the active form of ruthenium complexes in vivo. In fact, Ru(III) complexes have been 
postulated as prodrugs, being reduced in the hypoxic environment of a tumour to 
Ru(ll)." 32  The arene ring gives the complex a lipophilic centre. This could be very 
important for transporting the metal across the cell membrane. It is also known that the 
( flbC6H6)Ru(II) bonds resist hydrolysis and are indefinitely stable, at least in the dark, at 
ordinary acidities, even in water. 12  This style of complex also has potential for variety in 
two distinct areas, the 7t-arene ring and also the ligands that provide the "legs" to the 
piano-stool shape. 
Introducing variety on the arene ring allows investigation of structure activity 
relationships for the arene complexes. If a range of similar complexes is to be tested for 
anticancer activity, it is of interest to discover which parts of the molecule are important. 
What effect will changing the arene ring from benzene to p-cymerle, ester or biphenyl 
have? Does changing the halide have any influence, as these complexes are likely to 
find their reactive site upon loss of the halide? And how important is the ancillary 
ligand (en)? In this chapter a range of complexes are synthesised in order to investigate 
this. The arene ligand is varied from benzene to p-cymene, alkylbenzoate and biphenyl. 
The halide is changed from chioro to bromo and iodo and the ancillary ligand ranges 
from acetonitrile to isonicotinamide and ethyl enediamine. 
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All the complexes synthesised in this chapter have good water solubility. Even though 
the arene ring is lipophilic, the ancillary ligands and the fact that the complexes are 
generally charged give them their water solubility, up to 40 mM. 
4.2 Experimental 
[(116-C6H6)RuC1,12 and [( 6-p-cymene)RuC1212 were prepared according to the literature 
procedures.' [(r-C6H6)RuCl(CH3CN)2][PF6], complex 7, was synthesised by the 
published method.'3 
4.2.1 Preparation of [( 8-p-cymene)RuCl2(isonicotinamide)] complex 6 
[('r 6-p-cymene)RuC11]2  (0.129 g, 0.21 mmol) was stirred in benzene (50 ml), and 
isonicotinamide (0.052 g, 0.43 mmol) was added in one portion. The mixture was 
heated to reflux under argon for 4 h during which time a mustard coloured precipitate 
had formed. This was collected, washed with a little benzene and recrystallised from 
methanol/ether to give a red crystalline material. 
Yield: 0.061 g, 0.14 mmol, 33.8 % 
C16 H 0Cl2 N7ORu (428.30) 	Gale. %C = 44.87 %H = 4.71 %N = 6.54 
Found %C = 44.65 %H = 4.54 %N = 6.23 
4.2.2 Preparation of [( 6-C6H6)RuBr2]2 
[(floC6H6)RuCl2]2 (1 g, 1.99 mmol) was dissolved in the minimum amount of hot water 
and filtered. Solid KBr (8.75 g, 70 mmol) was added in one portion and the mixture 
shaken for five minutes. After leaving to stand at ambient temperature overnight, the 
dark-red precipitate was collected, washed with a little cold water and dried in vacuo. 
Yield: 0.583 g, 0.86 mmol, 86 % 
C12 H,2Br4Ru, (677.97) 	Gale. %C = 21.26 %H = 1.78 
Found %C=21.03 %H= 1.93 
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NMR (DMSO-d6) 	8 'H 5.92 (s) 
4.2.3 Preparation of ((16-C6H6)RuBr(CH3CN)2][PF6] complex 8 
This was prepared in a manner analogous to the literature procedure.'3 	[(ri6- 
C6H6)RuBr212 (0.4 g, 0.59 mmol) was suspended in dry acetonitrile (50 ml). N}14PF6 (0.2 
g, 1.23 mmol) in dry acetonitrile (2 ml) was added in one portion and the mixture stirred 
at ambient temperature. After I h, the pale precipitate was filtered off and the 
remaining red solution evaporated leaving a brownish solid. Hot acetonitrile (2 ml) was 
added and the brown supernatant liquid removed leaving a clean orange solid. This was 
dissolved in hot acetonitrile and ether was added to precipitate an orange-gold 
microcrystalline solid which was collected, washed with ether and dried in vacuo. 
Yield: 0.29 g, 0.59 mmol, 50 % 
C,0H,BrF6N,PRu (486.18) Calc. %C = 24.70 %H = 2.49 %N = 5.76 
Found %C-=24.52 %H=2.41 %N=5.48 
NMR (CD3CN) 	 8 'H 5.97 (s) 
4.2.4 Preparation of [( 6-p-cymene)RuCl(CH3CN)2][PF6]1  complex 9 
This was prepared in a manner analogous to that described in the literature.'3 reagents 
and quantities used: NH4PF6 (0.18 g, 1.10 mmol), [( 6-p-cymene)RuCl.,]., (0.31 g, 0.51 
mmol), dry acetonitrile (30 ml). Recrystallised as bright orange crystals from ether 
diffusion into an acetonitrile solution. 
Yield: 0.28 g, 0.56 mmol, 54.9 % 
C14H70C1F6N,PRu (497.82) CaIc. %C = 33.78 %H = 4.05 %N = 5.62 
Found %C=33.80 %H3.91 %N=5.53 
NMR (CD3CN) 	 ö 'H 5.35 (m, 2H), 5.28 (m, 2H) 1.23 (s, 6 H) 
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4.2.5 Preparation of [(16-p-cymene)RuBr2]2 
The procedure was described in Section 4.2.2. using fti 6-p-cymene)RuCl2]2  (0.3 g, 0.48 
mmol), KBr (12 g, 10 mmol) 
Yield: 0.37 g, 0.47 mmol, 97.9 % 
C20H,8Br4Ru-, (790.18) 	Caic. %C = 30.40 %H = 3.57 
Found %C=31.05 %H=3.78 
NMR (DMSO-d6) 	8'H 5.42 (m, 211) 5.32 (m, 2H) 2.87 (m, 1H) 2.13 (s 3H), 
1.24 (d, 6H) 
4.2.6 Preparation of [(r16-p-cymene)RuBr(CH3CN)2][PF6], complex 10 
Procedure analogous to literature. 13  [( 6-p-cymene)RuBr,]2 (0.24 g, 0.3 mmol), NH4PF, 
(0.12 g, 0.74 mmol), 12 ml dry acetonitrile. 	Final product recrystallised from 
acetonitrile/ether as deep red crystals. 
Yield: 0.28 g, 0.52 mmol, 86.7 % 
C14H20BrFN-,PRu (542.27) Caic. %C = 31.01 %H = 3.72 %N = 5.16 
Found %C=31.22 %H3.75 %N5.09 
NMR (CD3CN) 	 8'H 5.44 (m, 2H) 5.36 (m, 2H) 1.26 (s, 6H) 
4.2.7 Preparation of [( 6-C6H6)Rul2]2 
[( 6-CH6)RuC1,]2 (1 g, 1.99 mmol) was dissolved in the minimum amount of hot water 
and filtered. Solid KJ (8 g, 50 mmol) was added in one portion. A fine red precipitate 
formed within one minute of addition. This was collected, washed with a little water and 
dried in vacuo. 
Yield: 0.95 g, 1.10 mmol, 55.3 % 
C12H,2I4Ru-, (865.97) 	Caic. %C = 16.64 %H = 1.40 
Found %C= 16.12 %H= 1.25 
NMR (DMSO-d5) 	6 'H 5.83 (s) 
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4.2.8 Preparation of [(16-C6H5)RuCI(H2NCH2CH2NH2-N, N)](PF 6], complex 11 
The synthesis is based on a published procedure. 14  [(16-C6H6)RuCI,12 (0.167 g, 0.33 
mmol) was suspended in dry methanol (50 ml) and ethylenediamine (0.06 g, 1 mmol) 
added in one portion. This was stirred for 3 h, filtered and NH4PF6 (0.5 g, 3.07 mmol) 
added. The volume was slowly reduced to approx. 15 ml on the rotary evaporator. The 
product formed as a microcrystalline solid on leaving to stand at 277 K. This was 
collected, washed with ether and recrystallised from methanol/ether. 
Yield: 0.128 g, 0.31 mmol, 47.0 % 
C8H14 C1F6N,PRu (419.69) Caic. %C = 22.89 %H = 3.36 %N = 6.67 
Found %C=22.81 %H=3.24 %N=6.51 
NMR (DMSO-d6) 	6 'H 6.45 (b, 2H), 5.86 (s, 6H), 4.28 (b, 2H), 2.34(m, 2H), 
2.17(m, 2H) 
4.2.9 Preparation of [(r 6-C6H6)Rul(H2NCH2CH2NH2-N, N)][PF 6], complex 12 
The procedure was as described in Section 4.2.8. using [(16-C6H6)RuI,]2 (0.48 g, 0.55 
mmol), dry methanol (80 ml), ethylenediamine (0.12 g, 2 mmol), NH4PF6 (0.5 g, 3.07 
mmol) 
Yield: 0.41 g, 0.81 mmol, 73.3 % 
C3H,4IF5N2PRu (511.14) 	CaIc. %C= 18.80 %H=2.76 %N=5.48 
Found %C= 18.52 %H=2.43 %N5.14 
NMR (DMSO-d6) 	6 'H 6.42 (b, 2H), 5.86 (s, 6H), 4.22 (b, 2H), 2.35(m, 2H), 
2.15 (m, 2H) 
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4.2.10 Preparation 	of 	((16-p-cymene)RuCI(H2NCH2CH2NH2-N,N)][PF 6]1  
complex 13 
The procedure was as described in Section 4.2.8. using [( 6-p-cymene)RuCl,]2  (0.39 g, 
0.64 mmol) was stirred in methanol (60 ml) and ethylenediamine (0.12 g, 2.00 mmol) 
added in one portion. The reaction was stirred for 1.5 h and the green liquid filtered. 
NH4PF6 (0.52 g, 3.2 mmol) was added to the yellow filtrate and the volume reduced to 
15 ml. This was left to stand at 277 K for 6 h during which time orange crystals formed. 
These were collected, washed with a little cold methanol followed by ether and dried in 
vacuo. 
Yield 0.23 g, 0.48 mmol, 37.7 % 
C12 H22C1F6N,PRu (475.81) Caic. %C = 30.29 %H = 4.66 %N = 5.88 
Found %C = 30.05 %H = 4.41 %N = 5.98 
NIVIR (DMSO-d6) 	 VH 6.13(b, 2H), 5.48 (d, 2H), 5.32 (d, 2H), 4.22 (b, 2H), 
2.71 (m, IH), 2.43 (m, 2H), 2.32 (m, 2H), 2.11 (s, 3H), 
1.25 (d, 6H) 
4.2.11 Preparation of [( 6-p-cymene)RuI2]2 
The procedure was as described in Section 4.2.2. using [( 6-p-cymene)RuCl2], (0.44 g, 
0.72 mmol), KI (0.92 -,,5.54 mmol). 
Yield: 0.68 g, 0.70 mmol, 97.2 % 
C 0H,814Ru, (978.18) 	Calc. %C = 24.56 %H = 2.89 
Found %C=23.94 %H=2.62 
NMR (DMSO-d6) 	5 'H 5.43 (d, 211), 5.33 (d, 2H), 2.74 (m, IH), 2.1 l(s, 3H), 
1.34 (d, 6H) 
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4.2.12 Preparation of [(116-p-cymene)Rul(H2NCH2CH2NH2-N,N)][1], complex 
14 
The procedure was as described in Section 4.2.8. [( 6-p-cymene)RuI,]2 (0.34 g, 0.348 
mmol), ethylenediamine (0.06 g, immol), N}14PF6 (0.52 g, 3.2 mmol). The volume was 
reduced to 15 ml and left to stand at 277 K overnight. The red crystals which formed 
were collected and washed with a little cold methanol, followed by ether, and dried in 
vacuo. 
Yield: 0.24 g, 0.44 mmol, 63.2% 
C12 H,,17N,Ru (549.16) 	Calc. %C = 26.25 %H = 4.04 %N = 5.10 
Found %C=26.l1 %H=3.88 %N=4.93 
NMR (DMSO-d6) 
	
6 'H 6.15 (b, 2H), 5.51 (d, 2H), 5.35 (d, 2H), 4.24 (b, 2H), 
2.69 (m, IH), 2.37 (m, 2H), 2.29 (m, 2H), 2.08 (s, 3H), 
1.33 (d, 6H) 
4.2.13 Preparation 	of 	[(r 6-p-cymene)Ru(en)(9-ethyIguanine)][PF6]21  
complex 15 
[( 6-p-cymene)Ru(en)Cl][PFJ 13 (0.057 g, 0.12 mmol) was dissolved in degassed 
aqueous ethanol (70:30, EtOH:H.,O) (20 ml). 9-Ethylguanine (0.025 g, 0.14 mmol) was 
dissolved in degassed aq. ethanol (5 ml) and added in one portion. The reaction was 
sealed and stirred at ambient temperature for 15 h. The solvent was removed in vacuo 
leaving a yellow residue. The residue was taken up in H20 and loaded on to a short 
column of CM25 Sephadex cation exchange resin. The column was first eluted with 
0.05 M NaCl solution to remove any unreacted 9-egua. The yellow band which eluted 
with 0.2M NaCl solution was collected and freeze dried. The resulting solid was taken 
up in ethanol and filtered to remove NaCl. NH4PF6 (0.1 g, 0.61 mmol) was added and 
the solution left to stand for 3 h at 277 K. A yellow microcrystalline material formed 
which was collected, washed with a little ethanol followed by ether and dried in vacuo. 
Yield: 15 mg, 0.02 mmol, 16.7 % 
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C,9H31 F,2N70P7Ru (619.62) Caic. %C = 36.83 %H = 5.04 %N = 15.82 
Found %C = 36.54 %H = 4.83 %N = 15.46 
NMR (D20) 	 S 'H 8.22 (s, 1H), 6.00 (b, 2H), 5.72 (d, 2H), 5.59 (d, 2H), 
4.09 (q, 2H), 2.49 (m, 1H), 2.41 (m, 4H), 2.01(b, 2H), 1.95 
(s, 3H), 1.41 (s, 3H), 1.09 (d, 6H) 
4.2.14 Preparation of 1,4-dihydrobenzoic acid15 
Benzoic acid (15.5 g, 0.13 mmol) was added to dry ethanol (100 ml) in a I I flask 
equipped with a mechanical stirrer, Dewar condenser and cooling bath (dry ice/acetone). 
NI-I3 (600 ml) was condensed into the flask and Na metal (8.3 g, 0.36 mmol) added in 
small pieces over a period of 30 mm. When the final blue colour was discharged the 
mixture was left to stir for 20 min after which time solid NH4CI (20 g, 0.22 mol) was 
carefully added. The cooling bath was removed and the NH3 allowed to evaporate with 
stirring, leaving a white residue. The residue was taken up in chilled H2 O (500 ml) and 
acidified to pH-3 by addition of 10% HC1. This was extracted with ether (4 x 200 ml) 
and the combined ether layers washed with saturated NaCI solution (1 x 100 ml) and 
dried over MgSO3. The ether was removed on a rotary evaporator leaving a crude oil 
which was distilled under reduced pressure giving a clear oil. 
Yield: 13.56 g, 109 mmol, 90.8 % 
NMR (CDCl) 	 S 'H 11.0 (br, IH), 5.9 (m, 4H), 3.8 (m, lH), 2.8 (m, 2H) 
IR (neat, NaCl plates, cm') 3100-2500 (br), 1702 (st), 1640 (mcd) 
4.2.15 Preparation of 3-methoxycarbonylcyclohexa-1, 4-diene 
Conc. H2SO4 (1 ml) was added to a solution of 1,4-dihydrobenzoic acid (3g, 23.97 
mmol) in freshly dried methanol (10 ml). The reaction was heated to reflux in air for 1 
h, cooled, poured in to H20 (25 ml) and extracted with ether (3 x 50 ml). The combined 
ether layers were washed with 5% Na[HCO3] solution (50 ml) and saturated NaCl 
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solution (50 ml) and dried over MgSO4. The ether was removed on the rotary evaporator 
to leave a colourless oil which was used without further purification. 
Yield: 2.60 g, 18.8 mmol, 42.8 % 
NMR (CDCI3) 	 6 'H 5.93 (m, 4H), 3.82 (m, 1H), 3.55 (s, 3H), 2.64 
(m, 2H) 
IR (neat, NaCI plates, cm1) 3038-2821 (many sharp signals), 1743.7 (st), 1639.9 (med) 
4.2.16 Preparation of [(r16-C6H5CO2CH3)RUCI2]2 
3-Methoxycarbonylcyclohexa-1,4-diene (2.6 g, 18.8 mmol) was added to a filtered 
solution of RuCI3.3H2O (1 g, 3.8 mmol) in methanol (50 ml). The reaction was heated to 
reflux under argon for 8 h. The reaction was cooled, filtered and the volume reduced to 
20 ml. After standing for 12 h at 277 K the precipitate was collected, washed with a 
little methanol followed by ether and dried in vacuo. 
Yield = 1.08 g, 1.75 mmol, 93.1 % 
C,6H,6Cl4O4Ru., (616.24) 	CaIc. %C = 31.18 %H = 2, 62 
Found %C=31.05 %H=2.39 
NTVIR (DMSO-d6) 	6 'H 6.72 (d, 2H), 6.31 (t, 1H), 6.04 (m, 2H), 3.92 (s, 3H) 
4.2.17 Preparation of [( 6 -C6 H 5CO2CH3)RuCI(H2NCH2CH2NH2-N, N)][PF6], 
complex 16 
Ethylenediamine (0.09 g, 1.5 mmol) was added to a stirred suspension of [(1e-
Cf,H5CO3CH3)RuC12]2  (0.355 g, 0.576 mmol) in methanol (200 ml). After 4 h, the 
orange solution was filtered and the volume reduced to 20 ml. NH4PF,, (0.49 g, 2.3 
mmol) was added and the mixture stirred for a further minute. The sealed flask was left 
to stand overnight at 277 K. The precipitated yellow microcrystalline solid was 
collected, washed with a little methanol followed by ether and dried in vacuo. 
Yield 0.22 g, 0.46 mmol, 40.0 % 
C,0H,6C1N20,PF6Ru (477.75) Calc. %C = 25.14 %H = 3.38 %N = 5.86 
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Found %C25.18 %H3.12 %N= 5.50 
NMR (DMSO-d6) 	 8 111 6.70 (b, 2H), 6.39 (d, 2H), 6.10 (t, IH), 
5.68 (m, 2H), 4.32 (b, 2H), 3.28 (s, 3H), 2.22 
(m, 2H), 2.15 (m, 2H) 
4.2.18 Reaction of [( 6-C6H5CO2CH3)Ru(en)Cl][PF6] with 9-ethylguanine in 
aqueous ethanol 
[(fl'-C(,H5CO3CH3)Ru(en)C1][PF6] 16 (0.1 g, 0.24 mmol) and 9-ethylguanine (0.05 g, 
0.28 mmol ) were mixed in degassed aq. ethanol (70:30, EtOH:H-,O) (25 ml) and stirred 
at 323 K in a sealed flask for 72 h. The solvent was removed in vacuo, the residue taken 
up in HO and loaded on a short column of Sephadex CM25 cation exchange resin. A 
light green band was eluted with 0.05 M NaCl. This was freeze-dried, the residue taken 
up in ethanol and filtered free of NaCl. After addition of N}I4PF yellow crystals 
appeared which analysed for unreacted ruthenium starting complex by NMR and 
elemental analysis. A blue band was also present on the column but was unretrievable. 
4.2.19 Preparation of 1, 4-dihydrobiphenyl16 
A solution of biphenyl (10 g, 65 mmol) in freshly dried THF (200 ml) was added to NT-I3 
(400 ml) which had been condensed under argon into a 11 flask equipped with a Dewar 
condenser, cooling bath (dry-ice/acetone) and mechanical stirrer. Li wire (1.125 g, 162 
mmol) was added in small pieces over a period of 15 mm. After a further 15 mm 
stirring, solid NH4CI (15 g, 280 mmol) was added and the dark red colour discharged. 
The reaction was stirred at 213 K for 10 mm, then the cooling bath was removed and the 
NH3 allowed to evaporate under argon flow with stirring. The remaining residue was 
taken up in H20 (200 ml) and acidified to pH---3 with 10 % HCI. This was extracted with 
ether (4 x 150 ml) and the combined ether layers washed with saturated NaCl solution (1 
x 150 ml) and dried over MgSO4. The ether was removed on the rotary evaporator and 
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the remaining oil distilled under reduced pressure (319 K, 0.2 mmHg) to give a clear oil 
which was used without further purification. 
Yield: 6.45 g, 41.26 mmol, 63.5 % 
4.2.20 Preparation of [( 6-C6H5C6H5)RuCl2]2 
RuC13.3H10 (2.28 g, 8.70 mmol) was dissolved in dry ethanol (25 ml)and filtered. 1,4-
Dihydrobiphenyl (2.43 g, 15.50 mmol) was added in one portion and the solution heated 
to reflux under argon for 4 h. On cooling a brown solid settled out of solution. This was 
collected, washed with a little ethanol followed by ether and dried in vacuo. 
Yield: 2.77 g, 8.49 mmol, 97.6 % 
C,4H 4Cl4Ru, (652.36) 	CaIc. %C = 44.19 %H = 3.71 
Found %C44.36 %H3.83 
NMR (DMSO-d) 	6 'H 7.65 (m, 2H), 7.38 (m, 3H), 6.03 (d, 2H), 5.77 (t, 111), 
5.61 (t, 2H) 
4.2.21 Preparation of [( 6-C6H5C6H5)RuCI(H2NCH2CH2NH2-N, N)][PF 6], 
complex 17 
[( 6-C6H5C6H5)RuCl,]2  (0.30 g, 0.46 mmol) was refluxed in H.,O (25 ml) for I h. At this 
time ethylenediamine (0.06 g, I mmol) was added to the refluxing suspension. The 
brown suspension immediately became dark green. This was refluxed for a further 30 
min and filtered while hot. NH4PF6 (0.5 g, 3 mmol) was added to the yellowish filtrate 
and the flask briefly shaken. A yellow precipitate began to form almost immediately. 
The flask was sealed, allowed to cool to ambient temperature and placed in an ice-bath 
for 3 h. The precipitate was collected, washed with a little water, followed by ethanol, 
followed by ether and dried in vacuo. This was recrystallised from methanol/ether. 
Yield: 
C,4H,8C1F6N-,PRu (495.82) Caic. %C = 33.91 %H = 3.66 %N = 5.65 
Found %C=33.86 %H=3.43 %N=5.32 
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NMR (DMSO-d6) 	8 'H 7.78 (m, 2H), 7.50 (m, 3H), 6.48 (b, 2H), 6.17 
(d, 2H), 5.89 (t, 1H), 5.79 (t, 2H), 4.18 (b, 2H), 2.31 
(m, 211), 2.21 (m, 2H) 
4.2.22 HPLC of aqueous solutions of complexes 13 and 17 
The HPLC method used in the analysis of aqueous solutions of complexes 13 and 17 is 
shown in Table 4.1. The column used is a polymer C18, 5 tm. Detection is at 310 rim. 
Solvent A: 50 mM Nll4Acetate, 2 mM pentanesulfonate(PSA) 
Solvent B: 100 % CH3CN 
Time/mm %A %B 
0 92.0 8.0 
13 56.0 44.0 
14 92.0 8.0 
18 92.0 8.0 
Table 4.1 HPLC method for analysis of aqueous solutions of complexes 13 and 17. 
A = 50 mM NlH4acetate, 2 mM PSA, B = 100 % CH3CN 
4.3 Results and discussion 
The synthesis of the Ru(II)arene complexes used in this work are based on a procedure 
pioneered by Bennett et al' in the early 1970s. A cyclohexadiene is refluxed in alcohol 
with RuC13 and the Ru(III) is reduced to Ru(II) with concurrent rearomatisation and it-
binding of the cyclohexadiene. This forms what is generally assumed to be the dimeric 
species [(i-j6-arene)RuC1.,]2  with two bridging chlorides. From this point it is possible to 
either cleave the dimer in a polar solvent such as methanol, or remove the halides using a 
reagent such as AgBF4 to promote addition of other ligands. 
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The most commonly used complexes are the (i6-benzene)  and ( 6-p-cymene) 
complexes. The diene precursors for these (cyclohexadiene and cL-terpinene) are both 
widely available commercially. There is a shortage, however, of commercial derivatised 
cyclohexadienes. Therefore it is necessary to synthesise them. The synthetic strategy 
used in this work is reduction of an aromatic system using solvated alkali metals. The 
general reaction is dissolving an alkali metal in liquid ammonia to create an electron sink 
to reduce the substrate while also having a proton source present, such as an alcohol, 
THF or even water, 17  to protonate the generated anions. The reduction of aromatic rings 
by solutions of alkali metals in liquid ammonia was discovered by Wooster and 
Godfrey" who reacted toluene with sodium in ammonia, followed by addition of water 
to produce "a highly unsaturated liquid product". This kind of work was taken up and 
developed further by Birch, and now the Birch reduction is synonymous with reduction 
of aromatic systems with sodium.'9 By definition, a Birch reduction is one in which the 
metal, substrate, alcohol and ammonia are present at the onset of the reaction." The 
reactions, though, are not always straightforward. Experimental variables such as choice 
of proton source, order of addition and choice of metal are very important. 16 
A schematic for a typical reduction is given in Figure 4.1. A solution of sodium in 
liquid ammonia contains solvated electrons which add to a benzene ring to give a radical 
anion. The benzene radical anion is less stable than benzene and the ion reacts readily 
with a proton donor. Ammonia itself is too weakly acidic to react, but ethanol, for 
example, is sufficiently acidic to protonate the radical anion. 	The resulting 
cyclohexadienyl radical immediately reacts with another solvated electron to form the 
corresponding cyclohexadienyl anion. 	This anion is a strong base and reacts 
immediately with the proton donor to give the cyclohexadiene. Monocyclic benzene 
derivatives do not readily form anions, even in liquid ammonia, and require the presence 
of the proton source to displace the initial unfavourable equilibrium to the right. 
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Figure 4.1 Scheme for reduction of an aromatic ring by solvated electrons 
4.3.1 [( 6-p-cymene)RuCl2(isonicotinamide)] complex 6 
The reaction of [( 6-p-cymene)RuCI,]2 with isonicotinamide in refluxing benzene 
produced [( 6-p-cymene)RuCl2(isonicotinamide)] 6. Isonicotinamide consists of a 
pyridine ring with an amide group at the 4 position, so it has two possible modes of 
coordination, through the pyridyl nitrogen or the amide functionality. 
4.3.1.1 X-ray crystal structure of 6 
Single crystals suitable for X-ray analysis were grown from diffusion of ether into a 
methanol solution of 6. Crystal data are shown in Table 4.2 and selected bond lengths 
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are listed in Table 4.3. The structure is shown in Figure 4.2. The complex crystallises in 
the space group Cc with four molecules in the unit cell. The structure displays the 
piano-stool type geometry. The p-cymene ring is i6-coordinated to the ruthenium and 
the two chlorides and the isonicotinamide make up the "legs" of the stool. The 
isonicotinamide is coordinated through the pyridyl nitrogen. The Ru-Cl bond lengths 
are in the region typical for Ru(II) complexes .21,2'  The Ru-N1 bond length of 2.120(8) A 
is comparable to the Ru-Nis,, bond lengths in [cis-Ru`(NH,),(isn) 
]21 which has a mean 
Ru-N bond length of 2.060(4) A2' and the Ru-N bond length in the pyridine complex 
[(h6-C6Me6)RuCl2(py)Il, 2.1224 A.22 It is interesting to note that the Ru-N 5 bond length 
in 6 is not significantly different from the RUNen bond lengths in complexes 11, 13, 14, 
16 and 18, see Table 4.3. This implies a lack of dtiit*  interaction, since back-bonding 
between the metal and ligand would make the bond shorter, so the pyridine moiety does 
not act as a it-acceptor. There is an intermolecular hydrogen bond in the unit cell 
between two molecules, see Figure 4.3. It is between the N-H of the amide on one 
molecule and the amide oxygen of a second molecule. 
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6 11 13 14 16 17 
Emprieal foniiula C , II 20 C1 2 N 2 0Ru C 8 1l 14 CIF ,N 2 PRu C 2 11 	ClF 6N 2 PRu C 12 	22 I2 N 2 Ru C 0 H 16 CIF 8N 2 O 2PRu C 14 H 18 CIF6N 2PRu 
Formula weight 42831 419.70 475.81 549.19 477.74 49579 
Crystal habit colourless block yellow block orange block orange block yellow block yellow plate 
Crystal size/mm 0.43 x 0.23 x 0.16 0.27 x 0.19 x 0.19 0.58 x 0.39 x 031 0.39 x 0.25 x 
0.19 
0.43 x 0.21 x 0.16 0.56 xO.l2 x 
0.04 
Crystal system monoclinic orthorhombic monoclinic monoclinic monoclinic monoclinic 
Space group Cc Prima P P211c P2 1 In C 2/c 
Volume / A 1749.8(10) 1410 1(8) 1726.7(8) 1663.5(5) 1598.8(4) 3509(2) 
Z 4 4 4 4 4 8 
Density (calc.) / mg m 3 1.626 1.977 1.830 2.193 1.985 1.877 
Absorption coefficient / 
mm 
1.203 1.469 1.211 4.639 1.318 1.197 
F(000) 864 824 952 1032 944 1968 
0 range for data collection / 
deg 
2.80 to 25.12 2.65 to 25.03 2.53 to 25.07 2.78 to 25.02 2.67 to 25.03 2.82 to 25.03 
Reflections collected 3978 1894 4465 2925 3803 5399 
Independent reflections 2530 1345 3047 2925 2715 3080 
Conventional R( R1 ) 0.0623 0.0416 0.0271 0.0312 0.0400 0.0420 
00 
	 'Fable 4.2 X-ray crystsllographic data for complexes 6, 11, 13, 14, 16, 17 
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6 11 13 14 16 17 
Ru-N 2.118(4) 2.130(3) 2.124(5) 2.112(4) 2.110(5) 
Ru-N, 2.118(4) 2.136(3) 2.143(5) 2.116(5) 2.121(5) 
Ru-N, 2.120(8) 
Ru-Cl, 2.395(3) 2.406(8) 2.4418(8) 2.4035(13) 2.4080(15) 
Ru-Cl, 2.408(3) 
RU-1 2.7337(7) 
N-Ru-N 78.9(3) 78.98(10) 78.2(2) 79.00(18) 79.20(18) 
Table 4.3 Selected bond-lengths A and angles (°) for complexes 6, 11, 13, 14,16,18 
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Figure 4.2 X-ray crystal structure of [( 6-p-cymene)RuC12(isn)] 6 
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Figure 4.3 Hydrogen bonding between the amide oxygen of one molecule of 6 and an 
N-H of the amide of another molecule of 6 in the unit cell 
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4.3.2 Complexes 7, 8, 9 and 10 
Complexes 7, 8, 9 and 10 were formed from reaction of the appropriate dimer with 
NH4PF6 in acetonitrile, based on a published procedure.t3 NH4PF6 is a less aggressive 
halide extracting agent than, for example, AgPF6, and leaves one chloride behind to form 
the complexes [(r16-arene)Ru(CH3CN)2X][PF6]1  where X is the halide. However, the 
iodide complex could not be isolated. 
This type of complex appears in the literature as a synthetic intermediate in Ru(II)arene 
chemistry. However, due to the water solubility and lability of the ligands, it was 
thought that these complexes may be biologically interesting in their own right. (see 
Chapter 6). The complexes have three potentially available coordination sites, so they 
could form mono-, bi- or even tn-functional adducts with DNA. However, along with 
this reactivity comes the possible problem of toxicity due to indiscriminate reactions 
with molecules present in the body. The problem of transport through the body to the 
tumour site may arise also, as they are likely to react with blood proteins such as HSA 
(human serum albumin). 
4.3.3 [( 6-C6H6)Ru(en)Cl][PF6]1  complex 11 
[(n6-C6H,)Ru(en)C1][PF6] 11 was synthesised from the reaction of [( 6-CH6)RuCl,]2  
with an excess of ethylenediamine in methanol. The polar methanol promotes the 
breaking of the dimeric structure allowing coordination of the ethylenediamine. After 
filtration, NH4PF6 was added to provide a substantial counter-ion and the product was 
isolated in moderate yield. The 'H NMR spectrum of 11 in DMSO-d shows a singlet at 
5.86 appropriate for a m-coordinated benzene ring. The ethylenediamine backbone - 
CH- protons appear as two multiplets at ö 2.34 and 2.17 and the NH., protons show two 
broad resonances at ö 6.45 and 4.28. 
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4.3.3.1 X-ray crystal structure of 11 
Single crystals suitable for X-ray analysis were grown by diffusion of ether into a 
methanol solution of 11. The complex crystallised in the space group Prima with four 
molecules in the unit cell. A summary of crystal data is given in Table 4.2, selected 
bond lengths and angles are given in Table 4.3. The structure is shown in Figure 4.4. 
The structure is disordered about a mirror plane that runs through the Ru and Cl. The 
Ru, Cl and the two N atoms fit the mirror plane, however the benzene ring and the 
backbone of the en ligand are disordered about it. This makes the Ru-C and C-C bond 
lengths have high esd values (0.016 - 0.018 A). However the structure has been 
unambiguously established. 
In the molecule the ruthenium has the expected "piano-stool" style geometry typical for 
Ru(II)arene complexes. The Ru-N bond lengths are 2.118(4) A and are in the range 
expected for a nitrogen cr-bonding to a Ru(II) centre. They are statistically similar to the 
Ru-N bond lengths for [Ru(en)3]2 , which shows a bond length of 2.132(3) A.23 This in 
turn is within two standard deviations of the 2.144(4) A found in [Ru(Nl-l3)6]2 , 
indicating no important bond length difference between NH3 and en ligands cr-bonded to 
Ru(II).24  The bonds also compare well with those in potentially biologically important 
ol igopeptide ester Ru(JI)arene complexes, such as [(ri 6-05Me(,)Ru( Cl )(k-L-
AlaGlyGlyGlyOMe)] (2.124(12) A25 and [((ri 6-C6H6)Ru(triglycine-N, N)Cl] (2.118(6) 
A.26 
The N-Ru-N bond angle of 78.9(3)° is slightly less than that found in the octahedrally 
coordinated complexes [Ru"(en)3]2 (80.9(3), 81.8(3) and 82.1(3)0)23  and 
[Ru(en)2(CH3CN)(pph3)]2 (80.0(6) and 81.7(7)0)27  but this is to be expected with the 
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Figure 4.4 X-ray crystal structure of [( 6-C6H6)RuCI(en)} 11. The PF6 counter-ion 
has been omitted for clarity 
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Ru-Cl bond length of 2.406(8) A is within the range of values typical for Ru(II) 
'8 '9 complexes.-  
4.3.4 [( 6-C6H6)Ru(en)I][PF6], complex 12 
Complex 12 was formed from the reaction of [(i6-C6H6)RuI,] with ethylenediamine in 
methanol. The iodo version of the ruthenium dimer has a lower solubility than the 
chloro version and reaction time was longer in a higher volume of solvent. 'H NMR in 
DMSO-d6 showed a singlet at 6 5.86 appropriate for a it-coordinated benzene ring. The 
ethylenediamine backbone protons appear as multiplets at 6 2.35 and 2.15, and the NH, 
protons are two broad resonances at 6 6.42 and 4.22. Unfortunately, crystals suitable for 
X-ray analysis could not be grown.. 
4.3.5 [( 6-para-cymene)Ru(en)Cl][PF6], complex 13 
Complex 13 was formed from the reaction of [( 6-para-cymene)RuCl2]2  and 
ethylenediamine in methanol in a manner similar to 11, see section 4.3.3. The 'H NMR 
in DMSO-d6 showed two doublets with coupling constants of 5.6 Hz at 6 5.48 (211) and 
5.32 (2H), attributable to the four protons of the p-cyrnene ring. The tolyl protons of the 
arene give rise to a singlet at 6 2.11 (3H), and the isopropyl methyl groups give a doublet 
at 6 1.25 (J = 6.8 Hz) split by the C-H proton which resonates at 6 2.7 (6H) as a 
multiplet. The -CH,- of the ethylenediamine backbone are two broad multiplets at 6 
2.43 (2H) and 2.32 (2H) and the NB, signals give two broad resonances at 6 6.13 (2H) 
and 4.22 (2H). 
A 2D'H-'H NOESY experiment allowed the N-H signals to be distinguished. The 
spectrum is given in Appendix 2. The NH signal of the ethylenediamine ligand to high 
field has significant NOESY crosspeaks with the protons on the backbone of the 
ethylenediamine ligand, but not with the arene ring. The signal to low field, however, 
has significant NOESY crosspeaks with the ethylenediamine backbone and with all the 
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protons of the p-cymene ring. We can assume free rotation of the p-cyrnene ring due to 
the simplicity of the signals from it. Therefore the NH signals must correspond to one 
for the NI-I pointing away from the ring (the signal at high field) and one for the NH 
pointing upwards toward the ring (the signal to low field) i.e. each signal is for two 
protons, one from each nitrogen. 
As the complex contains a chelated ethylenediamine ring, there is potential for '5N NMR 
studies. As a preliminary test, to see if it would be of use, an HSQC ['H, '5N] correlation 
spectrum was obtained in 90 % H2O:10 % D20. This was done at natural abundance 
with a concentration of 40 mM. ' 5N is only present in nature at a level of 0.3 % so the 
high concentration was necessary. For biologically relevant reactions such as DNA 
binding, 'N isotopically enriched ethylenediamine could be used. The present study 
was performed to see if there was a significant difference in the shift of the intact 
complex and the hydrolysed form. A significant shift would mean that bound forms of 
the complex could be distinguished from unreacted forms. The spectrum is shown in 
Figure 45. The signals from the NH protons in the intact complex are in square boxes 
and the peaks from the hydrolysed form of the complex are in the oval boxes. There is a 
separation of I ppm in the ' 5N dimension and a separation of 0.3 ppm in the 'H 
dimension between the hydrolysed and non-hydrolysed forms. This indicates that '5N 
NMR studies may be useful in further studies of complex 13. 
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Figure 4.5 HSQC ['H,'5N] 2D spectrum of 13 in 90% H20:10 % D.,O after 45 min at 
298 K. The 'H dimension is on the horizontal axis and the '5N dimension is on the 
vertical axis. The signals from the intact complex are denoted by the squares and the 
signals from the hydrolysed form of the complex are denoted by the ovals. 
4.3.5.1 X-ray crystal structure of 13 
Single crystals suitable for X-ray analysis were grown by diffusion of ether into a 
methanol solution of 13. Crystal data are listed in Table 4.2 and selected bond lengths 
and angles are in Table 4.3. The structure is shown in Figure 4.6 and unambiguously 
confirms the structure. The complex crystallised in the space group P with four 
molecules in the unit cell. The expected piano-stool type geometry is shown, with the p-
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making up the three "legs" of the stool. The Ru-N and Ru-Cl bond lengths and angles 
can be compared to the same structures as complex 11, see section 4.3.3.1. 
4.3.5.2 Hydrolysis of complex 13 
We are interested in the potential use of the complexes synthesised in this thesis as 
anticancer agents. As the human system is largely an aqueous one, it is of interest to 
know how a complex reacts with water in order to give an insight into the biological 
reactivity of it. From initial cytotoxicity studies on the arene complexes prepared in this 
thesis, see Chapter 6, complexes 13 and 17 were chosen as lead compounds. With a 
view to the development of an assay to allow for in-depth biological studies in the 
future, a HPLC method was developed to study the hydrolysis of complex 13. 
After attempting various types of HPLC methods such as ion-exchange, the successful 
method turned out to be ion-pairing using pentanesulfonate(PSA). The method is 
detailed in the experimental section, section 4.2.22. 
Three species were detected in the assays, with the peaks eluting at (a)8.4, (b)10 and 
(c)10.9 mm. To assign them, various experiments were performed varying the 
concentrations of the solutions and by making up the solutions in 100 mM NaCl, a 
concentration that would prevent or significantly decrease loss of the chloride. These 
allowed us to assign which peak is the intact complex and which has reacted with water. 
Figure 4.7 shows the HPLC traces of a 10 mM solution of 13 in A) H2O and B) 100 mM 
NaCl. The peaks in the H2O solution appear in the ratio 3:1:7 in order of elution. The 
vast reduction in the relative intensities of the peaks (a) and (b) in the NaCl solution 
(ratios 2:1:21) as compared to the H10 solution indicates that these peaks correspond to 
hydrolysed species. Therefore we can assign peak (c) at 10.9 min as the original 
complex. Fig 4.8 shows the HPLC traces of 0.2 mM solutions of 13 in A) H10 and B) 
100 mM NaCl. This experiment backs up the observations made using the 10 mM 
solutions. It can be seen that in H10 the balance of the peaks has been greatly shifted to 
peaks (a) and (b) (ratio 5:2:1). In the salt solution these peaks are of low intensity. 
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Figure 4.7 HPLC separation of a fresh 10 m solution of 13 in A) H50 and B) 100 m 
NaCl solution at 295 K. Peaks (a) and (b) correspond to the hydrolysed complex and 
peak (c) is the intact complex. 
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Figure 4.8 HPLC separation of a fresh 0.2 mM solution of 13 in A) HO and B) 100 
mM NaCl solution at 295 K. Peaks (a) and (b) correspond to the hydrolysed complex 
and peak (c) is the intact complex 
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These observations allow the following conclusions to be drawn: peak (c), at 10.9 mm, is 
the original complex, and peaks (a) and (b) are species that have formed after the loss of 
the chloride. This is known by the significant reduction in the intensity of peaks (a) and 
(b) in the 100 mM NaCl solution. The high chloride concentration is inhibiting loss of 
the chloride form the complex. Also, at dilute levels (0.2 mM) practically all the 
complex has lost a chloride in H20 whereas at a higher concentration (10 MM) only 36 
% of the complex has lost a chloride. Assuming that drug dosage would be in the !.LM 
region (see Chapter 6), it is likely that the complex would lose chloride if administered 
in water. 
To confirm assignments and distinguish between the two reacted species, on-line HPLC-
electrospray mass spectrometry was performed. However, the experiment resulted in a 
change of retention times due to different column length and flow rates required for on-
line, and peaks (a) and (b) merged into an unseparable broad peak appearing in the mass 
spectrometer at the same time, see Figure 4.9. It was possible to identify species from 
these results though. Both peaks showed an ion at mlz 295.4. This corresponds to [(r 6-
p-cymene)Ru(en)]2 - H (theor 295.3 amu) due to fragmentation in the mass 
spectrometer. This is the only fragmentation seen in the experiment and indicates the 
fragility of the Ru-Cl bond, and hence potential reactivity. Peak (c) at 15 min gives a 
signal at m/z 331.4, which corresponds to the original complex without its counter-ion 
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Figure 4.9 On-line HPLC-ESIMS of an aqueous solution of 13. The top trace is the 
IJY detection at 310 imi of the separation and the Total Ion Count (TIC) detected by the 
mass spectrometer concomitantly. Peaks (a) and (b) have merged into a single peak. SF 
is the Solvent Front. 
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Peak (a + b) at 10 mm, produced by the merging of the two peaks, produces the ion at 
mlz 295.4 and two other ions. One is unexpected at mlz 447.5, but when the HPLC 
mobile phase was taken into account, it can be assigned as an adduct of the complex 
with PSA instead of the chloride (theor. 447.4 amu), and therefore an artefact of the 
HPLC method. There is also a species at mlz 315.1 which is for the hydrolysed form of 
the complex (theor. 314.3 amu). 
43.6 [( 6-para-cymene)Ru(en)I][PF6]1  complex 14 
Complex 14, {(r16-para-cymene)Ru(en)I][PF611  was formed from the reaction of [(if-
para-cymene)RuL,]2  with ethylenediamine in methanol. The 'H NMR in DMSO-d6 
shows two doublets for the p-cymene ring protons at ö 5.51 and 5.35, a singlet for the 
tolyl protons at 6 2.08 and a doublet for the isopropyl methyl protons at 6 1.33 which are 
coupled to the single isopropyl proton at 6 2.69. The ethylenediamine backbone protons 
resonate at 6 2.37 and 2.29, and the NH protons give two broad signals at 6 6.15 and 
4.24. 
4.3.6.1 X-ray crystal structure of 14 
Crystals suitable for X-ray analysis were grown by diffusion of ether into a methanol 
solution of 14. Crystal data can be found in Table 4.2 and selected bond lengths and 
angles are listed in Table 4.3. The complex crystallises in the space group P2,/c with 
four molecules in the unit cell. The structure is shown in Figure 4. 10 and unambiguously 
confirms the complex as having piano-stool type geometry. The p-cymene is if-
coordinated and the chelated ethylenediamine and the iodide are the "legs" of the stool. 
Unexpectedly there is no PF6 counter-ion present. Instead the counter-ion is an iodide, 
presumably the iodide displaced by ethylenediamine upon chelation. Interestingly, the 
iodide counter-ion links molecules of the complex via intermolecular interactions with 
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Figure 4.11 Representation showing how the iodide counter-ion links molecules of 14 
in the unit cell via N-H of the ethylenediamine moiety. 
The Ru-N bond lengths and angles can be compared to the same structures as complex 
11, see section 4.3.3.1. The Ru-I bond length of 2.7337(7) A compares well with other 
Ru-arene complexes possessing an iodide such as [(-C6H6)Ru(I)(2-
dimethylaminoethyl)-2-naphthyl], 2.735(1) A3° and [(TI 5-05H5)Ru(I)(CNBut)] which has 
a Ru-I bond length of 2.717 A?1  
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4.3.7 [(16-para-cyrnene)Ru(en)(9egua)][PF6]2, complex 15 
The reaction of complex 13 with 9-ethylguanine (9egua) in aqueous ethanol, with work-
up including ion-exchange chromatography, produced yellow crystals of [( 6-para-
cymene)Ru(en)(9egua)]{PF6]2. 9-Ethylguanine is a model compound for the guanine 
found in DNA, and this might be a possible target for Ru compounds in vivo.32 It is 
known that when cisplatin is incubated with DNA, intrastrand Pt(GpG-K2N7), G = 
guanine, chelates are formed in statistically larger amounts than expected. It is with this 
in mind that the reaction between 13 and 9egua was investigated. 
The product was formed in very low yield, hence only preliminary investigations were 
performed. The H NMR is the most insightful piece of information in this case. The 
spectrum in D,O is appropriate to complex 13 with an N7 bound 9-egua molecule 
replacing the chloride. The p-cymene moiety gives rise to two doublets at S 5.72 and 
5.59 (2H each) for the four arene protons, a multiplet at 5 2.49 (1 H) and a doublet at S 
1.09 (6H) for the isopropyl group and a singlet at 5 1.95 (3H) for the tolyl group. The 
ethylenediamine backbone is a multiplet at 6 2.41 (4H). Interestingly there is a large 
shift in one of the NH signals. The signal for the NH protons pointing away from the p-
cymene ring (see section 4.3.5) has shifted to higher field, from 5 4.2 to 2.01 This is 
probably due to the orientation of the ethyl group of the 9-egua. The other NH signal 
appears at 6 6.00. The fact that the NH does not appear to exchange to ND in D20 
indicates that the ethylenediamine does not ring open as this would allow for exchange 
processes to occur. The 9-egua ligand resonances are a triplet at 5 1.41 (3H) and a 
quartet at 6 4.09 (2H) for the ethyl group and a singlet at 5 8.22 for the H8 proton. In 
free 9-egua in D20 the H8 proton resonates at 5 7.8. The downfield shift of 0.4 ppm 
upon coordination to the ruthenium indicates that it is bound through the N7 of the 
guanine moiety. Coordination of guanine through the N7 is preferred by most metal 
ions 33  at neutral pH. This has been shown for 9-egua and Ru(II) in the complex [(p6-
C6H6)RuC1,(9egua-kN7)].34 Therefore, the complex [(r-para-cymene)Ru(en)Cl][PFj 
13 reacts with 9-ethylguanine to form the monoadduct with coordination at the N7 of the 
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guanine model, indicating a strong likelihood that this would be the reaction of choice 
with DNA. 
4.3.8 [(16-methylbenzoate)Ru(en)Cl][PF6] complex 16 
In order to introduce variety on the arene ring substituent of the complex [(p6-
methylbenzoate)Ru(en)Cl][PF6] complex 16 was synthesised. Starting from benzoic 
acid, this was reduced using a Birch style reduction (see section 4.3) to 1,4-
dihydrobenzoic acid and this in turn was esterified in methanol to give 3-
methoxycarbonylcyclohexa-1,4-diene. On refluxing this with RuCI3 in methanol the 
dimer [(rj6-methylbenzoate)RuCl,]2 was formed. Reacting this with ethylenediamine in 
methanol led to the complex [( 6-methylbenzoate)Ru(en)Cl][PF6] 16. 
Introducing an ester moiety to the it-coordinated arene ring was of interest for two main 
reasons. First, the possibility of the complex acting as a prodrug. The activity of 
hydrolases (for hydrolysis of esters) in cancer cells towards the ester moiety could result 
in trapping of the complex in the cell. The hydrophobicity of the arene part of the 
complex should aid passage through cell membranes (composed of lipids), thus raising 
concentration of the complex in cells. Once in the cell and hydrolysed, the complex may 
no longer be able to leak out through the membrane, and may be in a more active form. 
This methodology has previously been attempted with some cisplatin derivatives .35  
They found that the more hydrophobic the ester moiety, and the more susceptible to 
hydrolysis, the more cytotoxic the complex. Also, by varying the arene ring 
substituents, we might obtain information as to whether arene is important to activity. 
The 'H NMR in DMSO-d6 showed the appropriate resonances. The protons of the it-
coordinated ring gave rise to a doublet at 6 6.39 (2H) for the protons ortho to the ester 
functionality, a triplet at ö 6.10 (1H) for the para proton and a multiplet at ö 5.68 (2H) 
for the meta protons. The NH signals and are found at ö 6.70 (2H) and 4.32 (2H) are 
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broad. The ethylenediamine backbone shows 2 multiplets at 6 2.22 (2H) and 2.15 (2H). 
The ester methyl signal is a singlet at 6 3.28 (3H). 
4.3.8.1 X-ray crystal structure of 16 
Single crystals suitable for X-ray analysis were grown by diffusion of ether into a 
methanol solution of 16. Crystal data are given in Table 4.2 and selected bond lengths 
and angles are listed in Table 4.3. The structure is shown in Figure 4.12 and 
unambiguously confirms the structure to have the piano stool type geometry. The 
methylbenzoate is 716-coordinated  and the chelated ethylenediamine and chioro ligands 
form the "legs" of the stool. The complex crystallises in the space group P2/n with four 
molecules in the unit cell. The Ru-N and Ru-Cl bond lengths and angles are comparable 
to the similar parameters as complex 11, see section 4.3.3.1. 
Although one of the carbons of the arene ring is substituted with an electron 
withdrawing ester group, there is no significant difference between this Ru-C bond 
length (2.18 1(5) A) and those for the other ring carbons. Another arene-ester complex of 
ruthenium36 	{( 6-o-MeC6H4C01Me)Ru(NMDPP)C12 ], 	where 	NMDPP 	is 
neomenthyldiphenylphosphine, has been reported to have a longer Ru-C bond to the 
ester substituted carbon than the unsubstituted carbons but the authors attributed this to 
the carbon being pseudo-trans to a tertiary phosphine and its respective trans influence.37 
The C=O double bond length, 1.206(7) A is comparable to that in [(r-o-
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An attempt was made to react 16 with 9-ethylguanine in aqueous ethanol. After work-
up, however, the isolated product turned out to be unreacted 16. A blue band also 
appeared on the ion-exchange column, however this would not elute from the column. 
4.3.9 [( 6-biphenyI)Ru(en)Cl][PF6] complex 17 
To introduce another form of variety on the arene ring, the complex [(116-
biphenyl)Ru(en)Cl][PF6] 17 was synthesised. Starting with biphenyl, this was reduced 
using lithium metal in ammonia to form 1 ,4-dihydrobiphenyl. On refluxing this in 
ethanol with RuCl3, the dimer [( 6-biphenyl)RuCl,]2 was formed. This has quite a low 
general solubility and many variations on syntheses were tried before finally succeeding 
in producing 17. The complex was formed by addition of ethylenediamine to a refluxing 
suspension of {( 6-biphenyl)RuCl1]2 in H-,O. After filtration and addition of NH4PF6, a 
yellow solid precipitated which was purified from methanol-ether. 
The H NMR of 17 in DMSO-d6 was recorded. The coordinated ring of the biphenyl 
shows a doublet at 6 6.17 (21-1), a triplet at ö 5.89 (1H) and a triplet at 5 5.79 (2H). The 
pendant phenyl ring gives two multiplets at ö 7.78 (2H) and 7.50 (3H). The 
ethylenediamine backbone (CH2)2  gives rise to two multiplet resonances at 6 2.31 (2H) 
and 2.21 (2H) and the N-H resonances appear at 5 6.48 (2H) and 4.18 (21-1). 
The biphenyl group was chosen for two main reasons. The extra aromatic group 
increases the hydrophobicity of the complex. Complex 17 is still quite soluble in water 
(> 20 mM), but the solubility is certainly reduced when compared to other complexes 
such as 13. This may have the advantage of leading to a greater partition into the cell 
membrane which may aid transport into the cell. The biphenyl group is also a potential 
DNA intercalator. Ru-DNA intercalatoi-s have been of interest for probing nucleic acid 
conformations and in the development of new phototherapeutics.38 Ru(II) polypyridyl 
intercalators have a strong affinity for DNA" and may act as molecular "light-switches" 
for double helical DNA.40 These complexes show no luminescence in aqueous buffer, 
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but luminesce brightly when intercalated into DNA. Intercalating ruthenium complexes 
have also been used to study long range fast electron transfer that is mediated by the 
stacked bases of DNA.4' On a note more relevant to cancer treatment, an intercalating 
moiety is believed to be necessary for topoisomerase inhibitors.42 This point is further 
discussed in Chapter 6. As the biphenyl is not very large full intercalation is unlikely, 
but partial intercalation of the pendant phenyl ring is possible, and when combined with 
the potential covalent binding site on the metal through loss of the chloride, this complex 
could have some very interesting biological properties. 
4.3.9.1 X-ray crystal structure of 17 
Crystals suitable for X-ray analysis were grown from ether diffusion into a benzyl 
alcohol solution of 17. The structure is shown in Figure 4.13 and crystal data are shown 
in Table 4.2. Selected bond lengths and angles are listed in Table 4.3. Figure 4.13 
unambiguously confirms that the structure has the piano-stool type geometry, with one 
ring of the biphenyl ri6  bonded to the metal and the ethylenediamine and the chloride 
forming the "legs" of the stool. The complex crystallises in the space group C2/c with 
eight molecules in the unit cell. The Ru-N and Ru-Cl bond lengths and angles are 
comparable with those in the similar structure of complex 11, section 4.3.3.1. 
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This complex is the first example of a crystal structure of a monoarene complex of 
ruthenium where the arene is biphenyl. The only other Ru( 6-biphenyl) complex 
previously reported is the bis arene [bis( 6-biphenyl)Ru"]{BF4]21  the biphenyl analogue 
of ruthenocene. This has actually been reported twice, initially in 1990, when only a 
cursory description of the structure was made, and again in 1995, when a more 
thorough analysis was performed. It is interesting to see that both published structures 
show the two phenyl rings of both biphenyls in the complexes are twisted away from 
coplanarity, 24.60 for both rings in the early structure, 24.6° and 25.0° for the later one. 
This phenomenon is also seen in 17. One phenyl ring is twisted out of the plane by 
24.60. In the solid state, free biphenyl has been found to be planar.45 The twisting is 
probably as a result of the way the aromatic rings pack together in the crystal, but it is 
interesting that the twisting is a consistent occurrence. Another point to note is the 
length of the bond between the Ru and the substituted carbon, 2.244(6) A, 0.054 A 
longer than the longest of the other Ru-C bonds in the molecule. This also occured in 
[bis( 6-biphenyl)Ru"][BF4]2 44  where the Ru-C(substituted) bond lengths of 2.271(5) and 
2.262(7) A are also longer than the other Ru-C bonds. As there is no other ligand 
present which has a trans influence, this lengthening must be due to the electron 
withdrawing effect of the pendant phenyl ring. 
4.3.9.2 Hydrolysis of complex 17 
Along with complex 13, complex 17 was selected as a lead complex for cytotoxicity 
studies, see Chapter 6. Therefore it is of interest to study the fate of the complex in 
water, and to develop an HPLC assay to aid further biological investigations. 
Fortunately the same HPLC method can be used for both 13 and 17, see section 4.2.22. 
Like 13, 17 also gives rise to three peaks in the HPLC trace after dissolution in water, 
though with different retention times. Peak (a) elutes at 6.7 mm, peak (b) at 8.4 min and 
peak (c) at 9.3 mm. Online HPLC-ESI-MS confirmed that peak (c) is the intact complex 
(chloride still attached), found mlz 351.5, caic. 351.8 amu. Again when studied on-line 
peaks (a) and (b) merged into a single broad peak. The mass spectrum of this peak 
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contained an ion at mlz 467.6 which corresponds to a pentanesulfonate taking the place 
of the chloride (calc. 467.5 amu). The calculated value for the hydrolysed complex, i.e. 
a water molecule in place of the chloride, is 334.4 amu. The only ion in this region of 
the spectrum is at mlz 337.3, three units away. This is unexpected, and while it is sure 
from HPLC studies in H2O and 100 mM NaCl that 17 loses its chloride in water, exactly 
what this species is is unknown at the moment. 
Like 13, the proportion of the peaks varies with concentration. At low concentration, 0.1 
mM, only 30 % of the complex remains intact. At 10 mM, 60 % of the complex remains 
intact. This implies that at its IC,,, levels, which are <10 iM see Chapter 6, if 
administered in water, the vast majority, if not all, of the complex would have lost its 
chloride. 
4.4 Conclusions 
In this chapter the synthesis and characterisation of some Ru(II)arene complexes. are 
described. Arene complexes were chosen as they are known to keep the ruthenium in 
the oxidation state 2+ under normal conditions and the arene ring would introduce a 
degree of lipophilicity which could enhance cell-membrane interactions. Substituents 
were introduced on the arene ring to investigate structure-activity relationships and 
synethetic routes to derivatised arene complexes were developed. 2D ['H, '5N] HSQC 
spectroscopy of [( 6-p-cymene)RuCl(en)] 13 was studied and the complex appears 
suitable for further work with isotopically enriched '5N samples. This will be useful for 
solution structural determination of adducts to biological molecules such as DNA. A 
HPLC assay was developed for separation of aqueous solutions of two complexes, [(11 6_ 
13 and [( 6-biphenyl)RuCl(en)f 17, which have been chosen as 
lead compounds for anticancer testing and their hydrolysis investigated by a combination 
of HPLC and ESJ-MS. The assay will allow for more in depth analytical work and 
biological tests. 
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Chapter 5 	Interactions of [(r16-p-cymene)RuC1(en) with nucleotides and oligonucleotides 
5.1 Reactions of [( 6-p-cymene)RuCl(en)] 13 with DNA model 
compounds 
Nucleotides and their metal ion complexes are among the most widely used 
substrates in cell metabolism,' both in free form and as subunits of oligonucleotides 
and DNA. Indeed, it is believed to be a guanine-guanine chelate that gives cisplatin 
its excellent activity against certain tumours.5 ' Unfortunately, it is not a simple matter 
to monitor reactions of complexes with large pieces of DNA by physical methods, 
and so low molecular DNA components such as 5'-dGMP are often used. The 
structures of the nucleotides used in this section are shown in Figure 5.1. 
8 D14 2 
N N 	NH2 
H 	H 










d) 5 TMP 
Figure 5.1 Structures of mononucleotides used in this section, including numbering 
scheme. The numbering scheme for the sugar moiety in (a) is the same for (b), (c) 
and (d) 
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In particular, nucleotides, nucleosides and 9-substituted nucleobases can be used to 
model reactions of complex DNA, but in a less complicated form,' and they have 
often been applied as models in order to understand better the cancerotoxic activity 
of cisplatin.3 
With regard to ruthenium, it has been found that there is a direct correlation between 
cytotoxicity and DNA binding for the ruthenium am(m)ine and imidazole anticancer 
compounds cis-[Ru ... C17 (NH3)4]Cl, and [HIm][trans-[Ru"(Im),C14] in cell cultures.' 
Also, a number of ammine, amine and heterocyclic complexes of ruthenium inhibit 
DNA replication,' which implies DNA binding. Other effects indicative of DNA 
binding are mutagenic activity and induction of the SOS repair mechanism,' binding 
to nuclear DNA"' and reduction of RNA synthesis.' Polyaminocarboxylate 
complexes of ruthenium also show anticancer activity which is assumed to be 
through DNA binding. 
Knowing the location of the binding site of the metal to DNA could be crucial for 
understanding the mechanism of action of a drug. There is strong indication that the 
N7  of guanine is the favoured site of binding for ruthenium complexes. It has been 
shown that bispyridyl compounds of Ru'1 only bind to the N7 of the guanine moiety 
when the model bases 9-methylhypoxanthine and 9-ethylguanine are used (both are 
models for guanine residues in DNA).' 	Also, mer-[RuCl 3(terpy)] binds 
preferentially to N7  when reacted with guanine analogues,' and the reported binding 
ratio of trans-[Ru(S03)(NH 3)4(J-J,O)J to guanine-N7/adenine-N7  is 95,10 
Unusual binding of Ru" at gua-N' has been observed for cis-[RuC1-,(b1q)7] at neutral 
pH." Metal coordination at gua-N' is not uncommon, 12  although there are no other 
reports for ruthenium in the literature where the N' adduct is a major and isolable 
adduct. It is unusual at neutral pH as the metal ion has to compete with the proton at 
that site. For metals with slow ligand exchange kinetics, like Pt", mononuclear N' 
coordination to guanine is only observed at high pH" or when the basicity is lowered 
due to prior binding at the N7 site. 14 
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ICP-AES studies on the anticancer active complexes trans-[Him][Ru ... C14(Im)2 ] and 
trans- [Hind][Ru"C14(Ind)2] and their interactions with synthetic double stranded 
homopolymers have shown that they exhibit a very definite preference for the 
poly(dG).poly(dC) duplex to poly(dA).poly(dT) duplex." 
Studies of the interactions of both cis- and trans-[RuCl2(DMSO)4] complexes with 
nucleosides, nucleotides and DNA in vitro suggest that covalent bonds between Ru 
and DNA occur mainly at the N7 of guanine. 16  It was noted that reaction of these 
complexes with 5'-AMP yielded only an adduct through the phosphate group,' 7 
however a recent study with the dinucleotides ApG, GpA, d(ApG) and d(GpA) 
resulted in coordination only through N7 sites on both A and G.' 8 
Ruthenium(arene) complexes of guanine and adenine 5' -mono-, di-, and tn-
phosphates have been charactenised.'9 Reaction of [(i6-C6H6)Ru(D20)312  with 5'-
GMP leads solely to the formation of the N7 coordinated 1:1 and 1:2 complexes 
without any other adducts being observed. With 5'-GTP, macrochelate complexes 
involving N7  and phosphate groups were formed. Reaction with 5'-AMP resulted in 
a cyclic trimer being formed, again with coordination at N7 involved, as well as N6 
and N'. 
Therefore it is of great interest to investigate nucleotide binding properties of the 
ruthenium(arene) complex [( 6-p-cymene)RuC1(en)] 13 , Figure 5.2, in a bid to 
investigate its potential DNA binding sites and biological activity, and to see whether 
a prediction of N7 binding, based on previous literature reports, is correct. In this 
section the binding 13 to 5'GMP, 5'AMP, 5'CMP and 5TMP is examined, as well 
as the effect of changing the pH. 
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Figure 5.2 The structure of fti 6-p-cymene)RuC1(en)] 13 
5.1.1 Experimental 
NMR scale reactions of 13 and nucleobases were typically carried out in a 1:1.1 
molar ratio (Ru:nucleotide) in D,O or 90 % H,0:10 % D20. Concentrations were 
typically in the range of 20 mM. The solutions were incubated at 310 K for 24 h 
prior to acquisition of spectra. For details on spectra acquisition see Section 2.2.2. 
PKa curves were fitted using the Kaleidograph programme and pKA values 
determined by first derivatives. 
5.1.2 Results and Discussion 
The complexes were reacted with the model bases in 90 % H,0/10 % D20 or DO 
and the reactions monitored by NMR. Although strictly as DNA models the 
nucleotides used should be 5'-dNMP (NMP = nucleobase monophosphate) variety, 
i.e. deoxy, the presence of the hydroxyl group at the 2 position of the sugar moiety 
is not expected to affect the reactivity of the compounds. Deductions were made as 
to binding sites by observing changes in chemical shifts of signals appropriate to 
binding of the metal centres to sites on the nucleotides. 13 would be expected to 
only have one binding site available through loss of the chloride. Therefore, 
assuming a 1:1 reaction, a slight excess of the nucleobase was used in order to have 
some unreacted material as a reference point when analysing the shifts after the 
reaction. The affinity of a positively charged metal ion can be expected to parallel 
that of a proton and is therefore related to the basicity of the site. Diamagnetic 
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metallation of a nucleotide produces effects quite similar to protonation.2°  
Protonation of the base function of a nucleotide normally causes a downfield shift of 
the nucleobase signals," and from previous ruthenium-nucleotide studies,` 10. 416 
ruthenation of a base site would be expected to cause the same effect. 
The pKA values of the unsubstituted bases are:'2' 2 ' 
thy-N3 (9.8) > gua-N' (9.4) > cyt-N3 (4.6) > ade-N' (4.1) > gua-N7 (1.9) > ade-N7  (-
1.6) 
From the basicities it is clear to see that in pyrimidine bases, metal binding might 
3 	'I occur predominantly at N" - whereas purine bases exhibit a dichotomy between 
binding at N' or N7. In slightly acidic and neutral solutions both N' and N7 of 
adenine remain unprotonated, and hence are available for coordination, but for 
guanine the pKA — 9 for N', and so only N7 is unprotonated and the metal ion has to 
compete with the proton for binding at N'. Also, the N7 sites of G and A do not 
participate in Watson-Crick base pairing22 and are sterically accessible for a metal 
complex when located in the major groove of DNA. 
The N7 of guanine is the most electron rich of the DNA nitrogens23 and the most 
basic site of all the nucleobases24  and hence it has the greatest attraction for transition 
metal ions (Lewis acids). The N7 of guanine has stronger c7-donor properties than 
adenine N7 and successive guanine residues form the most electronegative regions in 
DNA. In fact, the preferred binding sites in nucleobases for cisplatin at physiological 
pH are gua-N7 > ade-N7 > ade-N' > cyt-N3 .25 
5.1.2.1 Reaction of complex 13 with 5'GMP 
The spectrum of 13 in D,O is shown in Figure 5.3. The peaks in the spectrum 
correspond to the presence of two species (a) 60 %, and (b) 40 %. The concentration 
of this sample is 40 mM. With our knowledge of the hydrolysis process of 13 from 
HPLC, section 4.3.5.2, we can assign the major species (a) as the intact complex and 
the minor species (b) as the hydrolysed version. The peaks corresponding to the 
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arene protons, the tolyl protons, the methyl groups of the p-cymene isopropyl group 
and the NH, signals of the ethylenediamine ligand all undergo a downfield shift upon 
hydrolysis. The fact that we can see the NH2 groups in D,O is significant as it 
indicates a slow exchange between the 1 H and 2H, which implies a strong Ru-N bond. 
The smallest of the shifts is for the tolyl singlet (6 2.22 - 2.26) and the isopropyl 
methyl doublet (6 1.28 - 131). This is understandable as they are furthest away from 
the metal centre and would be less affected by the change in coordination 
environment. The two doublets for the arene protons shift from 6 5.70 to 5.81 and 6 
5.50 to 5.59. The C-H of the isopropyl does not shift sufficiently to distinguish it 
from the original signal. The multiplet for the CH, groups of the ethylenediamine 






4.0 3.0 2.0 1.0 
o 
Figure 5.3 1 H NMR spectrum of a 40 mM solution of complex 13 in D,O. Peaks 
labelled (a) correspond to the intact complex, (b) corresponds to the hydrolysed form. 
155 
Chapter 5 	Interactions of [(r 6-p-cymene)RuCl(en)] with nucleotides and oligonucleotides 
For the reaction of 13 with the mononucleotide 5' GMP, the nucleotide was added to 
a solution of 13 in 90 % H,0/10 % D20 for a 1:1.1 reaction. The concentration of 
the complex was 20 mM. With knowledge of the hydrolysis of 13 from HPLC, 
section 4.3.5.2, it can be assumed that the complex was about 60 % intact when the 
nucleotide was added. The spectrum of the reaction after 24 h incubation at 310 K is 
shown in Figure 5.4. The reaction is essentially complete as nearly all the free 
5'GMP has disappeared (8 8.13). There are some very minor signals in the spectrum, 
but the major peaks, marked * in Figure 5.4, are assignable. The doublet for the 
isopropyl methyl groups ofp-cymene is at 8 1. 15, the singlet for 
9.0 	8.0 	7.0 	6.0 	5.0 	4.0 	3.0 	2.0 	1.0 
Figure 5.4 'H NMR spectrum of the reaction of complex 13 with 5'GMP in a 1:1.1 
molar ratio in 90% H20/10 % D,Q. The concentration of 13 is 20mM. The peaks 
marked (*) correspond to a 1:1 adduct of 13 with 5' GMP. The very small peaks at S 
8.22 and 8.60 are impurities that were discovered in the 5'GMP 
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the tolyl group is at 6 1.94 and the H-8 of the guanine moiety is at 6 8.79, shifted 
downfield from free 5 'GMP by 0.66 ppm. This H-8 shift is very indicative of a the 
nucleotide reacting with the metal at N7. The CH2 resonances of the ethylenediamine 
ligand are two broad multiplets at 8 2.49 and 2.40. They have become slightly 
resolved into two signals after reaction, as opposed to the one for the complex alone 
in D,O. The multiplet for the C-H of the p-cymene isopropyl group has shifted 
underneath this signal. The arene region of the spectrum contains many peaks now, 
some due to the nucleotide, and is unassignable without detailed 2D NMR studies. 
The NH, signals of the ethylenediamine have decreased to the extent that they are not 
assignable. 
These observations show that the reaction of 13 with 5 'GMP results in one major 
product, a 1:1 adduct, with coordination of the nucleotide occurring through the N7 of 
the guanine. 
5.1.2.2 pH titration of 13 with 5'GMP 
In order to further investigate the binding of 13 to 5'GMP, an NMR pH titration was 
performed. This involved incubating a 1:1 molar ratio sample of 13 and 5'GMP for 
24 h at 310 K and then acquiring the 'H NMR spectrum of the solution at different 
pH values. The pH was adjusted by addition of aliquots of either NaOD or DN03 
and was internally referenced to TSP. By plotting the shift of the H-8 protons against 
pH, Figure 5.5, pKA values for the bound nucleotide were determined. 5'GMP is a 
tribasic species.26  It binds two protons at the phosphate group and one at the purine 
moiety. For H3(GMP)' the first proton is released from the -P(0)-(OH)., group, the 
second from the H(N7) (pKA 2.4827) site and the third one again from the still 
monoprotonated phosphate group (pKA 6.2527). A fourth proton may be released in 
the alkaline pH range from the H(N') (pKA 94927) site. The release of the first proton 
in H3(GMP)-  occurs with a pKa of 0.3, and hence is deprotonated under all but the 
most extreme solution conditions,27 and is not relevant for this study. 
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Figure 5.5 Plot of 6 H-8 vs pH* of 5'GMP bound to [(nôpcymene)RuC1(en)J* 13. 
The steep change in chemical shift in the region ö 5-6 corresponds to the second 
deprotonation of the phosphate moiety. The change in the region 6 8-9 corresponds 
to deprotonation of N' of the guanine. 
The pKA of the deprotonation of N7 in GMP is given in the literature as 2.48.27  It can 
be seen from Figure 5.5 that this deprotonation is absent in the present case and this 
is further evidence that the 5'GMP is bound via the N7. There are two pH dependant 
effects seen though. The first is attributable to the ionisation of the remaining proton 
on the phosphate residue. This pKA of 5.75 for the bound nucleotide is a decrease of 
0.5 units form the literature value of 6.25 .27 It is known that protonation of the 
phosphate group should cause an upfield shift of the nucleobase proton signals 12  and 
this is what is observed here. As the pH is lowered, the phosphate group becomes 
protonated and the H-8 proton resonance shifts to higher field. The chemical shift 
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change that is observed in basic pH can be attributed to protonation of the N' of the 
base. In free 5 'GMP, the pKA of N' is 9•4927  As diamagnetic metallation produces 
effects quite similar to protonation,20 the binding of Ru(II) to the N7 should have the 
effect to acidify the proton at N', causing a decrease in the pKA of N'. This is 
observed in the present case, with the PKA of the bound nucleotide being 8.63, almost 
one unit less than the free molecule. Trans-RuCI,(DMSO)4 lowers the PKA of N' of 
guanine by almost two units when bound to N7 16(b), 28 and the coordination of Pt(II) 
in cisplatin decreases the pK, of guanine N' by one unit. 
5.1.2.3 Reactions of 13 with 5'AMP, 5'CMP and 5'TMP 
In order to investigate qualitatively whether or not 13 reacts with the nucleobases 
5'AMP, 5'CMP and 5'TMP, NMR scale reactions in a 1:1.1 Ru:nucleotide molar 
ratio were performed. This is of interest to see if there is potentially more than one 
binding site on DNA for the complex. 
Complex 13 reacts only slightly with 5'AMP in unbuffered solution (pH* = 5. 24). 
There are two proton NMR probes on 5'AMP, that of the H-8 and H-2. After 24 h 
incubation at 310 K, only a minor amount, 10 %, of a new species had been formed. 
This is indicated by the slight downfield shift of the H-8 proton (8 8.50 to 8.52) and 
the slight upfield shift of the H-2 (6 8.26 to 8.21). The major species in the NMR 
correspond to the intact and the hydrolysed forms of 13. The 3 'P NMR shows a shift 
of 7.24 ppm, from ö 1.12 to 8.36, so coordination to the metal is probably through 
the phosphate group. It had previously been found that both cis- and trans-
[RuCL(DMSO)4] do not react with the adenine moiety of 5'AMP,' 7 just through the 
phosphate group. 
The reaction with 5'CMP (pH* = 6.84), went to 40 % completion after 24 h. 
Binding appears to be through the phosphate group rather than the base. This is 
indicated by the upfield shift of the doublet for the H.-6 proton from ö 8.08 to 7.93 
upon reaction, and of the doublet at for the H-S proton from ö 6.14 to 6.10. Binding 
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to the phosphate group of a nucleotide causes upfield shift of the base protons," 
whereas binding to a base nitrogen would cause a downfield shift, such as that shown 
by the binding of Pt(II) to the N3. 29  There is also the presence of two other species in 
the spectrum, corresponding to the intact complex and the hydrolysed complex. The 
31P NMR spectrum also shows a large downfield shift of the signal for the phosphate 
group from 8 3.42 to 8.54. That 13 reacts to a reasonable extent with 5'CMP is of 
interest as in Section 5.3 the binding of 13 to a 14mer ODN containing equal 
amounts of G and C residues is investigated. 
Only 20 % of the 5'TMP has reacted after 24 h at 310 K. Again this appears to be 
through the phosphate group rather than the nitrogenous base. The H-6 proton shows 
an upfield shift 0.1 ppm, from 6 7.79 to 7.69. Again there is considerable presence of 
intact and hydrolysed forms of the complex. The "P NMR spectrum shows that the 
phosphate group signal has moved from 6 1.97 to 8.53. That the complex did not 
react with the thymidine moiety of the nucleotide is in agreement with the report that 
both cis and trans-[RuC12(DMSO)4] did not react at all with thymidine, even after 
prolonged periods.30 
It has been shown that complex 13 reacts all four DNA models. However, only 
5'GMP binds through the base moiety (via N7). The other three bases appear to bind 
through the phosphate group. 
5.1.2.4 Reaction of 13 with an equimolar mixture of 5'GMP and 5'CMP 
In Section 5.3 the binding of 13 to a 14mer oligonucleotide containing equal numbers 
of Gs and Cs is investigated. To see which base is the preferred choice of 13, an 
NMR sample containing 13, 5'GMP and 5'CMP in a 1:1:1 ratio was prepared and 
incubated at 310 K for 24 h and the NMR spectrum acquired. The reaction of 13 
with 5'GMP is very much favoured over the reaction of 13 with 5'CMP. This is 
clear from the 'H spectrum. There was only a negligible amount of unreacted 
5'GMP left, and a large singlet at ö 8.76 for the H-8 of reacted nucleotide, Figure 5.6. 
The downfield shift from 8 8.07 is indicative of binding to the metal at N7. There is 
one doublet corresponding to the isopropyl methyl groups (6 1.08), one singlet for 
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the tolyl protons (6 1.88) and the CH, groups of the ethylenediamine ligand are two 
broad multiplets at 6 2.05 and 2.41. The C-H of the isopropyl group has merged with 
the multiplet at 6 2.41. The N-H signals are not visible anymore. There is no signal 
for unreacted (intact or hydrolysed) 13. These signals inform us that there is only 
one product with between 13 and the nucleotides, and that it is from a 1:1 adduct of 
H-8 of reac 
ee 5'CMP 
I 	 I 
9.0 8.0 
Figure 5.6 'H NMR spectrum of the equimolar reaction of 13 with 5'GMP and 
5'CMP in DO. The marked peaks show that the complex has reacted with 5'GMP at 
the N7 as the H-8 peak has shifted to lower field as compared to free 5'GMP, but has 
not reacted with 5'CMP 
13 with 5'GMP. The doublet for the H-6 of free 5'CMP remains at 6 8.05, with only 
a negligible peak appearing upfield at 6 7.9, which would correspond to the metal 
binding the 5'CMP through the phosphate group, see section 5.1.2.3. Therefore, 
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when present in equimolar amounts, complex 13 has a much stronger affinity for 
reaction with 5'GMP than 5'CMP. 
5.1.3 Conclusions 
Complex 13 [( 6-p-cymene)RuCl(en)] reacts with 5'GMP in a 1:1 manner by 
binding at the N7  of the guanine moiety. On investigation of the reaction of 13 with 
the other nucleotides 5 'AMP, 5'CMP and 5 'TMP it was found that they reacted 
through the phosphate group rather than the basic nitrogens. A competitive reaction 
between 5'GMP and 5'CMP with 13 showed that the Ru(II)arene complex strongly 
preferred binding to the guanine nucleotide. From these studies it can be assumed 
that the main target for the arene complexes on DNA will be guanine residues. 
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5.2 Melting Temperature of 14mer oligonucleotide duplex in the 
presence of ((16-para-cymene)Ru(efl)CI][PF6] 13*  
DNA is almost always bound to various metal ions under physiological conditions, 
e.g. K, Mg2 , and these ions play a crucial part in the behaviour of DNA.31 Various 
studies using UV and circular dichroism have investigated the interaction of metal-
ions and DNA. It has been found that metal ions actively participate in determining 
the helical, tertiary and quaternary structures of DNA. The differing effects of 
various ions are due to the nature of the various binding sites and the affinities of the 
ions for the sites. 12   In the nucleoside, glycosyl links are formed and this blocks the 
N9  of the purine and the N of the pyrimidine (in the free purine, unsubstituted N9 is 
the most basic site). Hence in DNA the phosphate oxygens and the N7 site of guanine 
seem to be the most likely site of metal interaction.33 Knowing that complex 13 
binds to the nucleotides of DNA, see section 5. 1, and in particular the N7 of guanine 
it is of interest to investigate the structural impact that this has on the DNA duplex. 
Cisplatin and other Pt(II) drugs are thought to kill cells as a result of their binding to 
DNA.34 Healthy cells are able to remove the adduct by a complicated series of repair 
mechanisms, however in cancerous cells these mechanisms are unable to function 
effectively, resulting in apoptosis. NMR studies, in combination with X-ray and gel 
electrophoretic studies," have found that binding of cisplatin results in the DNA 
being unwound by 13 - 23 0  and bent by 34 - 550 in the direction of the major 
groove. The local area of binding becomes A-form while the rest of the molecule 
remains in the B-form.35 These changes cause the melting temperature of the DNA 
to be reduced by 10 - 20 0  depending on the type of DNA being studied. This 
The work in this section formed part of a final year undergraduate project by Nathan Hughes. 
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indicates a significant destabilisation of the duplex and it is therefore potentially of 
great importance to the drug/activity relationship. 
A series of proteins named HMG (High Mobility Group) proteins bind preferentially 
to bent DNA-cisplatin adducts.36 It is postulated that HMG proteins recognise the 
bent site of cisplatin binding and binds to this region. This step may be critical to the 
fate of the cell. Various mechanisms have been postulated for this process.37 The 
protein may mask the adduct preventing repair, the protein may attract tumour 
specific regulatory proteins resulting in cell death or the adduct may interfere with 
ribosomal RNA (rRNA) transcription thus reducing protein synthesis. 38  Such 
disruption may be crucial in cancer cells where rRNA synthesis is particularly 
stimulated. 
Nucleotides tend to have an overall negative charge as a result of their polyanionic 
phosphate backbone. The phosphate groups have a pKA<I and hence are 
deprotonated under most solution conditions.27 Positive ions, such as metals, 
counteract the overall negative charge of the nucleotides and reduction of the 
phosphate chain repulsion (charge screening) is largely responsible for structural 
transitions39 and stabilising of the DNA.4° Reaction of a positive metal ion with the 
phosphate group generally means stabilisation of ordered structures" whereas 
reaction with the bases means destabilisation of ordered structures . 4' Although high 
ionic strength of the medium stabilises the DNA duplex '47  it is thought that the 
stability conferred by the positive platinum ion is outweighed by the instability 
caused by the bending and unwinding. A good method of investigating the extent of 
the stabilising, or destabilising, effect of a metal ion on a DNA duplex is the process 
of DNA melting. 
Nucleic acids absorb light with a 	at 260 nm due to 7t7r*  electron transitions of 
the purine and pyrimidine rings,43 When a DNA helix is formed, base stacking is 
accompanied by a reduction in UV absorption (hypochromicity) compared to the 
random coil form.44 This makes UV analysis a convenient method to monitor the 
formation and breakdown of double helices. If the temperature of a solution 
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containing double-heliced DNA is slowly raised and the absorbance monitored, it can 
be seen that the absorbance increases suddenly at a certain temperature due to the 
dissociation of the ordered helices. The mid-point of the transition is known as the 
melting temperature (Ta,). 
Helix-coil interactions are essentially an all or nothing process, and since the 
absorbance of double stranded DNA is essentially 10 % less than the single stranded 
form, the transition between the two is easy to monitor. Analysis of the system 
A(pA)17 -  U(pU)17 at various temperatures" yielded exclusively either dissociated 
coiled monomers or fully integrated double helices, with only the terminal base pairs 
in rapid dissociation-recombination. 
Certain factors affect TTfl.  The thermal transition of DNA is greatly influenced by the 
ionic strength of the solution.46 Increasing the ionic strength of the medium increases 
the T,11.47 Increasing the chain length of the oligonucleotide also increases the Tm, 
with a steeper slope at the point of inflection, synonymous with enhanced 
cooperativity. It has also been noted that Tm  increases the greater the ratio of 
GC/AT.48  
It was of interest to investigate whether binding of complex 13 to the 14mer duplex 
1•II (Figure 5.7) causes any thermal, and hence structural, instability in the helix. 
The melting point temperature of the Ru-arene adduct was compared to both free 
DNA 14mer and the cisplatin adduct in solutions of varying ionic strength. The 




Figure 5.7 Oligonucleotide I and its complementary strand II 
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5.2.1 Experimental 
ODNs I and II were obtained as HPLC purified sodium salts from Oswel 
(Southampton, U.K.). Concentrations were determined using UV/Vis spectroscopy 
(strand 	= 149.0 mM-'cm' and strand II P-260 = 137.2 mM'cm). DNA melting- 
point UV/Vis spectra were recorded on a Perkin Elmer ? 20 UV/Vis spectrometer 
using a quartz cell with a path length of 10 mm. The temperature was controlled 
using a PTPI Peltier Temperature Programmer. The data was analysed using UV 
Winlab and PE Templab software for Windows 95 from Perkin Elmer. Drug (13 or 
cisplatin) and duplex I•II were mixed in a 1:1 molar ratio at a concentration of 3 mM 
and incubated at 310 K for 48 h. The buffer was 10 mM sodium phosphate (pH = 7). 
Ionic strength was varied (10 - 60 mM) by addition of aliquots of NaClO4 solution. 
5.2.2 Results and discussion 
In this experiment the melting point of the 14mer oligonucleotide duplex I•1I was 
investigated as the free duplex, after incubation (1:1 molar ratio) with complex 13 for 
48 h and after incubation (1:1 molar ratio) with cisplatin for 48 h at a range of ionic 
strengths. This allowed an assessment of the effect of the complex on the thermal 
stability of the duplex. 
The melting points of the free duplex and the drug/duplex mixtures are plotted 
against the ionic strength of the solution in Figure 5.8. It can be seen that all three 
follow the pattern that the melting temperature increases with increasing ionic 
strength.47 The Tm  of the 14mer ranged from 33 - 40 °C over the range of ionic 
strengths. It can be seen that addition of the Ru(II) complex to the duplex had a 
thermally destabilising effect on the melting point of the duplex, causing it to be 
decreased by 5 °C. This indicates that the complex has destabilised the structure of 
the duplex. 
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Figure 5.8 Effect of [( 6-p-cymene)Ru(en)CIJ[PF6] 13 () and cisplatin (o) on the 
melting temperature (T 1) of the DNA duplex I'll ( ), (molar ratio of metal:duplex 
1:1). Reaction conditions: 3 mM duplex, 10 m phosphate buffer (pH = 7) 
As a comparison experiment, the duplex I•1I was also incubated with cisplatin. It is 
known that cisplatin has a significant structural effect on DNA," and so we would 
expect it to decrease the Tm  of the duplex. This is shown in Figure 5.8. It is 
remarkable how similar the effects of the two drugs are. Since cisplatin's activity is 
thought to be linked to DNA binding,34 the ruthenium complex may also have 
potential as a chemotherapeutic agent. 
In Section 5.3 it is shown that it is possible to isolate the various adducts of 13 to the 
DNA single strands. An attempt was made to anneal the isolated adduct strands to 
their complementary strands. The annealing process was monitored by following the 
mer+ 13 
r + cisplatin 
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isothermal mixing curves.49  These showed that the strands did not anneal when the 
ruthenium complex is bound to a single strand first. Hence more specific melting 
point investigations were not possible. This was unexpected as the binding of 13 to 
the duplex did not alter the duplex's melting cooperativity, i.e. have an effect on the 
two-state melting behaviour of the duplex structure. This work does show 
conclusively, however, that 13 binds to the duplex ODN in such a manner that it 
significantly effects the thermal stability of the duplex structure. 
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5.3 Reaction of ((16-para-cymene)Ru(en)CI][PF6] 13 with 14mer 
oligonucleotide 
The N7  site of guanine is the most basic site on the DNA nucleobases.24 This makes 
it a strong candidate for interactions with Lewis acids such as the metal centres of 
metallodrugs. Indeed, DNA is thought to be the most likely bio-target" of the potent 
anti-tumour drug cisplatin, and its efficacy is probably linked to the formation of 1,2-
GG or 1,2-AG intrastrand bifunctional adducts.' 
1,12  A GG bifunctional adduct has 
been identified by recent X-ray crystallographic work" to severely distort the double 
helix by causing a bend towards the major groove and a widening and flattening of 
the minor groove, resulting in an unusual juxtaposition of A-like and B-like helical 
segments. It is possible that this feature could be important for the recognition of Pt-
DNA adducts by HMG proteins. HMG (high mobility group) proteins are thought to 
interfere with cellular repair processes when interacting with Pt-DNA adducts. 
Ruthenium complexes have also been found to interact with DNA and nucleotides in 
a variety of ways, such as covalent binding and intercalation. Indeed, much of the 
work involving antineoplastic evaluation has found that ruthenium is often selective 
for N7 of guanine. Examples of this are Ru" amine and aromatic imine 
complexes 4 ' 6578, and the Ru" complexes cis and trans-RuCl2(DMSO)4 9 '6016263  
which have been found to favour binding to two adjacent guanine residues. 
Therefore, it is of interest to investigate the binding of the ruthenium-arene complex 
[( 6-para-cymene)Ru(en)ClJ[PF6]1  13, see Figure 5.2, to DNA, and to elucidate its 
binding site. 
The DNA strand used in this work is the 14 base single strand oligonucleotide 
d(ATACATGGTACATA) I. This strand (and its complementary 
d(TATGTACCATGTAT) II), see Figure 5.7, was designed for analysis of the 
bifunctional Pt-GG intrastrand adduct. Its sequence is such that formation of AG 
intrastrand adducts is not possible. The benefits of the strand in the case of the Ru-
arene complex is that it contains a selection of all four nucleotides, and so 
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investigations will yield information on the base specificity of the complex. It also 
contains a potential GG chelation site. Complex 13 may form only monoadducts 
with DNA as it has only one available coordination site through loss of the chloride 
and therefore differs from metal-drugs such as cisplatin and cis-[RuCl,(DMSO)4]. 
There is a previous report of the significance of mono functional DNA adducts. The 
promising antitumour active trans iminoether complex" PtC12(E-iminoether2) forms 
predominantly monofunctional adducts at G residues" and induces local distortion in 
DNA .66  [Pt(dien)Cl] has been widely used to mimic the first binding step of 
cisplatin, and is itself capable of distorting DNA structure and inducing local DNA 
denaturation. 6768'69 	Recently, 	the 	binding 	of 	[Pt(dien)Cl] 	to 
d(ATACATGGTACATA) has been used to investigate the kinetics of Pt binding to 
the guanine residues on the 3' and 5' end of the strand.71  
The primary techniques used in this investigation are HPLC and electrospray mass 
spectrometry (ESI-MS). There are many examples of the use of HPLC in the 
separation of metallated biomolecules, and is a technique commonly used in 
bioinorganic chemistry." ESI-MS is a less commonly utilised technique in metal-
DNA investigations, yet is extremely powerful and versatile. 
ESI-MS has become an important tool for the investigation of large biomolecules 
since the late 1980s.72 This soft-ionisation technique is applicable to fragile large 
molecules such as proteins and oligonucleotides. Its high ionisation efficiency,73 i.e. 
[molecular ions produced]/[molecules consumed], makes it a suitably sensitive 
technique. It has been possible to determine molecular weight, sequence, the site and 
nature of chemical modification as well as other information 
.74,75,7677 The polyanionic 
backbone of nucleic acids allows these molecules to be investigated in the ESI-MS 
negative ion mode. The phosphate groups have pKA values <I and will be 
deprotonated under most solution conditions.27 However, it has been possible to 
observe positive ions of oligonucleotides depending on the solution conditions." 
The solution conditions determine whether or not the purine and pyrimidine bases 
will be protonated, deprotonated or neutral. This allows for simultaneous analysis of 
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proteins and oligonucleotides and illustrates the versatility of the technique. Laser 
desorption mass spectrometry techniques such as MALDI-TOF can also be used for 
analysis of biomolecules,79  but nucleic acid analysis is limited due to fragmentation 
of the DNA occurring during the MALDI process.808' The fragmentation appears to 
be initiated by protonation of a base followed by cleavage of the N-glycosidic bond, 
which in turn leads to cleavage of the phosphodiester backbone.8081 '82  Therefore, 
electrospray is the technique of choice. ESI-MS has even been used to detect intact 
DNA duplexes83'84  and it is possible to detect and characterise non-covalent 
complexes formed between molecules such as the minor groove binder distamycin A 
and duplex DNA.85 
This section describes the separation and characterisation of complex 13-DNA 
adducts by HPLC, ESI-MS and after enzymatic digestion. 
5.3.1 Instrumentation and Materials 
Negative and positive ion electrospray mass spectrometry was performed on a 
Platform II mass spectrometer (Micromass, Manchester, U.K.). The samples were 
infused at a flow rate of 0.48 ml h and the ions produced in an atmospheric pressure 
ionisation (API)/ESI ion source. The temperature was 363 K and the drying gas flow 
rate 300 L W. A cone voltage of 40 keV over 0 - 1500 Da was used. The acquisition 
and deconvolution of data were performed on Mass Lynx (V. 2.3) Windows NT PC 
data system using the Max Ent Electrospray software algorithm and calibrated versus 
a NaT calibration file. ESI-MS was used to detect the solvated species of a ruthenium 
complex and its adducts with the 14 nucleotide DNA strands I and H. 
HPLC was performed with the assistance of Dr. Socorro Murdoch, using a Hewlett-
Packard series 1100 Chemstation; including 1100 series Quaternary pumps, 1100 
series vacuum degasser and variable wavelength D2  lamp UV/Vis detector with 
enhanced integrator. The operating software was HP Chemstation for Windows 95. 
The chromatographic conditions were optimised on a Nucleosil C8 300 A (250 x 4.6 
mm ID, 5 .tM) stainless steel column (Hichrom U.K.). The detection wavelength 
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was 254 nm and the relative concentrations of the reaction species were determined 
from the relative peak areas. Time course reaction was followed at 300 K and all 
other separations at 298 K. 
The 14-nucleotide oligomer with the base sequence of d(ATACATGGTACATA) I, 
and its complementary strand d(TATGTACCATGTAT) II were obtained as HPLC 
purified sodium salts from Oswel (Southampton, U.K.). The calculated molecular 
masses are 4268.8 and 4250.8 amu respectively. Concentrations were determined 
using IJV/Vis spectroscopy (strand IF260 = 149.0 tM' cm' and strand 11 6,611  137.2 
j.tM' cm'). Tissue culture water was purchased from Sigma (W-3500). 
The phosphodiesterases VPD and SPD were purchased from Sigma and NPI was 
purchased from Pharrnacia Biotech. 
5.3.2 Experimental 
5.3.2.1 Sample Preparation 
Flame sterilised equipment was used throughout sample preparation so as to avoid 
bacterial contamination which might lead to DNA degradation. Stock solutions (200 
iM of the oligodeoxynucleotide strands and a 6 mM stock solution of the ruthenium 
complex were made up in double processed tissue culture water. Using dilution 
techniques, reaction mixtures were made up, sealed in Eppendorf tubes and incubated 
at 300 K for 48 h. Control 100 tM solutions of! or!! and the ruthenium complex 
were prepared and incubated at 300 K for 48 h. Aliquots of each sample were diluted 
x 2 in HPLC grade acetonitrile prior to infusion into the mass spectrometer. The 
spectrometer was flushed before and between runs with 50:50 v/v CH3CN:H20. 
5.3.2.2 HPLC Separation 
The following methods were used for the HPLC separation of the ruthenated 
oligodeoxynucleotide strands: 
Solvent A = 20 mM TEAA (tetraethylammonium acetate) in H20 
Solvent B = 50 / 50 v/v CH3CN / H 2O 
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time/mill %A %B 
0 75.5 24.5 
5 75.5 24.5 
17 60 40 
20 60 40 
21 75.5 24.5 
Table 5.1 Solvent gradient for HPLC separation of 14mer strand I 
time/mm %A %B 
0 78 22 
5 78 22 
6 77 23 
12.5 67 33 
15 67 33 
17 60 40 
18 60 40 
20 78 22 
Table 5.2 Solvent gradient for HPLC separation of 14mer strand II 
5.3.2.3 Enzymatic Digestion of Purified Strands 
5.3.2.3.1 Digestions with VPD 
Concentrations of purified oligodeoxynucleotides were typically in the region of 25 
M in H2O. VPD (venom phosphodiesterase) was diluted x 3 in H-,O prior to use, 
and typically 2 p.l of the enzyme solution was added to 200 p.1 of the ODN solution. 
The mixtures were incubated at 310 K and aliquots were extracted at various time 
intervals and diluted x 2 with HPLC grade CH3CN prior to ESI-MS analysis. 
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5.3.2.3.2 Digestions with SPD 
Digestions with SPD (spleen phosphodiesterase) were performed with the same 
procedure as VPD. 
5.3.2.3.3 Digestions with NP1 
1 mg of lyophilised NFl was dissolved in 10 mM CH3COONa (pH = 5.2) for 
optimum activity. An aliquot (2 jxl) of this solution was added to 200 41 of 25 jtM 
solutions of purified ODN in H20. The mixtures were incubated at 310 K. 
5.3.3 Results and Discussion 
5.3.3.1 Electrospray mass spectrum of [( 6-para-cymene)Ru(en)CI][PF5] 13 
Ruthenium has a wide isotopic profile, ranging from 96 to 104, with the most 
abundant species being 102 Ru, 31.6 %, see Table 5.3. This wide range aids 
assignment of peaks in mass spectra due to its characteristic isotope pattern. The 
predicted pattern for ruthenium is shown below in Figure 5.9, and it can be seen that 
this matches the patterns observed in the spectrum of the arene complex above. It 
should be noted that for the high molecular weight compounds, such as the 
oligonucleotide-Ru adducts studied in this chapter, that the mass of the ruthenium is 
too small relative to the overall mass to allow observation of the individual 
isotopomers in the spectrum. 
Ru isotope 96 98 99 100 101 102 104 
% abundance 5.5 1.9 12.7 12.6 17.1 31.6 18.6 
Table 5.3 % Natural abundance of ruthenium isotopes 
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Figure 5.9 Predicted isotope pattern for ruthenium. Top trace is mass spectrum, 
bottom is line spectrum. 
The positive ion electrospray mass spectrum of [(r16-para-cymene)Ru(en)Cl][PF6] 13 
is shown in Figure 3.10. This was taken at an intermediate cone voltage of 40 eV. It 
can be seen that the dominant ions in the spectrum are quasi-molecular ions, i.e. 1+ 
charge, corresponding to the intact complex (without the PF6 counter ion) at 331.1 
amu (theor. 331.8), the hydrolysed form of the complex at 315.1 amu (theor. 314.1) 
and the Ru(arene)(en) moiety at 295.1 amu (theor. for -W 295.3). There are also 
minor 2 + ions at Dale 148.4 and 167.0. It was found that as the cone voltage was 
increased these disappeared, and formation of the molecular ions was completely 
favoured. The lability of the chloride ion is also indicated by the effect of raising the 
cone voltage. As it was increased, the species at 331.1 became less important and the 
peak at 295.1 was dominant, showing loss of chloride. 
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Figure 5.10 Positive ion mass spectrum of an aqueous solution of ftr 6-para- 
cymene)Ru(en)C1] [PF6] 13 
5.3.3.2 Mass spectrum of -GG- strand ( I ) 
Sequence of strand I = ATACATGGTACATA 
ODNs contain a phosphate backbone which bears a negative charge at each 
phosphate group. The pKA values of these phosphate groups is <I, which means that 
they are negatively charged under all normal solution conditions. This makes them 
ideal for analysis by negative ion mode electrospray mass spectrometry. The 
negative ion mass spectrum of the 14mer strand I is shown in Figure 5.11. The 
spectrum provides an ion series, which can be transformed to determine the 
molecular mass of the species. The transformed spectrum is shown in the inset. The 
molecular mass of the transformed species does not correspond to the molecular 
mass of the free oligonucleotide. Instead, the peak at 4337.1 corresponds to I - 31-1- + 
3Na] (theor. 4335). Strand I was supplied as the sodium salt, and it is very common 
in ESI-MS to find that Na adducts are often the main species detected, rather than 
protonated species. 16  It can be seen that the most intense peak in the series 
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corresponds to the 8-  ion. This is appropriate for a 14mer strand of DNA in 
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Figure 5.11 Mass spectrum of-GG- strand I 
5.3.3.3 Mass spectrum of 13 + 14mer strand I 
Complex 13 was incubated at 310 K for 48 h with a sample of the -GG- I strand in a 
1:1 molar ratio, and the resulting mixture analysed by negative ion mode ESI-MS. 
The results proved conclusively that the ruthenium complex binds to the DNA in 
both a 1:1 and a 2:1 ratio. The spectrum is shown in Figure 5.12. It can be seen that 
the ionic series corresponding to the free DNA strand is still present, but it is the 
extra peaks that are of interest. Two new ionic series were detectable and these gave 
rise to the molecular mass peaks shown in the inset. The molecular masses are 
appropriate for free DNA (4338 amu) (theor. DNA -31-1 ± 3Na 4335 Da); 
Ru(arene):DNA. 1:1 (4609.3 amu) (theor. for -21-1 + 2Na, 4608.9 Da); 
Ru(arene):DNA, 2:1 (4904.9 amu) (theor. for -2H + 2Na, 4905 Da). It is 
understandable that free DNA is still present, since although the initial molar ratio 
was 1:1, some of the DNA strands have 2 bound ruthenium ions. With the 
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knowledge that the complex does indeed bind to DNA, the process was then 
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Figure 5.12 Mass spectrum of 13 + 14mer strand I (1:1 molar ratio) 
5.3.3.4 HPLC separation of 13-GG strand I adducts 
HPLC separation of biomolecules is well known.88 Isolation and purification of 
biological adducts allows more information about possible modes of binding and 
mechanisms to be elucidated. 
The separation of the Ru(arene)-GG adducts was undertaken on a reverse phase 
column. Such columns retain hydrophobic entities, which are eluted at various times 
depending on the solvent system used. 	In the present case, the buffer 
tetraethylammonium acetate was used. The tetraethylammonium ion-pairs with the 
anionic phosphate groups and also has hydrophobic ethyl groups attached. An added 
advantage of the buffer is that it is volatile, and therefore is lost during lyophilisation, 
and further purification, is avoided. The speed of the elution of the adducts is 
controlled by the gradient of the 50/50 CH3CN/H10 solvent system. The more 
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acetonitrile used, the faster the adducts are eluted from the column. However this 
can be at the expense of separation. 
The HPLC trace for the separation and collection of the Ru(arene)-GG adducts and 
their assignments are shown in Figure 5.13. 
free DNA 
A260 
2.5 	 7.5 	 12.5 	 17.5 
Time / mm 
Figure 5.13 HPLC trace of 13-GG strand I adducts. Assignment of peaks: (a) 13:1 
monoadduct (b) 13:1 monoadduct (c) 13:1 bisadduct. 13 and the DNA strand I were 
mixed in a 1: 1 molar ratio in unbuffered water and incubated at 310 K for 24 h prior 
to separation. 
The initial peak on the trace (SF) is due to the solvent front. All other peaks were 
conclusively assigned by mass spectrometry following the separation (see next 
section). By varying the Ru:DNA ratio, incubating for 24 h at 310 K and 
investigating this by HPLC, it was possible to decide which peak is due to a 1:1 and 
which peak to a 2:1 adduct. Increasing the amount of ruthenium present caused the 
size of peak (c) to increase accordingly. When the ratio was 5:1 Ru:DNA, this was 
the only peak present, see Figure 5.14. There was no free DNA, nor peaks (a) and 
(b). The method used was changed slightly from the method used to collect 
fractions, due to pressure change in the machine, hence the differing elution times. 
This specificity, despite the relatively high ruthenium concentration, lends itself to 
179 
Chapter 5 	Interactions of [(7 6-p-cymene)RuC1(en)] with nucleotides and oligonucleotides 
the idea that Ru binding is base specific. This base is most likely guanine. This in 
turn supports the idea that the 1:1 adducts correspond to a 5 'G adduct and a 3 'G 
adduct, and that the bis-adduct consists of two ruthenium ions bound at the -GG-
hotspot. In this particular strand, only guanine and cytosine appear twice (there are 
four thymines and four adenines and this would not allow for the specificity observed 
in the HPLC) and the binding of the complex to guanine is preferred than to cytosine, 
see section 5.1.2.4. 
Ru:DNA 
C 	 1:1 
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Figure 5.14 HPLC traces of 13-GG strand I adducts at different molar ratios. 
Mixtures were in unbuffered aqueous solution and incubated for 24 h at 310 K. 
5.3.3.5 Mass spectra of purified adducts 
The individual fractions were collected, lyophilised and redissolved in H20. 
Aliquots of these were diluted in 50150 CH3CN/H-,O to a concentration of 25 tM for 
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ESI-MS analysis. The spectra obtained agreed with the assignments given to the 
peaks in the previous section. 
Peaks (a) and (b) are 1:1 Ru:DNA adducts. Their spectra are identical and so are 
shown as one in Figure 5.15. As expected for the two isomers, peaks (a) + (b), the 
mass spectra are identical as they differ only by the location of the Ru(arene) moiety 
on the strand. The transformed spectrum (shown as inset) gives the mass value of 
4565.9 amu (caic. 4564.9 Da) which corresponds to the 14mer strand I with the [(r 6-
p-cymene)Ru(en)]2 fragment attached. This would correspond to activation of the 
complex via hydrolysis which would free the coordination site at the metal, 
previously occupied by the chloride ligand, for binding to a base on I. 
4565.9 
100 
400 	500 	600 	700 	800 	900 
Figure 5.15 Mass spectrum of 13-I peaks (a) and (b) 
The mass spectrum for peak (c) is shown in Figure 5.16. This gives the transformed 
mass of 4859.4 amu (theor. 4861.0 Da) which is correct for the adduct oft with two 
[(116_p-cymene)Ru(en) ]21 fragments attached. Therefore it can be conclusively stated 
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ATACATGGTACATA in both a 1:1 and 2:1 Ru:DNA manner in aqueous solution, 
and that there appear to be only two specific sites of binding. 
I 
le 
400 	500 	600 	700 	800 	900 
	
1000 
Figure 5.16 Mass spectrum of 13-I peak (c) 
5.3.3.6 Enzymatic digestion of purified Ru(arene)-GG strand I adducts 
With the knowledge that the Ru(arene) complex 13 binds specifically, it is of 
interest to identify the exact sites of binding. One manner of investigation is by 
enzymatic digestion of the metallated DNA and subsequent analysis of the digestion 
products. This procedure has previously been used to sequence strands of DNA89 and 
also for investigating sites of labelling on DNA.9° Typical enzymes used include the 
phosphodiesterases VPD (venom phosphodiesterase) and SPD (spleen 
phosphodiesterase). Phosphodiesterases hydrolyse phospho-ester bonds. VPD is a 
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products are 5'-mononucleotides. It is extracted from the venom of the South 
American rattlesnake, Crotalus Durus Terrfficus. SPD is a 3'-exonuclease, and 
sequentially digests the single strands from the 5' end, creating 3'-mononucleotides. 
Thus, these two enzymes provide complementary information. Their use is 
particularly advantageous in the case of labelled DNA as they tend to stop digesting 
at the site of labelling. A recent example of this is the binding of [Pt(dien)Cl] to the 
14mer strand ATACATGGTACATA.7° This study was undertaken to simulate the 
monofunctional adducts of cisplatin-DNA, and the successful enzymatic digestion of 
these adducts provided conclusive proof of binding to the guanines of the GG site. 
Mass spectrometry, electrospray and MALDI-TOF are powerful tools for the analysis 
of DNA", and oligonucleotides up to a 33mer have been sequenced using MALDI-
TOF in conjunction with phosphodiesterases.92 MALDI-TOF is the technique mainly 
used in the literature, and there is only a limited number of publications on DNA 
sequencing with electrospray MS, for which DNA size tends to be smaller. These 
include the partial sequencing" and complete sequencing "of a I Omer. Recently this 
has been applied to a 22mer and a biotin-labelled 1 8mer.95 
Other enzymes used in this form of analysis are Nuclease P1 (NPI), a non-specific 
nuclease from penicillium citrinum which hydrolyses DNA and RNA to 5'- 
mononucleotides.96 
VPD was the first enzyme utilised. The enzyme was added to a solution of an 
isolated fraction of Ru(arene)-GG and incubated at 310 K. Aliquots were taken at 
various time intervals and analysed by ESI-MS. The mass spectra provided ion-
series for the various intermediates, with new species appearing as the digestion 
progressed. Sequence ladders created by combining the transformed spectra of the 
ions present at various times are shown for peak (a) in Figure 5.17, peak (b) in Figure 
5.18 and (c) in Figure 5.19. 
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1 2 3 4 5 6 7 8 9 10 11 1213 14 
5 '-ATACATGGTACATA-3' 
Ru 
Figure 5.17 VPD digestion ladder of 13-I peak (a). It should be noted that all these 
species were not detected at the same time. The ladder is a convenient method of 
showing the progress of digestion from start (the right-hand side) to the finish (the 
left-hand side), with each "rung" corresponding to a species present. 
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1 2 3 4 5 6 7 8 9 10 11 1213 14 
5 '-ATACATGGTACATA-3' 
Ru 
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Figure 5.18 VPD digestion ladder of 13-I peak (b). It should be noted that all these 
species were not detected at the same time. The ladder is a convenient method of 
showing the progress of digestion from start (the right-hand side) to the finish (the 
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Ru 
1 2 3 4 5 6 7 8 9 10 11 1213 14 
5 '-ATACATGGTACATA-3' 
Ru 
Figure 5.19 VPD digestion ladder of 13-I peak (c). It should be noted that all these 
species were not detected at the same time. The ladder is a convenient method of 
showing the progress of digestion from start (the right-hand side) to the finish (the 
left-hand side), with each "rung" corresponding to a species present. 
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It can be seen from the sequence ladders that peak (a), Figure 5.17, digests as far as 
the T9, indicating the presence of the ruthenium on the 3'-G8. Peak (b), Figure 5.18, 
digests as far as the 3'-G8, indicating the presence of the ruthenium on the adjacent 
base, the 5'-G7. The doubly ruthenated strand, Figure 5.19, only digests as far as A5, 
one base before the GG site. This strongly indicates that both Ru ions are on G 
residues, which is a reasonable assumption to make at this point given the spectra of 
peaks (a) and (b). It is possible that having two adjacent Ru(arene) fragments has 
distorted the structure of the strand in that region to such an extent that the enzyme 
does not recognise it efficiently. There is also precedence for VPD digestion 
stopping one base prior to a labelling site on DNA. 97 
Although the sequence ladders are quite clear, there are inherent complications due to 
the nature of the ionisation in the spectroscopy and its low tolerance to detergents 
and salts. These give rise to noise and unwanted peaks in the spectrum. However as 
the sequence of the DNA is preset (i.e. known), the possible products are limited, and 
hence it was possible to identify the real peaks. 
These complications are well addressed by Wu et al.95 As multiply charged ion 
series predominate with ESI-MS, the regular mass spectrum must be transformed to a 
reconstructed molecular mass (RMM) spectrum. RMM spectra over ranges greater 
than 700 Da have not been reported" in the sequencing of DNA. This is presumably 
because interference such as harmonic peaks and chemical noise from 5'-
mononucleotides result in poor quality RMMs. Na ion adducts also produce 
additional peaks in a MS spectrum, which are extremely hard to avoid. The 
sensitivity drops as a result of spreading the ion current among multiple forms of the 
DNA, and this complicates the spectral interpretation. Also, as the strand shortens, 
the presence of mononucleotides increases. These produce very strong signals, not 
only in the mlz region of 289-329, but also in the mlz region of 600-700 due to the 
formation of non-specific dimers. Tnmers in the region of nilz 900-1000 are also 
known and these can severely interfere with MW reconstruction. 
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Although the digestion of the DNA by VPD alone is sufficient to point to binding 
sites at the guanine residues, it was decided to attempt digestion with another enzyme 
to provide corroborative evidence. Therefore digestion with the enzyme SPD, which 
begins from the other end, the 5' end, was attempted. Problems with this became 
immediately apparent when it was noticed that the enzyme itself gives a mass 
spectrum in the negative ion mode which masked every other peak. Even after 
subtraction of a blank spectrum of the enzyme from the digestion mixture, no 
assignable peaks were present. No previous mention of this is in the literature, 
despite many people claiming to have utilised SPD with mass spectrometry.99 
The digestion of the metallated DNA with the non-specific exonuclease NPI was 
also investigated. As expected it successfully completely digested strand I, and four 
strong peaks corresponding to the free mononucleotides CMP (mlz = 306), TMP 
(mlz = 321), AMP (mlz = 330) and GMP (mlz = 346) were observed. However, no 
peak corresponding to a metallated nucleotide appeared. No signal could be detected 
in either positive or negative ion mode mass spectrometry, and concurrently, no free 
ruthenium complex could be detected. This implies that the labelled base is still 
intact and that the problem is with the ionisation of the Ru-base adduct. On closer 
analysis it seems feasible that this should be the case. The Ru complex carries a 
charge of 2+ and the phosphate group in a mononucleotide carries a charge of 2-. It 
is possible that this overall neutrality prevented the detection of any charged version 
of the adduct. An investigation of the Ru-arene with 5 '-GMP supported this 
supposition. After incubating a 1:1 mixture of the two compounds at 310 K for 24 h, 
no assignable adduct peak could be found in the ESI mass spectrum, positive or 
negative ion mode. Therefore, this enzyme was of no significant benefit in the 
determination of the binding site of the ruthenium to the ODN. It does, on the other 
hand, indicate that the ruthenium is quite strongly bound to the ODN as the strand 
was fully digested and no free ruthenium was detected. 
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5.3.3.7 Time course of reaction of 13 with 14mer strand 1(1:1 molar ratio) at 
310 K 
The time course for the reaction of 13 with the DNA 14mer strand I in a 1:1 molar 
ratio in unbuffered aqueous solution at 310 K is shown in Figure 5.20. The relative 
concentrations were calculated from the integrated areas of the HPLC peaks for free 
DNA and (a), (b) and (c), detected at 260 rim. It can be seen that the reaction is 
essentially complete after 4 h. It is interesting to note, however, the change in the 
amount of species (a) and (b) present after this time. Up to 17 h, more of species (a) 
is present than (b), but after this time there is a shift and a decreases, while (b) 
becomes more prevalent. This invokes the possibility that Ru(arene) bound to the 
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Figure 5.20 Time course for reaction of 13 with 14mer strand 1(1:1 molar ratio) at 
310 K in unbuffered aqueous solution. Detection is at ?. = 260 rim. Assignments: 
free DNA =(•),(a)=( ),(b)=(A),(c)=(') 
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5.3.3.8 Mass spectrum of 13 and 14mer strand II 
Sequence of 14mer strand II: TATGTACCATGTAT. 
The ruthenium complex 13 was incubated for 24 h at 310 K with the -CC- 14mer 
strand II (complementary to the -GG- strand I) in a 1:1 molar ratio in unbuffered 
aqueous solution and analysed by ESI mass spectrometry. The results were found to 
be similar to those for the -GG- strand in that both mono- (found 4568.5 amu, theor. 
for -IH + iNa, 4568.9 Da) and bi-ruthenated (found 4837.0 amu, theor. 4843.0 Da) 
adducts were detected in the reaction mixture as well as free II (found 4299.1 amu, 
theor for -2H + 2Na, 4294.8 Da). This reaction is consistent and reproducible, and 
again shows that complex 13 is specifically bound to guanine residues. Again there 
are two guanine residues present in II, compared to 6 T and 4 A residues. Binding to 
either of these would result in a more complicated mixture of products. There are 
also 2C residues, but binding to guanines is much more favourable for metal-based 
drugs in general, and for the Ru(arene) complex used here in particular, see section 
5.1.2.4. 
5.3.3.9 HPLC separation of-CC- strand II adducts with complex 13 
Separation of the species present in the reaction mixture of Ru(arene) and II was 
attempted by HPLC methods, see Figure 5.21. Peaks (a) and (b) were collected as 
one fraction as they could not be separated sufficiently to collect individually, and 
peak (c) was collected as a single fraction. It seems likely that peaks (a) and (b) are 
both mono-ruthenated II and that peak (c) is the bi-ruthenated species, by 
comparison with the separation for adducts of strand I, see section 5.3.3.4. 
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Figure 5.21 HPLC trace for separation of 13 + -CC- strand II. A 1:1 molar ratio of 
II and 13 were incubated at 310 K for 24 h prior to separation. 
5.3.3.10 Mass spectra of purified adducts 
The collected fractions were lyophilised and redissolved in H2O. Aliquots of these 
were taken, and diluted in 50/50 CH3CN/H20 to a concentration of 25 iM for ESI-
MS analysis. The mass spectra show that peaks (a) and (b) combined, Figure 5.22, 
contain a single species, mono-ruthenated II. This corresponds to II with a [(re-p-
cymene)Ru(en)]2 fragment attached (found 4546.8 amu (theor. 4546.9 Da)). 
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Figure 5.22 Mass spectrum of combined HPLC peaks (a) and (b) from the 1:1 molar 
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The mass spectrum of peak (c), Figure 5.23, is consistent with assignment as II with 
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Figure 5.23 Mass spectrum of HPLC peak (c) from reaction of strand II with 
complex 13. 
5.3.3.11 Enzymatic digestion of purified 13-CC strand adducts 
To confirm the Ru binding sites on strand II, enzymatic digestion of the isolated 
fractions with VPD was performed. This enzyme begins digestion at the 3' end, 
creating 5 '-mononucleotjdes. If the site of metal binding is guanine, then digestion 
of the mixed fraction (peaks (a) + (b)) should result in two products: one for TATG-
Ru, and one for TATGTACCATG-Ru, two species sufficiently different in their 
molecular masses, and hence ionic patterns, that they should be easily distinguishable 
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The digestion ladder for this mixed fraction ((a) + (b)) is shown in Figure 5.24. As 
can be seen, the digestion did not proceed very far. It seems that only the end two 
bases, Tb  and A'6, were removed in the reaction. As it is known that VPD 
sometimes stops one base prior to a labelling," it can be assumed that the ruthenium 
is indeed bound to a guanine residue. The alternative is that the ruthenium is bound 
to thymine, but there are four available thymines in II, and this does not seem likely. 
28 27 26 25 24 23 22 21 2019 18 17 16 15 
5 '-TATGTACCATGTAT-3' 
Ru 
Figure 5.24 VPD digestion ladder of HPLC peaks (a) and (b) combined, separated 
from reaction of-CC- strand II with complex 13. 
An interesting factor in this experiment is the lack of a second post-digestion species, 
the supposed TATG-Ru, where the ruthenium is located on G25, and the bases T'5 to 
T24 have been cleaved by the enzyme. The reaction was monitored at various time 
intervals up to 48 h, with incubation, and no other species were detected at any stage 
during the reaction, and the -T and -(T-A) ions were present from an early stage. As 
the HPLC shows two definite peaks in this fraction, it can be assumed that these 
species are different, and so the mass spectrum of the digestion should have shown 
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more peaks, corresponding to oligonucleotides of other lengths. This gives rise to 
the interesting possibility of isomerisation. This would mean that the assumption 
that one peak is the II with a Ru(arene)(en) on the G'8 towards the 3'-end and the 
other peak is II with a Ru(arene)(en) on the G25 towards the 5 '-end is correct. After 
lyophilisation and redissolution of the fraction, the Ru(arene) on the G25 may migrate 
to the possibly more favourable G18, hence only one species arises after enzymatic 
digestion of the fraction. 
The VPD digestion of the bi-ruthenated -CC- strand, peak (c) in the HPLC, is shown 
in Figure 5.25. The similarity with the digestion of the mixed fraction is easy to see. 
The digestion proceeds only as far as removal of T'5 and A16, as would be expected 
for II labelled at the guanine residues. If both guanines are labelled we would still 
only find the strand digested as far as the first label as the digestion is specifically 
from the 3'-end. 
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Figure 5.25 VPD digestion ladder of 13-I peak (c) 
5.3.4 Conclusions 
In this section it has been shown that the Ru(arene) complex, [( 6-para-
cymene)Ru(en)CI][pF6i 13 specifically binds to guanine residues in a l4mer 
oligodeoxynucleotide strand containing a selection of all four DNA bases. This has 
been proved using electrospray ionisation mass spectrometry in conjunction with 
HPLC and enzymatic digestion of the metallated DNA. This is very interesting in 
the field of metallodrugs as anti-cancer agents as it is known that the highly 
successful drug cisplatin has a preference for guanine residues in DNA. Also, the 
fact that the enzyme cannot pass over the bound Ru may be significant for inhibiting 
the 	function 	of 	repair 	enzymes 	in 	cells. 
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6.1 Introduction 
Cisplatin is one of the most widely used drugs in anticancer therapy' and has proven to 
be very effective in clinical therapy of several human solid tumours such as testicular 
carcinomas, ovarian tumours, head and neck cancers, bladder tumours and 
osteocarcomas, however it only shows a weak effect against many other malignancies of 
relevant social incidence such as breast cancers, lung cancer and cob/rectal 
adenocarcinomas.2 Thus, there is much room for the development of new antitumour 
agents. The current trend for organisations such as the National Cancer Institute is to 
use. as a first selection process, tumour cell lines of histologically defined solid tumour 
entities which are used to determine the cytotoxic activity of the compounds tested and 
those qualifying go on to in vivo testing.3 
Some ruthenium compounds have shown promising effects in these form of cell line 
tests. 1vfer-[Ru(terpy)C13 ] shows a very high cytotoxicity against leukaemia and human 
cervical cell lines.' In cell-free media, this complex was found to coordinate to DNA 
preferentially at G residues, and this suggests a cisplatin type mechanism of action.' cis 
and trans-[RuC1,(DMSO)4] were found to exert an anti-leukaemic effect on a cisplatin 
resistant cell line, which indicates a lack of cross resistance and hence a different 
mechanism of action, despite binding preferentially to Gs in DNA. 	[(116 
CH6)RuCl2(metronidazole)] is cytotoxic towards E. Coli, more so in fact than free 
metronidazole (metronidazole is a nitromidazole, a range of compounds which sensitise 
hypoxic tumour cells to radiation).' Other Ru(arene) complexes such as [Ru(cp).,Clf 
and its ring-oxidised analogue [Ru(cpO)(cp)Clf, however, show weak cytotoxicity, in 
the region of 100 riM, whereas the osmium analogue has very good cytotoxicity against 
several cancer cell lines.' 
* This work was performed in collaboration with Dr. Duncan Jodrell, Dr. Jeff Cummings and Rhona Aird 
of the ICRF, Western General Hospital, Edinburgh. 
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Yet the property that renders ruthenium complexes unique among anticancer agents is 
principally the lack of evident cell cytotoxicity at doses that increase lifetime expectancy 
in tumour-bearing hosts.9 Na[trans-RuCI4(DMSO)Im], NAMI, a ruthenium 3+ complex 
that is very effective against metastases is not cytotoxic towards tumour cells" and 
NAMI-A, [HIm][trans-RuCl4(DMSO)Im], the more recent version of NAMI, is virtually 
devoid of in vitro toxicity in doses >100 .iM against a cell line against which cisplatin is 
effective.' 	Yet, despite their lack of cytotoxicity, both NAMI and NAMI-A are 
effective in both preventing formation of metastases and in reducing their growth when 
already present at the beginning of drug treatment.9 ' Metastases represent the greatest 
obstacle to post-surgery and/or radiotherapy cures, in that they often show a low 
chemosensitivity to the available anticancer drugs. 12 
Perhaps lack of penetration of the cell membrane is the reason for the lack of direct 
cytotoxicity, and hence the compounds bind to extracellular components. Here Ru 
interactions may deprive tumour cells of normal cell-cell and cell-matrix contacts which 
are essential for cell growth, division and formation of metastases.'3 This idea is 
supported by a study performed on a series of eighteen Ru(III) complexes that are 
structurally related to NAMI. These complexes only showed in vitro cytotoxicity at 
concentrations >10 M, yet reduced the formation of metastases by a mechanism 
unrelated to direct tumour cell cytotoxi city. 9) The absence of direct cell toxicity may 
actually be an advantage as it may decrease the side effects on healthy tissues.' NAMI, 
in fact, has very low side-effects on normal cells of host tissues such as liver, kidney and 
lung epithelia.'4  Any cytotoxicity which has been found, however, seems to be related to 
the lipophilicity of the compound, suggesting that lipophilicity allows the compound to 
enter the cell and exert its cytotoxic action. 11b ' This fits in well with part of our rationale 
for using Ru(arene) complexes. The arene ring should confer a degree of lipophilicity 
on our compounds, and increase interactions with the cell membrane. It was also noted 
in the publication that cytotoxic compounds can also be anti-metastatic, 9(b)  so although 
cytotoxicity is not necessary for anti-metastatic activity, the two may be related. 
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With the knowledge that ruthenium complexes do not always exhibit cytotoxicity 
against cell lines, preliminary tests were performed on a selection of complexes prepared 
in Chapter 4. These tests were considered worthwhile as [( 6-p-cymene)RuCl(en)] 13 
has been shown to bind to DNA in a G specific manner, section 5.3, and the arene ring 
confers a degree of lipophilicity on the complexes that should aid passage through the 
cell membrane. Tests were performed against human ovarian cancer cell lines, and their 
cisplatin resistant and adriamycin resistant strains, with a view to obtaining an insight 
into cytotoxic effects of the complexes and possible mechanisms of action. 
6.2 Experimental 
The compounds were tested on 24-well trays by Rhona Aird, Dr. Jeff Cummings and Dr. 
Duncan Jodrell at the ICRF Unit of the Western General Hospital, Edinburgh. Cells 
growing in a flask were harvested just before they become confluent, counted using a 
haemocytometer and diluted down with medium (cell-culture medium containing 5 % 
foetal calf serum) to a concentration of 1 x iO cells ml'. The cells were then seeded in 
the 24-well trays at a density of 1 x 10 cells per well (i.e. 1 ml of the diluted cell 
suspension was added to each well). The cells were then left to plate down and grow for 
72 h before the drug was added. 
The Ru complexes were weighed out and made up to a concentration of 1 mg m1' with 
deionised water and then sonicated until dissolved. The appropriate volume of the Ru 
solution was added to 5 ml of medium to make it up to a concentration of 100 tM stock 
solutions for each drug. This 100 iM solution was then serially diluted to make up 10 
tM, 1 M and 0.1 1iM solutions. The medium was removed from the cells and replaced 
with I ml of the medium dosed with drug. Each concentration was made up in 
duplicate. A set of control wells were left on each plate, containing medium without 
drug. The cells were exposed to the drugs for 24 h and then washed with phosphate 
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buffered saline before fresh medium was added. The cells were allowed to grow for a 
further three days before being counted using a Coulter counter. 
To prepare the cells for counting the medium was removed and 1 ml of PBS was added 
to the cells. An aliquot of 250 p.1 of trypsin was added and the cells left in an incubator 
for a few minutes to allow the monolayers to detach. Once trypsinised, 250 41 of media 
was added to each well to neutralise the trypsin. An aliquot of 200 41 of this suspension 
was then added to lOml of NaCl for counting. 
Resistance was derived in the cisplatin resistant A2780cis and adriamycin resistant 
A2780AD cell lines by stepwise exposure of A2780 to increasing concentrations of the 
respective drug. PEO1 cisplatin resistance was obtained in a similar manner. 
6.3 Results and discussion 
Potential ruthenium anticancer agents are often compared to cisplatin as they both 
contain a heavy transition metal of Group VIII. The management of ovarian cancer has 
been improved by the introduction of cisplatin into clinical use" and for these reasons 
we performed the cytotoxicity tests reported here. The cell line used was A2780, an 
ovarian cancer cell line. This is a cell line quite commonly used for cytotoxicity tests of 
platinum drugs in its original form, or its cisplatin or adriamycin resistant form.'6 This 
cell line has also been used as screens for cytotoxic gold(III) compounds. 17  In this 
chapter, complexes 6, 8, 9, 11, 12, 13, 14, 16 and 17 (see Table 6.1) were tested for 
cytotoxicity against the A2780 cell line. Any positively-charged complex has the 
counter-ion PF, except for 14, which has an iodide counter-ion. NH4PF6 has previously 
been shown to be devoid of cytotoxic activity' therefore any cytotoxic effect can be 
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Complex Formula 
6 [( 6-p-cymene)RuCl2(isn)} 
8 [(r 6  -benzene)RuCI(MeCN)]+ 
9 [( 6-p-cymene)RuCl(MeCN)] 
11 [(ii6-benzene)RuCl(en)] 
12 [(q 6-benzene)RuI(en)] 
13 
14 [( 6-p-cymene)RuI(en)} 
16 [( 6-methylbenzoate)RuCl(en)] 
17 [(iq'-biphenyl)RuCl(en)] 
Table 6.1 A list of Ru(arene) complexes tested in this chapter. The positive metal 
complexes have PF as the counter-ion with the exception of 14 which has an iodide 
counter-ion. 
A graph showing the IC50 of the complexes on the A2780 cell line is shown in Figure 
6.1. IC50  is the concentration at which the complex causes death of 50 % of the cancer 
cells as compared to the control (no ruthenium). 
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6 	8 	9 	11 	12 	13 	14 	16 	17 
Complex 
Figure 6.1 Bar chart showing the IC50 values in tM for the Ru(arene) complexes tested 
against the ovarian cancer cell line A2780. Cisplatin showed an IC, value of 0.6 .tM 
and carboplatin showed an IC50 value of 5 tM against the same cell line. Figures shown 
are a mean of two tests. The formulae of the complexes is given in Table 6.1. 
It can be seen from Figure 6.1 that all the complexes with the exception of 16 exhibit a 
reasonable activity. Although the value for cisplatin is a factor of ten less (IC50 = 0.6 
jtM), the values are close to carboplatin, another clinically used anticancer drug. By 
comparison of the results from each complex we can draw certain conclusions. Firstly, 
the difference in cytotoxicity brought about by changing the halide from Cl to I is 
negligible. This can be seen by comparing the results for 11 and 12, and 13 and 14. 
Secondly, changing from a complex that is likely to form polyfunctional adducts to one 
that is likely to produce only monofunctional adducts actually brings about a decrease in 
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the IC,,, value. This is demonstrated by the lower IC,,, values of the ethylenediamine 
complexes 11, 12, 13, 14 and 17 (the monofunctional complexes) as compared to 6, 8 
and 9 (the polyfunctional complexes). Where a really noticeable effect occurs is on 
varying the arene ring. It is not so much in changing from benzene to p-cymene (11 and 
12 to 13 and 14), but there is a decrease in the IC,,, value. On changing to the 
methylbenzoate group, however, the complex becomes virtually inactive, with an IC,(, of 
almost 100 tM. This change has to be due to the ester moiety on the arene ring as the 
complex is otherwise identical to 11, 13 and 17. Thus, the proposed idea of 16 acting as 
a prodrug which is hydrolysed in the cell by hydrolase enzymes to an active species 
appears not to be beneficial. Possibly the complex hydrolyses prior to entering the cell 
and this hinders its uptake. It should be remembered, however, that cytotoxicity tests 
have proven to be misleading in the past for Ru compounds and the complex may still 
find an effect as an antimetastatic agent. 9°' The final complex, 17, is the biphenyl 
complex. This is the most active of the group against A2780. These results show the 
merit in introducing variation on the arene ring in an attempt to increase the cytotoxicity 
of the Ru(arene) complexes. 
From these initial tests, complexes 13 and 17 were selected as lead compounds due to 
their low IC 0 values and their different arene moieties, for further investigations of the 
mechanism of action. 
6.3.1 Further cytotoxicity tests of [( 6-p-cymene)RuCI(en)] 13 
The results of some further cytotoxicity tests with ft1 6-p-cymene)RuCl(en)] 13 are 
shown in Figure 6.2. The complex exhibits good cytotoxicity against the parent cell line 
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.iM. The cell line containing the mutant vector, but not the mutant itself experienced a 
decrease in cytotoxicity as compared to the parent line, but the complex was still more 
effective against this than the mutant cell line, with an IC,, of 9 jiM. When tested 
against another ovarian cancer cell line, PE01, and its cisplatin resistant analogue, 
PEO1cDDP, the complex exhibited a low cytotoxicity, with IC,,, values of 70 and 82 jiM, 
Cell-line tested 
Figure 6.2 Bar chart showing the IC50  values of[(116pcymene)RuC](en)]* 13 against a 
series of cell lines. A2780 is the parent cell line, A2780 mp53 is the parent cell line 
mutant in p53, A2780 vector is the A2780 cell line containing the vector of the p53 
mutant, but not the mutant, PEOI is another ovarian cancer cell line and PEOI cDDP is 
the PEOI cell line with acquired resistance to cisplatin. Cisplatin displayed IC50 values 
of 0.6, 2.2, 0.6, 5 and 44 jiM for the cell lines, from left to right. 
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The implications of these results is that it is likely that [(ij 	13 has 
a mechanism influenced by p53. This can be inferred because of the decrease in activity 
against the cell line that is mutant for p53, i.e. p53 does not function properly in this cell 
line. As a control, the complex was tested against a cell line which contains the vector 
that transfers the mutation to the cell line, but without the actual mutation. Against this 
cell line, there is a slight decrease in cytotoxicity, but not as much as in the p53 mutant 
cell line. Cisplatin shows a p53 influence against this cell line, as shown by the IC50 
values of 0.6 mM against the parent cell line and 2.2 mM against the p53 mutant. 
Against PEO1, the complex has such a low toxicity, that the fact that it is slightly worse 
towards the cell line which has become resistant to cisplatin is insufficient to gain any 
insights into the complex's activity. 
Mutation of several specific genes involved in the control of cell growth and apoptosis is 
part of the process involved in the development of a malignant tumour. 18  Mutation or 
deletion of p53 has been shown to be one of the most common features of human 
cancer.'9  Its normal function is important in preventing cells from turning malignant. 
p53 protein is normally only present in the cell in minute levels and is generally thought 
to be inactive. However, when the cell starts to divide uncontrollably or its DNA is 
damaged, the protein becomes switched on and p53 levels rise,20 and for this reason p53 
is thought to act as a "molecular policeman" and has been termed the guardian of the 
genome.2 ' When it has been activated, p53 may switch off replication to allow time for 
cell repair, or if this repair fails, it can trigger apoptosis, so preventing development of 
damaged cell S.22 Certain radiation and chemotherapy treatments are thought to function 
to some degree by triggering apoptosis and the function of p53 is important in this 
respect. Tumour cells which are mutant for p53 cannot perform this function are 
genetically unstable and can easily accumulate mutations.22 Mice which do not possess 
wild-type p53 (WT p53) develop normally, but are very susceptible to tumours.23 
Intracellular levels of p53 increase dramatically in response to a variety of DNA 
damaging agents.24  p53 is also thought to play a role in controlling DNA replication25 
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and transcription. 16  DNA binding is necessary for its tumour suppression activity27 and it 
can bind DNA in a sequence specific manner.28 
Mutations of the p53 gene are associated with development of resistance to cisplatin in 
human ovarian cancer cells,29  and one proposed reason for the efficacy of cisplatin in 
testicular cancers is the low frequency of p53 mutations in this type of tumour.3° 
Cisplatin has also been found to suppress growth of oesophageal cancer cells that are 
wild-type for p53, but not for the mutant strain .31  Interestingly, and encouragingly for 
future treatments, reintroduction of WT-p53 into the human ovarian cisplatin resistant 
cancer cells resulted in a resensitisation.32  It has been proposed that interperitoneal 
dosing with WT-p53 gene therapy could be beneficial in combination with cisplatin for 
treatment of ovarian tumours expressing mutant p53.32 It is important to note, though, 
that some cells which are devoid of functional p53 function can be killed by cisplatin by 
a p53 independent route. 33 
Other platinum drugs have been found to have their activity linked to p53. Carboplatin 
has been found to stimulate an increase in p53 levels in tumour cells and trigger 
apoptosis.34  JM216, an orally administered drug currently on clinical trials induces p53 
in human ovarian cancer cell lines, including a line with induced cisplatin resistance. 
This is relevant as JM216 is thought to exert its cytotoxic effects through induction of 
apoptosis.35 
Not all metal drugs are effected in the same way as cisplatin. [1,2-diaminocyclohexane 
diactetato-dichloroPt(IV)] can actually reactivate WT-p53 in ovarian tumour cell lines, 
yet cell lines which are devoid of or mutant for p53 are cross resistant to it.36 Peculiarly, 
a charged tnnuclear platinum complex has been reported to be very active against 
mutant p53 cell lines, yet experiences a ten-fold reduction in cellular chemosensitivity 
for WT-p53.37  These results emphasise the point that there is no general mechanism by 
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6.3.2 Further cytotoxicity tests of [( 6-biphenyI)RuCI(en)] 17 
Figure 6.3 shows IC,,) values for [( 6-biphenyl)RuCl(en)] 17 against a series of A2780 
cell lines. The IC50 values of this complex increase only very slightly from the parent 
cell line to the p53 mutant cell line, 5 jiM to 6 tM, and the vector cell line has a lower 
IC,,, value of 4 riM. There is no difference between the cytotoxic effect of complex 17 
against the parent cell line and the cisplatin resistant cell line A2780 cis, but the complex 
is reasonably inactive, with an IC50 value of 70 .iM against the adriamycin resistant cell 
line A2780 AD. 
These results indicate a lack of p53 influence in the mechanism of action for complex 
17. If there was a p53 influence, it would be expected that there would be a more 
significant increase in the IC50 value for 17 against the cell line mutant for p53. 
Interestingly, the complex does not appear to share cross resistance with cisplatin. 
While cisplatin showed a four-fold increase in IC, value against the A2780 with 
induced resistance, 17 showed no change from the parent cell line. This is promising as 
ideally an anticancer agent should possess a different mechanism of action to cisplatin. 
The most significant result from this test comes from the adriamycin resistant cell line. 
Adriamycin is an anticancer agent whose efficacy is linked to topoisomerase-11 
inhibiton.43  The fact that the cytotoxic activity of complex 17 is severely reduced in this 
cell line is an exciting result and points to a cross resistance with adriamycin, and an 
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Cell-line tested 
Figure 6.3 Bar chart showing IC, values for [(q6-biphenyl)RuCI(en)f 17 against a 
series of A2780 ovarian cancer cell-lines showing different properties. A2780 is the 
parent cell line, A2780 mp53 is the parent cell line mutant in p53, A2780 vector is the 
A2780 cell line containing the vector of the p53 mutant, but not the mutant, A2780 cis is 
the cell line with acquired cisplatin resistance and A2780 AD is the cell line with 
acquired resistance to adriamycin. Cisplatin displayed IC,,, values of 0.6, 2.2, 6, 4 tM 
for the respective cell lines. Doxorubicin showed IC50 values of 0.2 jtM for A2780, 0.2 
jtM for A2780 cis and 22 M for A2780 AD. Doxorubicin is an alternative name for 
adriamycin. 
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Topoisomerases are a group of enzymes that can interconvert different topological 
isomers of DNA. The faithful replication and segregation of chromosomes as part of the 
cell division cycle requires that topological changes be imposed upon cellular DNA and 
topoisomerases catalyse these changes. 38  They relieve the torsional stress in unwinding 
DNA and resolve topological problems that arise during the various processes such as 
transcription, recombination, replication and chromosome partitioning during cell 
replication.39  Type I topoisomerases only introduce breaks on one strand of the duplex, 
while a type II topoisomerases catalyse a double strand break.4° These are vital enzymes 
for all organisms from bacteria to humans.38 Many antibacterial and antitumour drugs 
are known to target topoisomerases I and II and effect their catalytic cycle.4 ' The 
chemotherapeutic actions of many of these drugs correlate with their abilities to stabilise 
the covalent topoisomerase TI-DNA cleavage complex,42 thereby shifting the equilibrium 
of the enzymes DNA cleavage/religation cycle toward the cleavage event.43 Drugs may 
also act at other steps of the catalytic cycle such as inhibiting the DNA religation step" 
or enhancing the enzyme's forward rate of cleavage.44 
Anticancer drugs that target topoisomerase II are grouped in two categories depending 
on their DNA binding properties: 	binding, but nonintercalative,45 and 
intercalating.42 ' 	The majority of the clinically effective topoisomerase poisons work 
through the cleavable complex, bind to DNA with high affinity (usually by intercalation) 
and induce extensive site specific damage. 121c)  Most of these drugs, however, are not 
selective enzyme inhibitors, but exhibit secondary mechanisms of action that contribute 
to their host toxicity.46  A structure-activity relationship for these drugs has recently been 
proposed .4' The model suggests that a polycyclic ring is necessary for intercalation into 
DNA, and a further aromatic ring substitution, with a sterically unhindered hydroxy or 
amino function, is necessary to extend out of the plane of the DNA and interact with a 
hydrophobic pocket of the enzyme. Our complex [( 6-biphenyl)RuCl(en)] 13 could be 
viewed in a similar manner. The pendant ring of the biphenyl could act as the 
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intercalating moiety and the positive metal ion could bind to the DNA or enzyme, in a 
covalent or ionic manner, and hold the complex in place. 
The platinum drugs used at present appear to have no inhibitory effect on topoisomerase. 
In fact, cisplatin resistant cell lines have been shown to have an associated increased 
topo-II activity" and cells with increased topo-II levels contribute to the cisplatin 
resistance, but cells with reduced levels of topo-11 were found to be more sensitive to 
cisplatin.49  Cisplatin and topo-11 inhibitors have been found to have a synergistic effect 
when used together against cisplatin resistant cell lines.50 Oxaliplatin, too, has been used 
in conjunction with a topo-I inhibitor, SN-38, with synergistic results.5 
Recently a publication52  reported that two ruthenium(II) complexes interfered with the 
catalytic effect of topoisomerase II, and the authors attempt to elucidate their molecular 
mechanism of action and relative neoplastic activity. The Ru(arene) complex [(p6-
C6H6)RuCl.,(DMSQ)] was found to inhibit the DNA relaxation activity of topo-11 by 
cleavable complex formation. It should be noted, though, that the characterisation: of 
this complex, and the second complex tested [Ru"(trans, bis-salicylaldoximato)] was not 
convincing. This view is supported by Clarke in his recent review .5' The Ru-saldox 
complex was found to not induce cleavable complex formation, even though its DNA 
binding and antiproliferative effects are similar to the Ru(arene) complex. These 
complexes are relatively inactive though, doses >150 .iM were required to give 50 % 
inhibition of cell proliferation. They also tested the complexes for their effect on the 
melting temperature Tm of calf thymus DNA. They report that, for the arene complex, 
the Tm  increases with increasing drug concentration. This is in contrast to the work done 
on the effect of[(fl 6-p-cymene)RuC1(en)j 13 in section 5.2, where 13 caused a lowering 
of the Tm  of an oligonucleotide duplex. The published results52 imply an ionic 
interaction of the complex with the phosphate backbone, which would stabilise the 
duplex due to charge screening" rather than destabilise it by covalent binding to the 
nitrogenous bases .5' Although this publication points to a topo-11 inhibition by a 
Ru(arene) complex, the characterjsatjon of the complex itself was very poor, and the 
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doses required for efficacy are very high. Complex 17, on the other hand, is well 
characterised by NMR and X-ray crystal structure and shows efficacy at a much lower 
dosage, hence showing more potential for development. 
6.4 Conclusions 
Preliminary cytotoxic studies were performed on nine Ru(arene) complexes against a 
human ovarian cancer cell line. All complexes except one showed good activity. An 
important structural lead to take from these investigations is that varying the arene ring 
of the complex can have a significant effect on the activity of the complex. Two lead 
complexes, [( 6-p-cymene)RuCl(en)] 13 and fti 6-bipheny1)RuCl(en)f 17, were chosen 
for some further studies. Interestingly the two complexes appear to display different 
mechanisms of action. Complex 13 appears to be p53 influenced and possibly cross 
resistant with cisplatin. Complex 17 does not seem to be influenced by p53, but instead 
shows a cross resistance with adriamycin, a topoisomerase-11 inhibitor. This is 
potentially a very exciting result for a metallodrug. 
It should be noted that these are preliminary results and repeats of cell cytotoxicity 
studies need to be performed to provide confirmation. On the basis of this study though, 
17 has been chosen for more in-depth biological testing. This includes investigating 
accumulation of the complex in the cell, binding to DNA and testing in tumour models. 
The HPLC assay developed in Chapter 4 will be of assistance in these tests. 
These complexes have great potential for structural variety and hopefully further 
investigations will elucidate structure-activity relationships. These tests mark the start of 
an exciting body of work linking chemistry and medicine, and hopefully it will prove to 
be of benefit in the treatment of cancer in the future. 
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